var title_f40_1_40976="Jugular venous pulse in constrictive pericarditis";
var content_f40_1_40976=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Jugular venous pulse in constrictive pericarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal jugular venous pulse waveform is represented in blue. In comparison, the jugular venous pulse waveform in a patient with constrictive pericarditis (CP) is shown in red. Note the sharp, prominent y descent in CP, which represents rapid passive filling during early diastole that abruptly stops when the ventricular volume reaches the maximal capacity allowed by the stiff, thickened pericardium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_1_40976=[""].join("\n");
var outline_f40_1_40976=null;
var title_f40_1_40977="Adenomatoid malform CXR I";
var content_f40_1_40977=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic adenomatoid malformation (Type I) in a newborn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 453px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The initial chest radiograph shows complete opacification of left hemithorax with compression of the right lung, which is hypoplastic and surrounded by a small right pleural effusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_1_40977=[""].join("\n");
var outline_f40_1_40977=null;
var title_f40_1_40978="Comparison of OCT and IVUS";
var content_f40_1_40978=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Comparison of OCT and IVUS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 445px; height: 452px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Comparison of intracoronary Fourier domain OCT (St. Jude/Lightlab Imaging Inc, Westford, MA, USA) specifications and conventional intravascular ultrasound, as typically used in the catheterization laboratory.",
"    <div class=\"footnotes\">",
"     * Based on specifications of the current generations of Volcano, Boston Scientific, and Terumo IVUS systems.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Evelyn Regar, Thoraxcenter.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_1_40978=[""].join("\n");
var outline_f40_1_40978=null;
var title_f40_1_40979="Visual analog pain scale";
var content_f40_1_40979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F82442%7EPC%2F67351%7EPULM%2F50711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F82442%7EPC%2F67351%7EPULM%2F50711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Visual analog pain scale",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 228px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 589px\">",
"   <div class=\"ttl\">",
"    Faces pain scale",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 569px; height: 135px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the faces pain scale, rated from 0 to 6 left to right.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Bieri, D, Reeve, RA, Champion, GD, et al. Pain 1990; 41:139. Copyright &copy; 1990 with permission from Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Monthly pain scale",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 387px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_1_40979=[""].join("\n");
var outline_f40_1_40979=null;
var title_f40_1_40980="Preventing complications in diabetes mellitus";
var content_f40_1_40980=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/1/40980/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/1/40980/contributors\" id=\"au5149\">",
"       David K McCulloch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/1/40980/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/1/40980/contributors\" id=\"se6384\">",
"       David M Nathan, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/1/40980/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/1/40980/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/1/40980?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      DIABETES OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Diabetes mellitus is a chronic condition that can lead to complications over time. These complications can include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Coronary heart disease, which can lead to a heart attack",
"      </li>",
"      <li>",
"       Cerebrovascular disease, which can lead to stroke",
"      </li>",
"      <li>",
"       Retinopathy (disease of the eye), which can lead to blindness",
"      </li>",
"      <li>",
"       Nephropathy (disease of the kidney), which can lead to kidney failure and the need for dialysis",
"      </li>",
"      <li>",
"       Neuropathy (disease of the nerves), which can lead to, among other things, ulceration of the foot requiring amputation (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/5/21587?source=see_link\">",
"        \"Patient information: Diabetic neuropathy (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Many of these complications produce no symptoms in the early stages, and most can be prevented or minimized with a combination of regular medical care and blood sugar monitoring.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CONTROLLING BLOOD SUGAR IN DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     The long-term complications of diabetes are caused by the effect of high blood sugar levels on blood vessels. Two important studies, the Diabetes Control and Complications Trial (DCCT) in patients with type 1 diabetes and the United Kingdom Prospective Diabetes Study (UKPDS) in patients with type 2 diabetes, found that people with lower blood sugar levels had fewer complications than those with higher values.",
"    </p>",
"    <p>",
"     Thus, keeping blood sugars close to normal can help prevent the long-term complications of diabetes mellitus. However, there are some risks associated with tight control, particularly an increased risk of hypoglycemia (low blood sugar).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H818612012\">",
"     <span class=\"h2\">",
"      Monitoring blood sugar levels",
"     </span>",
"     &nbsp;&mdash;&nbsp;Monitoring blood sugar with finger sticks at home can indicate how well diabetes is controlled and serves as a guide to adjusting therapy. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/43/39603?source=see_link\">",
"      \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .) For most people, a target for fasting blood sugar and for blood sugar levels before each meal is 80 to120",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     (4.4 to 6.6",
"     <span class=\"nowrap\">",
"      mmol/L);",
"     </span>",
"     however, these targets may need to be individualized.",
"    </p>",
"    <p>",
"     A blood test called A1C is also used to monitor blood sugar control; the result provides an average of blood sugar levels during the previous one to three months. An A1C of 7 percent or less is recommended; this corresponds to an average blood sugar of 150",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     (8.3",
"     <span class=\"nowrap\">",
"      mmol/L)",
"     </span>",
"     (",
"     <a class=\"graphic graphic_table graphicRef76310 \" href=\"mobipreview.htm?6/10/6316\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     The A1C target may be somewhat higher in people who are older or who have conditions that increase the risks associated with hypoglycemia. Even small decreases in the A1C lowers the risk of diabetes-related complications to some degree.",
"    </p>",
"    <p>",
"     The combination of A1C and fingerstick blood sugars provides information about the average and daily blood sugar levels.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Type 1 diabetes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Blood sugar control in type 1 diabetes requires some form of insulin, which can be given with insulin injections or an insulin pump. Most healthcare providers recommend intensive insulin therapy, which requires frequent blood sugar monitoring in addition to frequent injections or use of an insulin pump. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/31/35317?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Intensive insulin therapy increases the risk of low blood sugar, is more expensive than traditional insulin therapy, and requires that the person monitor their blood sugar levels, diet, and activities. Some people who use intensive insulin therapy gain weight, although regular exercise and controlling the amount eaten can prevent weight gain. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/63/4083?source=see_link\">",
"      \"Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Type 2 diabetes",
"     </span>",
"     &nbsp;&mdash;&nbsp;With type 2 diabetes, it is sometimes possible to control blood sugar levels with lifestyle changes, often in combination with oral medications. Insulin injections may be needed when a person is first diagnosed or later in the course of treatment. Most people with type 2 diabetes who take insulin require only one or two injections per day. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/28/18886?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      EYE COMPLICATIONS IN DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     Regular eye examinations are essential for detecting eye complications (called retinopathy) at an early stage, when the condition can be monitored and treated to preserve vision.",
"    </p>",
"    <p>",
"     An eye exam should include dilating the pupils (with medicated eye drops) to completely examine the retina. Unless the pupils are medicated, they contract in response to light, making it impossible to view the entire retina. In some people with retinopathy, photographs of the retina will be taken to monitor the changes. This examination should be performed by a doctor who specializes in the eyes (called an ophthalmologist or optometrist).",
"    </p>",
"    <p>",
"     The risk of diabetic retinopathy varies with the type and duration of diabetes and with other life events. Thus, the screening guidelines differ from one person to another.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Type 1 diabetes",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with type 1 diabetes should have an eye examination by an ophthalmologist or optometrist beginning five years after they are diagnosed with diabetes, although screening is usually not necessary before puberty. People who have difficulty with their vision or who require glasses or contacts may need to be seen sooner. The frequency of subsequent examinations will depend upon the results of the initial exam. An eye exam is usually recommended every one to two years after the initial examination.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Type 2 diabetes",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with type 2 diabetes should have an eye examination by an ophthalmologist or optometrist when they are first diagnosed with diabetes. The reason for this is that blood sugar levels often increase over a period of several years before the person is diagnosed. Eye complications can develop during this time and often have no symptoms. Having an eye examination soon after diagnosis can help to determine if there are eye complications, the extent or severity of the complications, and if treatment is needed.",
"    </p>",
"    <p>",
"     The frequency of subsequent exams will depend upon the results of the initial examination. An eye exam is usually recommended every one to two years after the initial examination.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      FOOT CARE WITH DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     Diabetes can decrease the blood supply to the feet and damage the nerves that carry sensation. These changes put the feet at risk for developing potentially serious complications such as ulcers. Foot complications are very common among people with diabetes, and may go unnoticed until the condition is severe. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/5/21587?source=see_link\">",
"      \"Patient information: Diabetic neuropathy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Self exam",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with diabetes should examine their feet every day. It is important to examine all parts of the feet, especially the area between the toes. Look for broken skin, ulcers, blisters, areas of increased warmth or redness, or changes in callus formation; a healthcare provider should be notified if any of these changes are found. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/38/43618?source=see_link\">",
"      \"Patient information: Foot care in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     This examination can be a part of the daily bathing or dressing routine. It may be necessary to use a mirror to see the bottoms of the feet clearly. Anyone who is unable to reach their feet or see them completely, even with the help of a mirror, should have someone else (such as a spouse or other family member) assist with the examination.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Clinical exam",
"     </span>",
"     &nbsp;&mdash;&nbsp;During a routine medical visit, the clinician will check the blood flow and sensation in the feet. In people with type 1 diabetes, annual foot examinations should begin five years after diagnosis. In people with type 2 diabetes, annual foot exams should begin at the time of diagnosis.",
"    </p>",
"    <p>",
"     During a foot examination, the clinician will look for changes such as ulcers, cold feet, thin skin, bluish skin color, and skin breaks associated with athlete's foot. The clinician will also test the sensation in the feet to determine if it is normal or diminished. People with decreased sensation are at risk for foot injuries that can go unnoticed due to lack of pain.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      KIDNEY COMPLICATIONS IN DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     Diabetes can alter the normal function of the kidneys. A urine test that measures the amount of protein (albumin) in the urine can determine if diabetes is affecting the kidney's filtering action. Microscopic amounts of albumin in the urine (microalbuminuria) can be an early indicator of diabetes-related kidney complications (called nephropathy). The amount of albumin in the urine can also help the provider determine if nephropathy is worsening. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/35/15921?source=see_link\">",
"      \"Patient information: Protein in the urine (proteinuria) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Urine screening tests should begin in people with type 1 diabetes about five years after diagnosis, and in people with type 2 diabetes at the time of diagnosis. If the test shows that there is protein in the urine, tight blood sugar and lipid (cholesterol and triglyceride) control are recommended.",
"    </p>",
"    <p>",
"     A blood pressure medication (an ACE inhibitor or angiotensin receptor blocker [ARB]) is generally recommended if albuminuria does not improve, even if the blood pressure is normal. People with elevated blood pressure and albuminuria are also treated with an ACE inhibitor or ARB. These medications decrease the amount of protein in the urine and can prevent or slow the progression of diabetes-related kidney disease.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      HYPERTENSION AND RELATED COMPLICATIONS IN DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     Many people with diabetes have hypertension (high blood pressure). Although high blood pressure causes few symptoms, it has two negative effects: it stresses the cardiovascular system and speeds the development of diabetic complications of the kidney and eye. A healthcare provider can diagnose high blood pressure by measuring blood pressure on a regular basis. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=see_link\">",
"      \"Patient information: High blood pressure in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     A blood pressure reading below",
"     <span class=\"nowrap\">",
"      140/90",
"     </span>",
"     and perhaps below",
"     <span class=\"nowrap\">",
"      130/80",
"     </span>",
"     is recommended for most people with diabetes who do not have kidney complications; a lower blood pressure goal (less than",
"     <span class=\"nowrap\">",
"      130/80)",
"     </span>",
"     is recommended for people with diabetes who have kidney disease.",
"    </p>",
"    <p>",
"     If a person is diagnosed with prehypertension",
"     <span class=\"nowrap\">",
"      (&gt;120/80),",
"     </span>",
"     the healthcare provider may recommend weight loss, exercise, decreasing the amount of salt in the diet, quitting smoking, and decreasing alcohol intake. These measures can sometimes reduce blood pressure to normal. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=see_link\">",
"      \"Patient information: High blood pressure, diet, and weight (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If these measures are not effective or the blood pressure must be lowered quickly, the provider will likely recommend one of several high blood pressure medications. The provider can discuss the pros and cons of each medication and the goals of treatment (see",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"      \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      CARDIOVASCULAR COMPLICATIONS IN DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     In addition to lowering blood glucose levels, a number of other measures are important to reduce the risk of cardiovascular (heart and blood vessel) disease.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Quit smoking.",
"      </li>",
"      <li>",
"       Manage high blood pressure with lifestyle modifications",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       medication(s).",
"      </li>",
"      <li>",
"       Have a blood test to measure cholesterol and triglyceride levels, and modify the diets if needed. Some people will also need a medication to lower their LDL (\"bad cholesterol\") or triglycerides.",
"       <br/>",
"       <br/>",
"       If medication is needed, a statin drug should be included whenever possible. The statin drugs have been shown to decrease the future risk of heart attacks, strokes, and death in people with diabetes who are over age 40, even when cholesterol levels are normal.",
"       <br/>",
"       <br/>",
"       The American Diabetes Association recommends that people with diabetes have a low density lipoprotein (LDL) cholesterol level less than 100",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (2.59",
"       <span class=\"nowrap\">",
"        mmol/L).",
"       </span>",
"       Some studies suggest lowering LDL even further, to 70 to 80",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (1.81 to 2.07",
"       <span class=\"nowrap\">",
"        mmol/L).",
"       </span>",
"       (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=see_link\">",
"        \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Aspirin (81 to 100 mg per day) is recommended for anyone with diabetes who already has or is at increased risk of cardiovascular disease. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/54/40803?source=see_link\">",
"        \"Patient information: Aspirin and cardiovascular disease (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      PREGNANCY AND DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     Control of diabetes and its potential complications is especially important for women who are planning to become pregnant, as well as in those who already are pregnant. Controlling blood sugar levels",
"     <strong>",
"      before",
"     </strong>",
"     and",
"     <strong>",
"      during",
"     </strong>",
"     pregnancy decreases the risk of many complications in both the mother and the baby. A separate topic review is available on this subject. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/45/10966?source=see_link\">",
"      \"Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H151\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15454964\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=see_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/40/22144?source=see_link\">",
"      Patient information: The ABCs of diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/42/21156?source=see_link\">",
"      Patient information: Recovery after coronary artery bypass graft surgery (CABG) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/2/36898?source=see_link\">",
"      Patient information: Diabetic ketoacidosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/6/25699?source=see_link\">",
"      Patient information: Hyperosmolar nonketotic coma (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/13/210?source=see_link\">",
"      Patient information: Gangrene (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/21/44369?source=see_link\">",
"      Patient information: Detached retina (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15454972\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/45/10966?source=see_link\">",
"      Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/38/43618?source=see_link\">",
"      Patient information: Foot care in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=see_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=see_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/6/43108?source=see_link\">",
"      Patient information: High cholesterol treatment options (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/43/39603?source=see_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/5/21587?source=see_link\">",
"      Patient information: Diabetic neuropathy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/31/35317?source=see_link\">",
"      Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/63/4083?source=see_link\">",
"      Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/28/18886?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/35/15921?source=see_link\">",
"      Patient information: Protein in the urine (proteinuria) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=see_link\">",
"      Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/54/40803?source=see_link\">",
"      Patient information: Aspirin and cardiovascular disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38758?source=see_link\">",
"      Diagnosis of diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11993?source=see_link\">",
"      Estimation of blood glucose control in diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20794?source=see_link\">",
"      Medical management of type 1 and type 2 diabetes mellitus in pregnant women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/20/24906?source=see_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30089?source=see_link\">",
"      Insulin therapy in type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26233?source=see_link\">",
"      Management of diabetes mellitus in hospitalized patients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/16/2312?source=see_link\">",
"      Screening for diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/42/682?source=see_link\">",
"      Treatment of type 2 diabetes mellitus in the elderly patient",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Diabetes Association (ADA)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(800)-DIABETES (800-342-2383)",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.diabetes.org/\">",
"      www.diabetes.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.hormone.org/public/diabetes.cfm\">",
"      www.hormone.org/public/diabetes.cfm",
"     </a>",
"     , available in English and Spanish)",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/1/40980/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 12, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/1/40980?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40980/abstract/1\">",
"      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40980/abstract/2\">",
"      Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40980/abstract/3\">",
"      Abraira C, Colwell JA, Nuttall FQ, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care 1995; 18:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40980/abstract/4\">",
"      Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40980/abstract/5\">",
"      Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40980/abstract/6\">",
"      Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMJ 2000; 320:1373.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f40_1_40980=[""].join("\n");
var outline_f40_1_40980=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           DIABETES OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CONTROLLING BLOOD SUGAR IN DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           EYE COMPLICATIONS IN DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           FOOT CARE WITH DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           KIDNEY COMPLICATIONS IN DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           HYPERTENSION AND RELATED COMPLICATIONS IN DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           CARDIOVASCULAR COMPLICATIONS IN DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           PREGNANCY AND DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/10/6316\" title=\"table 1\">",
"           A1C and blood sugar PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f40_1_40981="Chlorhexidine gluconate: Patient drug information";
var content_f40_1_40981=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Chlorhexidine gluconate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     see \"Chlorhexidine gluconate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/9/44180?source=see_link\">",
"     see \"Chlorhexidine gluconate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Avagard&trade; [OTC];",
"     </li>",
"     <li>",
"      Bactoshield&reg; CHG [OTC];",
"     </li>",
"     <li>",
"      Betasept&reg; [OTC];",
"     </li>",
"     <li>",
"      ChloraPrep&reg; Frepp&reg; [OTC];",
"     </li>",
"     <li>",
"      ChloraPrep&reg; Sepp&reg; [OTC];",
"     </li>",
"     <li>",
"      ChloraPrep&reg; [OTC];",
"     </li>",
"     <li>",
"      Chlorascrub&trade; Maxi [OTC];",
"     </li>",
"     <li>",
"      Chlorascrub&trade; [OTC];",
"     </li>",
"     <li>",
"      Dyna-Hex&reg; [OTC];",
"     </li>",
"     <li>",
"      Hibiclens&reg; [OTC];",
"     </li>",
"     <li>",
"      Hibistat&reg; [OTC];",
"     </li>",
"     <li>",
"      Operand&reg; Chlorhexidine Gluconate [OTC];",
"     </li>",
"     <li>",
"      Peridex&reg;;",
"     </li>",
"     <li>",
"      periochip&reg;;",
"     </li>",
"     <li>",
"      PerioGard&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hibidil&reg; 1:2000;",
"     </li>",
"     <li>",
"      ORO-Clense;",
"     </li>",
"     <li>",
"      Peridex&reg; Oral Rinse",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat mouth infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2739759",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to clean the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701770",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to chlorhexidine gluconate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697218",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have front-tooth fillings or gum problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect clothing and fabrics from staining.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698237",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth and lip irritation. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dryness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad gum pain or swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698986",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your mouth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Staining of your mouth, teeth, or fillings.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705484",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral rinse:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694570",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Brush and floss your teeth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse with 1 tablespoon (15 mL) of this drug for 30 seconds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694754",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not swallow this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695601",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse 2 times a day, in the morning and in the evening.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696228",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wait 30 minutes before eating, drinking, using mouthwash, or brushing teeth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral chip:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694704",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not floss close to where the chip was placed for 10 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705532",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin (cleanser):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694773",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, ears, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705533",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin (hand sanitizer):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696284",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Work under fingertips.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Spread over hand and to just above elbow.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694444",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put 1 more pumpful on both hands and spread over hands and up to the wrists.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rub into hands until dry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705534",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin (hand washing):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696269",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wet hands and forearms.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put 1 teaspoon (5 mL) on hands and wash for 1 minute.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695590",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse affected part with water. Make sure to it dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705531",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin (before surgery):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696362",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696359",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may put on the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705535",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin (surgical wash):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10830 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-89ED0DCEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_1_40981=[""].join("\n");
var outline_f40_1_40981=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149625\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149626\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011746\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011745\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011750\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011751\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011753\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011748\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011749\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011754\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011755\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=related_link\">",
"      Chlorhexidine gluconate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/9/44180?source=related_link\">",
"      Chlorhexidine gluconate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_1_40982="Hemodynamics with contractions";
var content_f40_1_40982=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Hemodynamics with contractions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 672px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bonica JJ, McDonald JS. Principles and Practice of Obstetric Analgesia and Anesthesia, 2nd ed, Williams &amp; Wilkins, Baltimore, 1994. p.66.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_1_40982=[""].join("\n");
var outline_f40_1_40982=null;
var title_f40_1_40983="Well different E cadherin";
var content_f40_1_40983=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Well differentiated (intestinal type) adenocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 277px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEVAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0uzN5L4XS00gh74YWOW5HmbNzHduHfGTjtXPatqGoaF4k07/SHGl2Y8l7C3jCjUZnAy/AwqqTyfUcV1k0lxoPhua/gtXuJLeLzFiDhTI/QAk4A68/yqnoOoXkfgeDVNXghgu5mjeRYcMgYkng854x3612UWqdO6V09F3/AKt+fcJ+/Kzep11pfC4i8u6tPLVzJF5csg3SIcZOOorig3iPT9YljWzji01SVgmiI+UHgHByc9etcdB4Zu7hbG5vNTuLzUbK5lmS6aUo5ilIbyyvP+T6cV1I+1XP2a3hkuILaT967nKksCQFHpyOce1c9WVKkpRvzPXp59Dop05yaeyLHiCybxDJd6Xc2txJYXWYRJn54lIG4oT0Gc/nVlZtT0zxI9gsFvpnhKwsUxcyhT5hCgYJPQKBya1LPVTba3YWbTCS1kzHcM3VT/Cc+54/Gsfw1pcGoap4mB1mx1fRL24MarMxaSE9GhdW+UqOQPWtMPJSjLm6W/G2q6XsjKtdSRx2q21vDe+Rp7s8EsqXUexvMWbeMlsHp1716P4H1U2GlTtd2ohupifKjRcB9q9Selczrwj0zxlfRWWnmK1jt0WB44sKNuAVU9AMdOO1WUvZrmJr2/8AtNnHHbeZ5hUeUicggn+8SASP92pr023GyVt/N+prTkpJ3u/66Bq0+o61Pb3LyW/2pkZooWj+6OMqWHT2zXNwNLbxQS+U4gdmy/yggAYJcg4IGMZ78U5WtRqun2FxdGHUb6NZII4lJkY/3iAemOp44rsbyyj0bw+mm21ra7NqxtHcruygxwV7fSkoTi1GL0ktf+AN1I21Wq2KMB1mLSRr3hdtOktfJIeC5bZ52Dg4Jxjp14p/hvxffajY3l8+kqxjbaDHcrJGxzgjK5xjviuolt7DU9Is7V7S0vLZ4/Jktnx5ar1IOOAP51ktqFnZXCaf4f1GKIRMc2pgVUVAQTtC4HTjOM10UuRU+Xl+fl52OWfM5Xb3Max0fw/rkd3qOoaTcWs9zKWk/wBLO6QqDwOOFyeBUs2hTa9oMFpp2rx6HeK4WOBSGV41+6gJ7gZ568069uoGvrmGaO4aF3MbS78Ybkhgo4ABB/8Ar1z9reyiK1uPKAuY1EsrSLtAYgYXt0HpUVcRUjKKtu9L6/nc2p0IOLd9tyLUNI1BLx4bwTS6buTPmdQynJ56nPQ9QasTaemv+LNI1S+E6WWkeZKkQjJUsf4ie3TiuiutVm1fwxcCLUILS8SXeJJPlEsYH3VPOPcVzes+MY9H0e20yzvF1LxDqaBUtoedm/jzGI4VFGcetZunNT9xpSemnRL+tzWMlONpLRHdxeIw1vJb6UhjU7t1zId2GA5yM5rN0zxHceHfCGranrccV3cQRPdGawtzH5kZPyjaeN/qeKydOt7v7bazXKBYQi7UjOPmAADHHUEc07S77+zPHMqW8rXK3A33CuuVRsfcyPr36cChVIRjd7aP+n0JdJydluV9QsoLjULLUI9QntigS4Ochl3L0x3HPQjitPR/Dto2qWsf2t5JJH6+ZhmXPY9vUd+KXxXpVv5sN9CJPOWOQRsBkx7sZAPp7YPFceutzRahFCRcW4kI3yBgNkoBA2lecY7+uBV1YOtSXJK9t0Kk+WTvpc2fG4u9MjuPs3n3tzaqVW1E3k+blsAFjzkAg++at6azl5Bp0LXF4sWCzEvsHU5IHJU8Hp19qxtTvbfWtWhsb+2murmMKVMyklge+Rya3fC+vvY315YaLpgnkt7g5hGR8gGCQf8AHuaFQU6XJGKvve/5hKo6cuZt+hyN6k+l5ks3kZGfMiXE2Fd+4BPTuePao7uSB5BdzB3Cpv8AMhX5nboFHcD/ACa9c8XeD9D8UCyu9Ut5Umt3+0DJ2EHvkA89q5uDT9ImijXSdKu7nzbiSKe4uZDG0BB5ZU7g9iOKyqU/bpSteS+5L7y6eJVPTp+Jk6VJJC0L25isbtoyOeS5HXGP17H04FYA1fUteuzK5S3tIA2ZZcESOO2FxwMH866e/wDD0tlBubE0kCytDt2mRVYdh69uvviq/gLTmvtBsbu9h8lET96JcLg55znqePwqoQhBqcNX1/4A5VHKL5ju/DthDoGhvcX0yPq2rkSse4AAwg9lX9a4vxfqEd1A7wyrK0PMW1vn8wHqMc9zXT+JbxLbTre5VEnkwUt1zvyuOwHbA/SvLrezm1e8e7hjaJJP3pmUhSwXqACOmOMHmtIrmftKjt5+nQxgrK0dTX8KWd7q+oiAxXAtXjW4kuHjAiQDOSwzkNnoOp59DXpmmaZokdttWy+3DJj3XB37uc4C/dAz2qHRo5LHwtYxCLyRPCk0ylQMlhnbnsFyB+dFlpmo3ksElnH9mtC5YycYxnqF61zP325S1LlK2i0sbNxqZtQ0MCRoyj5ILdNzH2AFX9J00iwddQiR5Jm8xo2wwU9hn196dpOhWmmyecoaW6wVM0hy2D29hWtSaXRGTl2PE/iBY6fYaqwVJYri1n+0xLtKrJuXsRwcdMH8q5Gw8R6vLrMMNtpjxafN9/gM3A4C5ODXp3xBNunii0aGKOS+e3KSkAsY1ByvHvk1w01lb/2zb+cL0xdN5YAIegwOgPJ6VtQq8ydGS0/rzRs4JJVOp2dlc3/kSCzu7kEuCnygMAP4TjqKG1jxv/wkBkuLfR4PDkcI/e7s3Esu3kKM4HzccjGKrJ5tvFaWVh5ci3E+PMckAoASWJ4xjB49qqSa48muXekQWkrQ26hpb+YFVlkJ+6vooGec9qKTdmopPT+vmTNK927HUWN7deITc2cuno8cW3dMXCgk8/54q5bW8FvcI8EaicHBcc8eucZ/OjQdRjlsZHhRERAWcyNtXaM/MD3+pri/Emq6Rf3C3Nqtzd3Dyqm63lZEHYHAIyPyojD3tdCW21ZGx44sX1KGyAlty5kP38rg9OPzrL1rw0NB0cakQt5qAbakjHKxnGSSvc8cVsrpg1XwzcWLar9jv3XC3DqdwQntyD0GMg5qv4R1SCTQtX0dZ5tROjqiedMp8yZgOWwc9x+lFGnF/vI62evoE6ko/u3oUh4m1C28K6gdDVtX13TUi86AMS/zcswHfGTxWlpun6drepadrWs6Z5etToFTAKuikdGHp/Srvhq402F7q+srO3so75FlafcUkdh2ZT0PJrM8X/22PEmi3miaz5VqpPn2cdvvFwTnAaQdM9PbGa3S5pOK93fX5baGbdldmJ44v2h+INlpCSTTW66fLPPpgi3QSIoZsyH3YKABWzo3iCF7TToPENjGbe+MYS2aIOgkYGTBB9Nv6iprW61DS/EOmWx0mKf7Qu28nkfLIDn5EOPmxxnOM1sa/a239ofaLmKIW8DB0diFRCBjJOeKKkoqME1olvf1FG7vY5rUry+s9blur+9uLywnuSYY3AURKw/1fHUcE+tZeprc3JnlS2kt1+/GFA2CNeSAD0J7n3NZra9HbXENmENxY2M+Unzh5SRxtQ/eA3Ads9vWtKC6gt9tjKZW3KfMJj8tChOdigZ69/aueU0/fW+y0/E6o0nBKLWj3KumrcalaQXNwArylp2tN374KMbD6YHHQ+lZirb297LLIX38BWhO95B3yo6YPc1tX09jaxfbohHPNEpW3iYES+mwAdfzxWPNp1pFpNvca/CReeeLj7HZyiRt54G7AGQPSsqc6dNuOuu7tsayUpe9+BoQanLY6rpupR2VvHG7eVCLiQF2JHLjg9vxr0nw34vW91qXR9R+zx3oG6LymJD8ElcdiAM15Xq1vd3Enm3IaKOAKYVY7HDPwOvIJ9q2LKyTRNIFuib72XAM5yG3/wCA/OpU4RppQjr1CdPnb5mera5r9ho1r513MAD90Dqemf51w3izxPDqJa3RnOnFAJPkOM5yKo+Ibe11XSvsiozTQbXSUSck8K2R2GM1yllqQe7aC6a5aVZCrLbAMNy5Bz3x9Oeacac6s3TttqRGNOEefcvQz3F3flo7dGhdgodRhnBOOo468VGkGh6ZrMJ1C9tLI3UmRHNIELyJ1Yr7Y69Kkv8Aw8J7iOWO/wDsqxDq0myRV5Kgr6Z6Z5rI1bw3f61Jp1zq15CkdmgK37qqu4DbixB5IP8ASutKjGcbzaXXv/wxKlKSdl/X+Z0cCW994QvLDXNMt7uJ2EiWklyQquM4JbjH1rWFsdV+GL6TZabHo81nIIltmZigC8hg3XBB684PrXnWo3gmMlkFSZLk4kC4CevzfXAr0Pwtey31iIluS00qFow43bflHyqp6qD2rONWVNRSd1e6fb9DOdJfH16o5ey0traxgS8uhdRKBlwQ+FUdmIy31q9eatq9zdLFp3lGJYVMf2kFX4zu2kA7cjGM1p+N7TURolunhyys7o27CO7tYZAjqnqgBwD/ALNTaVoNra2wfU7+4e6mXlAoUIP7rEHr9KmtTulOWrd7u+v/AAC6VZbLp0scsltLDqcV9cxTxw71kC+dw5GOM57+nrW7qOneHrjT9S8PWRFje6gn2u5xnc2csMc9uuOwqeTR4Dfwy3EsjW0AaUQ8FZn7AN2wRx6ZrnTdxS6/pevavoc+lai/nWy22/zSsS8LJgccg4wa66D5rOMtUundarTr11Oes9dVp+h0Wm6zq1joS2kH+nvZ24jRJsNJcsF4LE+vpWL4c8S3b3cem+MNH0611CeIyi3tYcLHGOhkweCeOKtapMuY7eJ5IbWRtsrqhMvIxtHoeevar2l6O1hpsG+ZJ44vkJWLc6rzwxyTkVjKrSUZKUU307mrpy5k1sc+nimObV7vULPTEtL5IzGs6/MSgH8Jx8i/keKdbyzalbR3txJFcbGRfMEmWbc20g4+v6VO8smnziWWUJBFlioIwVBBD9Mg4GMHIwaZb63ZQXxu7DTbBtVvCE87ycCNBglm5w3TrjOSKjEyv8NmmvM1oJpa7lHX9VfwwnmRyxm53hYYYmOW5+7gV6DoMdpr2gC4FkumXV7G0MrRxgPFJjOASOO9cLY24he4vkgt5J9zLHdffCNnGcHpxzWr8NL3Uz4jvIpruS506eB3kimYu1ttGAxb/aOMD6+lVShz0pOL2/q1iK8uWSui3qUN/YajEk3kvEGXfO0IDOgOcD+8T04HrUM12dZ1BzqjqwMmVEEZjLr/AAg59B6eldneahZzfa5YlW6W2kCsrcrGcZxx0Irzj4i/2+fJh8Oy29hcSgOxAJZE75Y1l7GLkozdvXt+ZUasrNxR0b+GRqMEc8Fqz28BZmt2ZjuOOAFJwa4W30n7Prc18llC15dfu2dwcKvcZ7H9Kv8AhtL7T9Pto7XUp5WfPmztPvDMTywIPYjoK6iPF7p8lnJv/tJATHcj7kh75Y/zrJtUqrUV9+l0aq8oLmf/AABbfTp4tNuvI1aC0EaqsTyKJGiJz8gBPXIGAc4zWBFot3YWkshuFhupkY5Ukpk9dx6knrxjPNVLieXzrmzgkgSSGbMcQkG5mxzv3YGQe+a6Wz0vVb+Sa11ae6inEAm3QhfL56KD347in7JwmnJXW9hOonF2la5o+AtX0pNO/sLWrqykvowZ1h/5aCMnG/bklRk8HPetO68JeHHvIruCJwz42sMshx0z+fBrjdW0KEi/lsrK3s9QuQiSXMP+tkVMfeft0Gfwq/4WdrKwtbHX9Q8tXuwbXyic8DO1vbnn8K61GnNOdN2v0/PbockuaD94sePNCdYLax0m4OlXLSqUuocsWxyFcjkLn0q5o+mpoE9/eXMTy395OSyR4BZMZHPAAzmk1j+0NMg1i4gvIZ/LBuIBLjEeB0JHUcZzVy4166l8KaXqFjpE17c3LItxD5qfuQfvOSf4e+R7VcXJwUI7fd5kPe73KmqeIdK8N3Ub6jPOwulSOKDbuYMRyBtHOSeadr1jPLqWj3Qn+x2drI0rKCVaTcBtH86VvEM1jNd232O3lvIRm2mmK5YlcnaBzgHjrzXJ6ze3VzNHcRXBuda87aqzqSFU4DDYCNoI6ZGKdKPM97efyCSatZHpGleSkkkWfLkmQAM65PJ7c981x/inw/aal40itLy/ngg+yC2NkRmOXLFlcH1JGOnbFQXcF9oenxNLuMjSfulVWKgschQfQelak0D67eeHdYuimyzfy7iTGCJAwIGOuD0rGjU5Kjae19TSpT5oq/U5Txl4Y1XRZ7zVrmUJo1k1sLC3STHlRqjK4OPrk461l6Lrd/cy2trLpcNrazusX+jnKAHJXkkkep4Fe63ENzLp2p/b1ingZT5MSR7mAx3z1OeleM6hod/p93vlZoLZNsm148Mx2/KG75B9Kmdbmv7R79f6/HzNKO1ktUeq+Eby1m022gurmGeWEssbhSqkZOBgk8gV1YwAABx7V4dp1wL+0uY4SJLSIgziMdW6gEdl+vX86zbTxVf2ztNBc31slvdbVjYkRvCT2z97jn2qHFauL0QOk5Oz3Z9BswH3iB9a5TxF420/TVaGzkW7vyD5cSnCn1yx4rzi91651LTlkvry8aGNw21DjcO5YjoMHgVk+J9UgNsl5FH5lrb5T9wN/J4I47jPNEKcqj0WglTjB+87s3NV1Jo9V8+3jnae5jLTNtBY9QAOvr29Kv6DDPqzQnASKEYkDEbEAGSSTk4698fjWXpdje3tjHcaYpuGAxGjnG7jABGOnOaqa9rd3b69H4S06waXT4087UrxMKszjqCT0jXgH1PHrWlGnaUqafe7CrK6Ttr0KfiX4h2vg/V7e4kN1NZEtHFEgUkrjAIB7msrWfGOr6hpVxqV1pdvYaNEV3xzzDz/AC2I+cpjpk47Zrd0i3tNV8TyRaDosl/NYkGO6u0BiiORnac4PsRXXjwNoNu+o3uqWcl5cXK7p97blkOfu/mOldn7iilKcdUv60vpp1/Awc5ydos841maXVNBfSnD2dhM6CPypDmaLb8oCHkLnORXU+EfDGm6V4a8+4vZzcGT7QkCyBQ+1cAFc9BWHqAZNSuLUGK2d2MkciqXKjptx0IA6E4xz1qbT7GSa9Nq7sbLy8yBpMMW/vsR/L3ry69WVTRbb+X39WehTgorfU1rPUJpbNdS1fba6bg72nfAUHAAVR1HPXvXeaZ4XsLS5k1q3d1ae3COoOBKOCCR2P8AjXlF/psMOsWAs7WG7eZgIHuH+VSOF29QgHfjn1rubK81mfVlOo36PFuLLGi/IcA49zWvu0qcbPWW5hNOrJ6aIf4is2kgNnDB51vc5Wb59rIp7jP6iqWgT6h4W8QWcN/qBk0G43QCS4Iz5rNlee3oK6cx6hPeW6XH2W3ibJZDkl1/vKfX2NZMugvceIS19qEj6fGn7yydMqxz8si57/8A161pVUlaWz/r7zCUW3odpc6tpWn4FzdW0UhyERpAGcgfwg9a8c8S65P4iu5URzZW1mxZlKKwdyPkznjHt79q9G1m2sII5hHbIbq6iVA8pydq9ACemPavK7a2lh1iSzi2xy3BL/aW6hDyRz168Vz81Jrlkmb0YST5kcz4qt7SwktryOQobhI7mMzyFtrN94jPTPXFa2l/arvUIA8sqQlS7yKM+cewGc4611nhlNMsoDp17NDKLR9qrcYYzp2GT+Rqx4f8PXOq3t1aWDm0tLOfMdwq5RVbkoo746e2RU05qnH2dr9fQ6aju+ZuyRz2qPLp0V9JFIHmWONlcx4aM7hnP6GmNE90qXupW22GIMxuJS6pIuOQ2Ack9q9rez0/RLdmgijW5lwBIy7ndunJpNPuZZbqWNXcuwAYMMhOOo9u1FFVKbcoswnWU48ttDzHw7pl7q7C7uV8q3tY3SxMxO5QTnJzzgcYJHFU/wC1zpeoXVrCyyMzBmcklARj5pGPAJORj0r0T4iWQg0FprOI+bvG6GIhPOJ/w6/nXly2Ilu3hnjh3lPmicEqQeufXtV0KqlNwnG9wa5oqcXax19rd26X66h9hjLupj3lsqVbqM4zj/OaxbHQ4fCSXN7qcEqTXE0gto0IZ7gsflAH97GBj2zRNF4huZr5NKngks0gxYWWAkaygAcnHIzWtq2vav4X0WS6bS5dd1J5ow6Ww+aM7cEjg9DnGPWtoRvPnv5WvbTtqZTfKuVdTD8b3t7J4jhsNLs4BcJHHG+7aW4I+c9sg56+lWbOzbU7e4GqSmS7lZliWWIBdnOGQdPf8aoaFdW13481IXkbbLC3e5uFkHzgKM4P54+ua09F1BvFelzeJLOKSxsWU2sNsxysx3KVkDEAjaAQAPWohG8FO1kvzf8AWho242hu3+CI5vDEZnMUzRxTQnaBx09vamCWLQZZYdKiF3qsMLFY15cs3Cn2HU/hUera29hBJeXCMBE4Ep84+WpzjJU54+gzWH4X8f2GpeJWl0wzLcXP7mRUthtO0HncxyB+dZ0qM3G6heMdSpyTunKzZ0XhewvfD015PfXUKWMo8xLaIfvJZSfnkfIzwTgEHBpup6yLqORrdXk3yjG9Mfwjj8Kzta1ye8Vmiii3xOCHfIfAPzZJ6+1dLrd8BFY21isdxDDGY5ZHO0lzjLeua1xM5VZ8svievy/zM6MfZRutjE8OXN1dalJZ3k4uViHzoq8pwMdv5V0mpyXT3mEaGODja8mVK/LyVI75xWbZOuiq95cyRGM7S0Sjkgn5eT/nrS+LtWktNRggDRAsokdVUsVyPlqFUjGbnCOiQ/ZymlGTMu412O1njhlRJbxIxukEZcuwH3lUctjJJ9KsPreoR61ZxWz+VKsYlkdBtWbDHKkfTBqlpVlNrmrLFpyrLHkSFiuCrd8t2HtXpWr6Jp9loVvaMB5pmVhKCFZmzljkg9u1VUnTdlTWu7Ek4yakU9f8jWdFWaexSUSLiXyW+ZExycj0z3rz+x8IQavcW40zVy+j3ES+RdwgO74bHAPHXO7PpXcWlhFaakDpN6IFkXY1nIhO4k5OGXjHoMcZqvpGi23gzw3Da2cvnG0ilW2kblgWYlcj1Bb8cUQl+7aT1/rUnVS8jkrXxNYX+tzeFbW2F3d2eY7sxnEMe04J38E8+n0rQ8VWlzDoF/Bo9tDZW0lyjgzSCM3QHUZ5O0cGqvhLwdbeE/Dkr2t3FPqRuBJqBaUNKpJ3BWA9c8j3PWiW+uNV1iKbUIPNJHzKJdmUH93+6uMcd+etWpwo1E6ey2vu/O3n+Q3B1Yu+x2EPiLSZBBoc5khu7iNWREgLBuMZZhkHJB5PWnR+EJ7qDcbmMwFT5e7O5R1HPPA9K53S760L3Qs2C3NjMm+MqdhTA4VjjPB610P/AAkTxWKW13L9j81PMEvUqM5wB3rGa5ZpSVmhpNpuGqZ5tLr3hDRNYmtb7WZLeS0kaeRTayHDMQDgcdTzgfWu/tVjl0211KFJZreclo0dNpC9uBwMnnBqj4jls/7Ya/1rRNEuNFjhWVtQeHzLiVlBxtUd84xnjmlF1qWvw2VzZ6xY2fhW8ULHEY9lySCcqOcDkHkZ6V31IRq8tRfNt36bKy3OaM5RTia76HHfSvcanpiIAyvFcpIEdML1JHscY54puq+INH0O2jt4QN74iVAcYxxyTXRTxWc2kCwa6jlEaBdyvnHucd6wNf8ABwvbASWu2534VopkUg4PBGehFcqkpNe0ehotNUtSlFdK0r7UYk8DAzk9Me/NVtcsbKPXNDuLy4lhdGxGkcBYqAclsjhV9SfStgaYuk6Re/YrV7jUbG3Lxw5AEjYyFyeMnGPxrlNB1aFLiyPi7fp3ie9RzHo5mMu5DntjK5HYntW1CD1nD/g/8N5k1Z3tFm/o19a63fh9LuzdWSs0MzrGFjDf7zdT7CsvxvJoukXVhrWq65qcOjRobb7HBFlJnY43ueuB79MVqxahYaTNuuoLaFE+W3gTAWH6DofeodbudA8SW8llqVq6pExRkKn5SRn5fQ88EUoSjGqu3lvb7huLcLkNxothqGrT6hp+oRXJto9skUcgdkU4P3fT3qLRNT02DWpR5okcw/JGuBs64Zv8aq/DzwTYaDDew6dqE8+pmF41uZxsjMbAbR15xx+tU/EllD4XRr7XLlrW1LbVUyGQbiMYUgZ29Tz61NXDxqTcVJtrbTf5FU6zikmrJ7nQ694g0zw/oEsOsXy3dzeTecyQKZxEox029D0/E1J8M/EFh4hkuZ9LkIs1k2zrKQCJABjI5wcYrP0TS7G+jtLqSOGWx3LIq8qSMjkggY6dPat/w/b6PGbqy8P2tvZ2olaRmQgtK7HliD+Bwe1TFw9m4te9+ATT5rrYk8UeKrjR4Gaz0+XWp5bpIktbYH93njcxAPGcfTqaqx+Jrm88V6npdxot1DbW4ZV1KcKI2cYwApGWBz1GelUtQtJPDWrX17aNOk1/Epkt937neuclO4zkf54qhbSXt9OXu71ny2NqDKg4yQMenvVS5FGyjfTf+uwoQk9W7Fyw1u5XxK0ctiAgUxrPBGVMnPRlHGOc81m654IuNVv4ZLKRI4hnKOpGMggZ/E5x7UnjvWNT8JaZY3jB7m5nLQ2lnESZJGYAg5xxgA5+tc4vi3X9OigS7kuInuGbzyfmWEjJBX1GccjvWPIq9kkop3672N4t0/eTv/wTp18BazKyB2W3ijJDENtWTjBJAPT0z0q9dabDpNqVurqOZ7eMusVtAC8jdRk9MnjnFQ6P4suTMkmrJJeIFAIZ2UKTj+HoT9RXS3l1puqs93ZIsV7HCxL4Ayg5IBHBNJPnUVPZaESUoN2K3kXuleEku2gCvMQ0yREsYoiMkcck9iRwBmuGGsG/hvHvbaK4s4U+0NDHGcnHIG7+L9RWlpvjrxdp1zpNtq2lWV3BdXbQebbMzCGLjaWOOuCeTwcVp29rZ/8ACT3CmSQSxQb1toyDFHubv3J74PArrVFUb8yTvtb1MVUcrWZnfDPxhJr2mzw22k/2N9nl8tkx8rE84B456fnWuttq097vvrx0gkTYDGPmTPf8M9qtXSPcakZWSNYX5ZY8AKccZ/Ks/wATXnl6rpjNfSW8aArJGgyX3DAb3welZO1STUVZPpuXflSk2ZD+C5rSHTmdLa5uVc7vnKqf+mmfvNuwCR0BJ61LrOomEbbGO3EgIjMTH5oycDBA69+tXPFV8VWJbaZkESIoQYIA68nrk1VtbuG4RkiJWTO14348xQB8wB7c9faskqsk7fZXU2vFWlLW7IvCugRPqt5rWs3Cw6XYRb2LnAUjk4PoAKq6brdn49a2udEhngSC8MKMz4EoHzZwKn8T6Lc+KvhbcaNpjf8AEwZhPNCsm0yDOQvpyOfwrR+HXhq38OW+iaMdsS2cf2y4lC/6yY8sxbsBkD9KupGEqF38Sdkuy7/MmM5RqvsdtcXttHotymqqiiNG3xFtrLxzg/yIrxrxFqt3P4m8NLps2VnQNdLCOFhVgFU/rWt4+1S01PxELiKeGY4AhiZ9oVVP+sJ7An8xiobtIdPsoryUiLUEEjzSOwES45yMYwMDOKmnTvBSirt6eSGpcjvJ2Os8YajJq2lQDTRsnMqpFnCsjBhuP4KDzXDa34i06DS5wbee41N7po5UHytAvAUsRyRzxjqaq+JPHF3ZadpVlZ2sVxql7cLJHJCgYpGP4wg+9nJH51Z/smaee7vbxAmqTXhmjsGfYoi27UlJGewPGTgk9DzWNXDunVjzbP8ATQ3ozTpu3QjSBbmeGNtMmj+0lI2EqbiQcDkdua+gNI0+DStMt7K0jWOGFAoVRj614i8f2LT3uLy5D6hA6rbwwn5N2AV65Le7H3r1nwx4mt9bj25WO4C7inPAzjv71KgoTlFb3M67lOnGS2MvUblFmuZ2mkkjWQ4OMn12gexrovDsHlWCyn703z4xjA7D8qLvSIp7qOZG8vaRuQKMNzn86TWtYtdItHklYEoPuKRmtHNKOpz/ABaI5n4pat9lsrW0tpljvZJVdGZSQgGck+3XjPcV5hql3Jdzpa3t8HSM7lMNska8EHk4OTnBArf1ua9nuLmS9uFEtyAUidFYYP3UU5AOetVrO0ltIYSt1bmPaq7PL2Y9iMmnRvRi68l6G9k0qSfqWtAvIIr2L/SLl5p0IRmZ8ZAJJIIx75HtWl4givD4UvLvT97XsblljD+W52jjDdc8kjHUVg6nbWWmahpms3tybi6itnghiDBY49xG+Rh154Fa6TS6zMsllqEWJwSYkfCE4IAJIyfajmi+WMHru77Xvew5ResntsjG+HmhT2jT3l5mH7fGxukK72Y8Yye/9TW1/bdndXUel2sqJFazCK3hWI4dsZ3+49e3FZy6rrVhHfQ2+mfa7lY8QxeftXzB2B7AZ59aWwa4gsU8uBIzAuyWXIZw5GWG4dFHqOtbVKVSVZym7r1+75IzhUh7P3Vb+tTnfGOlJJo+qadcW5meTY72sUgWVQeTkk4ByfyqnoWk6L4X8M6nc+HodQOviwkaJpmE2JFXoihQGI4r1K/8PwXOu214u25vHhO2T/lmVJ/i9elaFvbadfaZcyWqRyrDmFz5Xl47FlJ6/Uda0WJnaKWq0v8A5Pp0MWotWa1PB/hhp13FG11rokupJH8+USSbVaUHofp0x0zXolz50rzzsbO2sJpBKJLjgwsVAZRggFcjPX1rROm29lqEd1pjWMmmKhjmEuN6MDnepHXuCv41DdX2m6lapLeKn2TcTFN8rgYB5Yfw85GPWsasHUbqx1k9W1+XkbwqK/JLRbJFrUPCD32jR29jdC5uFlEzSyAqHfknJUY4AGM8VyXiLTZbi8XUJ3cyYwWWI5KjqDx04rp/CF7c2No2+8JtZcuIJj90eintxjisfxTeXb3sC2+0wbirhw3yqejKAOSPf0qMNKTtBvl33/rqOa5W3a56L8OtGXTNJacyiaa5wxYHIAA4Ud/zqh8S7jxBb2tv/Yf2Ztzku8jgbABwMHqTz3rU+HPnHwzGbiTzGMjYbBGR06Hnrmp/Gfhz/hKNM/s+S6mtIt6SCWBsPkHJH0NTh+WEtdUYzbbuznbRZIdGV70Ml/ckMPKIy5PVQeo9z7VLY2/2PURbTL5twkP2hlY5Ct1VVHc/Ln8q2W0uz0uxaS7CzeSp8ncSMADIGfUkV5lff2heeLbO/wBUYyW9o32hoYW8sPNnjLdSoHaiEb35tF+Zq3zKyLug3Fnreg6trf8Awj50i9uLoQN5gKyTBDnOOOeSMeueapXgsTZu6XFr51lIJpIvK81iASVwR/GOnGTkV1njDUre80W41CdvKijQFI2XO1s8vgck4zXGeGNMg1UpK1tcE3Eg2LGhQR45DMwwd3PU+ldDqQVT22z7b/1oRGEnT5HsUdG1z7c7alf+fBbM7iBJDl1A5OR2JweKggurxruRL25FrcXLj7AHyD5TAbQGPHViG9DXQaz4ZjtbazZ7ITJHLIWeGXeoYZ2+/fGa5m5gvrwSQhLy3uvNEgjKB2ZAegBHKnvj1oeI9rVio2j6lRoqFOTevod1B4ZvtMthca7fRNHCp3wo/wAj7icqQeo579TUmr2+gjS9Ou7lI7SSxVooh91UGcjanTPvjPNUm8nTvCq33jSAyeXINsZUMygnI3444IrmCw8QeBtD1LUJdr3e92BTevzuSgHuFAxV0qcoN1JStG+66+n9dTOUlUsktTtItWl/4R+8l02F5plj3LBFCGlcgcADvWH8KPHnibXpb0eIdNbTbWBjHAzqwYSAjIZT+vArVisLDR9PsUt9QlZUhfEYbBfJG3cuMfKO/vmqviDULhYHnhM3lvkl1zuT5flOO54zii0fgSu5bPsCbkrvZFzxN4gl1XX49BlE0F5DIl0+wBYp0AO1A3Xk9M1iDT9Zm0r7Xra2Fr4tlZ/LngjDNb27NkRFh3x3FdX4f006r4Vt73W44JrsMg3yx4kHQr3yOT0zWJ8QbiaG9uZZROQuBtjID7cDpnqfarUmrU6fTf8AX5MhRUm3MzZ9GvHsok1Hy7yEW/lzzBeWwpBOB0JGKbbaXqrpbm5SKxspikguLzgq+3kDPGc5w2enatrw3pdvfaKZr+71EzSnaI97qoB424zz05zzUB1aWKWAanPaXBgmeGBrpS+Vz909t3QZHpXBUrVXUSjutu52wjBRdyjaXmnC/tbKaRp0tDuQ79yluQckdT39K6LW/FyQ6pZ6Xf6bqtzFdzi1gu/sYlijfYCso46fN94e/oazNcS8vo3l06SOHdhHi2hvLZTkgADOCOh7g+tblrpl/cada32malfWV3axGMRRvmGQ9SHQ8YG7qPSu2CWk5tWa89GclTX3Utjj7yPXfDGrw2+palGtm7y7Lhtz5HLbCvUD2556VPfWNtZ3lrd6Feq1kF/f+WxG1sZJx2zkda67xDeadqHhCxm8ZBI7lHAWSJsfvRxuGP8APNZ9h4X0+x0wXi6hNcRqA000/wAm8L0DAenSueVOUU5Prp5G0aqlZdi1bWd3qcXm3dxNb3cka+XFKFKcDjoM555AP0rzzW7u/wBAurkxbLa1SfbKAuGBb+LPUZ6Z611h8RwXmszWLXltZ3EmHFpcMcgBeCDxgkEHGehFZXiS2l1RYwLixkZVKrOynaF4wM5+c56ZOKwpScJcs07M2snqmiBtRutZ1CGGO0mub2RVKuse4gHI+92A454xWlreoS3msJoNnaz3WrITiCIDZEo4LyP0Ayen9ak0SGx8OaXeRW8lzJeXQEcsUL/O+M424+6OSc57100MC+FdMto4cSXWox5knbmRnPPJ7gA4A9qUrTltawX5Vo7mVJ4G16/0q2O7T7W6tyzou8ylZCCMg4x+ecVzk09z4IubePUVeB7eMzbd27eeQSDk7gxJGMZrto5byF0kguHST+Jc9Tj/ADxU3j/SrPxb4Ba4uZI1u7dS8UobAEgOCh9QehH0rrpVdFTm/d/I5ZpqXOjFm0jTNFvZfGthNK8txbrbw25lJgXPOAuOg5bmqWi6zetbTajeiOSYyFGnRgWm/uqo+hFUtSgm0/wtYRX7yTInyiNWKbW6n3+g/Osc30bJBBMsgV2PlvgKDj/WgAdCoB5IyR3q589Ve7ql18kVBQp6N79PM7vS9djMLXV3GREOZIwoDIMHryc9KuandWt5C0SQQgPAx8wIGwowBtPQnJGBXE2kVxb2lzDFc74/PEQmSLzAu88Z5+bHAJ7ZrY1e4hbY1oDEI1O/YuFB44GOvQfTj0rBwavOL0voVZXUWtSlMu6PY7yyxoAChTY5OOmatW1tDA1v58uYpkw6sMSpx04656dKx7a6u9RdRFp/nFCG2sWQZz13dq7vQPs9rpklxqMtpY3ynKs3zFV7hSSTn6Vz1JXbitDdLljd6nns14Q11NcC6iT5Vto+VbYM8nHOSemR0qve3GtTWVnFq+ou92kYVzGmxAcdOOoHv1rt763h1u5mV5kS0CgpOhCNuzwzOeeuMCur0PwlZadGvmQi6mVs75MkDPsf/r1UatTSy2FLkinzbs830Xw7dS6Vf3v2FztYhvOjG2UKBtILYyPX8a2r3TIl0hLfVIZB5m2SS4lXCbiCPlPpjjGOleha54i0zRIgLyYGYj5baIb5G+ij+ZwK8g8Yapc+I7wS34nhtSdtlFsby0PRt2OGf3P4U1OekIy2M4rnblKOhgeKJTZ3eixeEraWO/R1h+3NFvitUbqwJHLbc8VtaLb36RX0N8819qtzcSPDc+ZGEWIDHl8dSMZwBgZ7c1U0+eystUtYNXs0vZJ1KW9r52G2hTudgDgAep6Z9aSfVLW0a2h0+N7WaOIoium+Xd3ERycAjHJzXRLdUp20W/f5jjeznC++wkFiDYsfPa81NowwgQ8K3u3oBgYPvVWO9a082LO+7KlY5VIG9upPB4Vepq74LkTRJHeGBZdQuI2e9WVeXBPHOOOePzqK9MV74q0+y2RwtdlhMPLIEYPITPbP9RXLVlCL5JJc3dHTCMpO6vbc7rwxrmvXGiCc3iPsX5RKh3FQAAWPqcZ/GuQ1/U9R1G8+WNH1Ep5rIwzEqkcY9e3J/Kt2K1a2troeRJArTYKoSCyAjjHfoeRxisG606B7yO+itmEx/wCW0hYEr6AZ5PartShVSk3L/Mwi5Si5RSj/AJFjTHR4JLm/b7P5KEgxOQwIIx7Z9uau6OkGmafNd3A+0LMzFGJyS5znk9ufwxVVNAvdV1aGK23CFo8xyPgxptGSWU857DFeg2PhHS5LC4SOFpbkpjzZc7GY8kgehI5pTqznzXVhNU4JO++p4lptzPbatdX9zGrwA7izxl8AcYTH4V31n4pt54zHLbEI0W4EJ17hh3HbgjisOSCVbtoFa4snhkKSxoRsQg8new6fSuk0Dw+Y3L6hCJJF3OJs52R4+bJ7nFbOtSqpJJ+oOEoaysM8YXF3pogTTLCKK+v499zLIM+VxkjjqTnA965aK4vJWi+1kxx4Hmq/ueRx9Aa7nWNdHijw9qDaHHKj2kuQZV+8uOHGP5GuCnmnszGLy1Et+5DxO/3Gz1x64qKtR07w5bS/GwYeKnrfQ27TW77StD8uOaMzu4CRq3ygdMc+pyapf2nqdzcSKr3UwhZUcrtIcY5wDgZyc8dqwbeUXVzFFd2sjwCd3jePa+OcqT3xnPI7Vo391a6NIun3ltJK05Mh2AEuo6gnPA6e9RH2VFcjeqfYpxlPZLUQ38Vu8zwiNIpXaOdWQoYnXJOQeQce3NMmmhu7tIZFeOxIWWSItwTj5R7HqT+FddZJ4fvLxdR1mF1vri3Aa0RgUwCcEn+JxjH4kU3xHLZatp8c1vpkEGmja6FTh2yc9B/KubnqO/s3a/4/I1ThdcyOatrafVr4xm+JtkXYTu+aRfbtn3q94h1TS7CK2S6Ejyj9yvlq7OSMYGF6k8e1QzsnmJcW0E0UbkR/MAqqemSuc1oWUPm24jnS3baSZHkXBb0OfX/GuiMnzKdXXTVbGUlo1DQ6vwL4hsLWeTSDcKm0NIA8mQp4JwT656HvXX3mu6dYorz3UQDfcwwO76V45f2DCQ/ZN1ugYEhVAYDPftzVYaJcanqEdxbGKZpZCjBmKkKoIUrx1Byc8da2jCCnZuyf4HPON4827NDxjrep+JdSMcX7mytJW8tIxvDEd3HcEce1UXvvEB8fW+kx6dD/AGJHEJZ7uQHLjafutgr1wMV0L+BdZiuYXOri2tDlpYok+aRuw3fkTWrJp915MNizoscMe2RlcF920Dco9+etbusklFxTVnby8/UhRV207HPeK9Re48JrGohUrOAyEEmQbxgKwxg44qv4PuLjTL2GT7S01zGP9IkmY7I1xwoAxufHUnp+NZniGePS9ct47WG01W9Iia4R7grb2ar0Z0Ul2kPOFUAfWt3XfAC6nq9rq1nqlxp1oUZZLYzERurA5Gwc7uTkmoqUXCHLfR6+v9efqaQqwb1HWni6TxBaQPcSQWkk53RxohIC7iFY4OQG69MDNX7vULTRfB93rtxqNlbX6L5MM10+VU7vmx1y3Bx9K4+81bw7Y6RfahdPd21hFH9ngwnkyTgf3A3zYB6HHasv4X20njW3h0TTPDccPhSzdrgXt+xllE78+YNw+ZvbpXVDB8kFUqXst72+5GFStzNxhoeh6Vpdv4x0CcG5lu49RtxFJJnbhSMblX+Huc9a6yDwZpcWl6bYqJltbHb5MQ4UYUqMg9Rgn8ayPhdo2v6Dea5b6vFaW+k+ePsEcR3O47u7ep447VlfFr4kah4Oe6mtYrM2Nsinc4LNJKf+WfoB0965KvNOXs1qr/mXTTTvE6i80HRZZxpe5UuTGCQ45ZAf5Z6159eo0BuwL6S5hEzrFsG1WGOGP1xwTxzmvQrHVbfWdG0/XbVot95ZngdiVzwT6HivFb3xDHY+I7TStNjGoyTruVI4SXkz90Dkf4YHWlSoOrU8138i1U5Iep6D4F1MQQNJdFIFCxySJK4wkmTwW6f3a0/F+nrqiG6kmRhHJ5kiRsCrAdic9QcH8KYvhozaX5N/DAjlklNvGxYrIOfmbufzrkdb1nTPhjphtJoJJbW6LSZABwWOWBz7k+tXy+392mvefREJ+zlzN6GRrXiO18OaQlzDeSwyPsMuCzF1PO3uF4JwQK1xq+gaxYWI0u4gntlUN9nCZIOOM54U55J681gyTxeKkM0tkyWsiYhR4fLk8v16d+vPat+z0L+w7K1is1mgKRJKVwNnOTtHHXIxnrg1grUWkr8/rp/w51Ne0WuxZjsY0Wa412+n02yKEny5QJJDnIUZBIUY/ACtvRPFNnbWlsYLl5rMZChkHmkcjAOAOuOcc1wmoxapqeLK7EK6dKgWZC2MZ9COTWxqWjS6Votlb6eoWNVwjZBYgHPOfUGt2oqC5patmNm52todLrGsae1kZ4LH7U9rE8yRToMIAMllUDJJz/8AqrnfAviifxSsLanpU1tbTZSJOgwO+O/15x60qyFdMy0c5uo1LRyAbWjJ7B+nSo9PjniUyW0RkHliQ3W8MfXbuOQT1ziueVXSVO133v09DWNJK0lp/XcTU7n7Pq99KYMKrkC4OwPuXGxCMbmyDjHpity+W3WzJ1KC7itvL3Wu6E4MnJCHjjnBGcd65bxnB4lvtMsdc8P2edSuB++SEpmJRgKcvxu9W7dKd4T1fxInhuK112782SGdnNyZc7k4KqpwMjryR9M9a0qU+alGomk9kr6kwdpOPTq+hTsre40yGTVInDzLCCUOMMOSCCPrz7CvQfCfivTdSsf7D8STQrf26D94eF2n7pz/AAnp1POK47T5NPs5YZY4WFtMxMpkkZ2kznkEHAyTXbaB4Z8ParZrcC0Z14BR5GwTxg4zz/8AWqYzTdqq1tpboFWOl4vqSzR2FvMzT69p3lL8uE+dyCcDIB61g+OrO71K60OHS5bTS9Ftbnz2aQnzJmxwQmMYPI5Oe/tVC4vNN1HWtY8O6Tb3OnTRLIl5K6MJIkPAeLAIPPrVj4cnSNV0T+x9GtdSFvpr71vtSUxmaUE7uTkk856Yrshh3TXPLp0t0fX/ACOWVW+iZak0a5uNCmWSaO5m3FkaHIKAnn9RXJW+lW+lmZb3c0cLGVBHn94/pjt6Y7109n4Y8c6d4r1nVra4srhLuNILZTN+7hQYycEcfqad4y1nUfDvh+O61Twza63q7TrCHtXLR9ch2UDIGR+dDhNvkpST5umxUZxXvTWxQ8Ovc/Z/Im3bmZmkGNxbOSRj61pzxx3em4jAFxCcqig7evO71b+WK6DVL++jjsYbO2S0mKJd3brApABHMeM8E9M81zumShNPkXW5Et7q4lkn+X5VCs5wv4KFFck6cVFyl8kawqSlK0SG1vJYmKRxRqf7sh+bHrgevuayJp5Ib24udR+ceXvUhwBnsoXsO+famOk0d3eRwR7BHGwS4jbbswSeOMbQMHPNVruVGjjjaZby5ZPO/djKIn94Dqx9B09qJU2leC5jWE1e0tDofD3ibQLHTJP+EjjgIubgSw26qX2xovDt7ZyefUV1Nt4zbWllaCOaysgPkZvlkkHrjqo9O9eOW9vby+KopJo5Hjt8AsADtOCRnPrnnjtXfad9pvobq909BJLI2wMUBEZVQAdvQg+lZUUpJKTt3KrwSbkl6EF3caYNQVDIoeXc0JUgSOR15PJx6GpYrBX0svdX4itySoSQ4LFf4lH4Vai0yO2ke41y6js1VhGPMVQSGOeSchST7in3EkGqNJp2lwzRzWjHzHCOodOMhH/i/DjnvXRUoqEH7HXv2OaFbmklM4fTtDhvdTkuY0t7R51Vdp+V5COCzHqM+ntXRy+EYtIukLyRzxSgEESkc+o75Fa2n6romkR3kl5YfaL53xC843Mx6BeR8gHc/jXKy+LfDn9q/wBmaQYb7UmU5jtv3pU9yX52/nXJGdXW/vNnXJJtJaJGxocV1d6tFLNIsmT5SFo/kmgI75HXPTFO8QapZ+GtLjW7sPMLyhE8wMcOOM7hyMVRshcJb28dxKDciX5UAJjILcKq5A3YPXua07jRbdJUXV7KUy73kgSQMqlSAMEZwSMZrWTpqEZSS9FuZtS52k2NguY00T7ffyLYwogMpZjIACckqe/Hb14rG1PU7qbTpLmFLpLG4RXt3aPbIYycBcHG3JGeua6Dwu9teNf6Zp721yyKsj2t0BKIo92MhepwR+FaWuWbnxA11dwtLDDGiwwgApuz6epOAPSqpunTSfLu+vYmpzSk432MbwXfx2V8r3xeK1mjaAySNk5PTj8+RXpJ1SBtAlksb23vHWI7GhYHtxwD2ryifUmgkuzPYsl5Mm95whUR4YgID2x6d6VLCzSyieCR1v3cTSGM/Ku45Kn3/rUVYVY3Vt+3Qdqc7Nst20oF/aQeQyxkqzy7NyuDyRn3B6UfEr7RYeH54PCt3fWusTFfs8WnRmR3Ctk8dsjA9OtZN/YahdtAdLuHaO3Xy3gaQgSDJxg9j6/hW1o8up+G9KjvfKjvdR3ti3lnEaxA5+856gD0BrppQp0nCd1ddP8AO5lVlKd4rYufCnwz4vs4rjWfHOqQJLcxk/2csS7bdfdgQAcdcA/Wm6v4JfVNHjudIvftCudyrG4+Q8gFG7Y9KqXfxB1S50eePWLK1t0uUIiWAO2/0XccdfpXPeBvEd6bhtQnleKBUMdvCo2oT0zgDoOg9auo6k6jq2s1bbb0RNOHu2uVmtrdbe4TTbm9ZrcKkkiogIOOMAnqB2H4VTsZUkKEXEb3CyMC5bJZeeD78dD3rT0wWes2tvLPOiahflnWLd93HAG3sNoGT61l6Lo2peJfENoPDmq6U1rAxXUbbyw0vU8HtyOOx+tclBTalK682+3/AATprShHRou2gt5UuZb6CS7ukYxK6thoEBBURj26k/XtWVfalNfrLHbyNGQSP3I/dy8Hayjvu9R0NaWpW19p2tyPp2nXcumwgrqN7M4gitlHBKKRuYkenXAq/wDDuK+17QLC50iwtpY1mcmSSJg2Bwj/ADHAPfFdiwypL2jim+7ff8noc0sRzOyehg6jren2f2WbWJHsJVZIXkeIvlh/CiqNzn+Vd1PZW+lW6kW95q0gx5UVrblmXvz6V3mmeGY3W3n1iK2muom8xQIwdr92z/e+ldHFGI+IwFFZTqU5KKs3be737dCFKerWhyWlabPq9gJ73TU05pTkxTfO49PbH1qleeDdTnuUfTfEa2caDbLGlqjHd/vHkcdq0dQ8e6DZeLYvDkl7GdUfG6EH5lyMjj6VznjzxzcWO6y0NrXTL6eVF+2XqZVgQR8oHVhx17VVOFRztFW9V0+dyZP3btnW6XotpprF727uZ7iKPfJczMQm3J79OMVyV/JBqkMtpFcy38DysUFu7ttGeFds8A+lOudUa+8OwaZrWsLcXTAG4ntlEayMOSB2A/wrIsvEmn6Jb3FtolnHC8BBlknO7exzzuydx70o1YxXNe8r/IuNGb0toaPhPRvC2g6lfy2cVi2tTAyXSwy7mQejcnv2HSq/iHxN9htUvLu382RpNkKqfLRc9PUisjwxrOjWsc8X9lWSi9kLs1lB5fmsT8wfnOSa1/ElxdGyjTw1p9g85lXzlvpSI4osfeBGcnOKbkpVVz3s++g1Fxi7b+RS8KWek63Impa1o1sb5G2q7OWYE9ueMV6xoEFrbaaiWcKQw5PyquK8b0+eK2guLm5t7VIhc7bY20xInAJ5YYyMHj3zXbDxL9o0MQ23+j5AEk5HyKD1OTRilabs20KmnKKuHjbxIbiR9K0e8aCUcSXEfVcdl/kT71xviTwlY6vpMVvqbKztMJmSUs6nByS20859KzTHZ2fmXTXatasxkjdFLZbozk8/LkD8quKl3qFvNOJmOIyheNg+1iOGA4JxjOPp1pU48klPmskaSXu8iRu+JI0mi07T4PLisY2SIiEbVXoMDuB6065vNT061k+y28UU6p5KSiAAxqR1U+px096s6Ho12unWtxqCsFiQBXlGJJiVxu29hzn8Ks6pBLbWELG68/Djau3rxj865lO0npc0cU0lfY5U6hfLdve3195BjmAV3uCAkfHz4Ixk8/KKbqXiaDV7o7oLS7tftDJbYiE6hwOW9Otcn4n8P6h4j1+OK6a5mtIiGiSJPLiQdSzN/E3HbgDiu18E+FbKK3VLudo4WO4xxrtT0/Doea7KmIirNRu/LRL59zONCybbOw8LXE2p2MhuEtl5CiQRgNs/iAwPpg1D4zuIo5LCDzYyWDboiwDEfwk47daseNJ7extbW1syq3U7LDHsbbhepOfpXmXiiSzvb11ijnmmwN1wXwoA9+/8q4oxcnyrc1il8T2LgFte3KiQKYSNzRYKgkNjDY7e+a6PWtDgm8KQSeabVI5BIhLFsenX+HI6VW8JmC50aUw6bFd3skyxbWkVI1U8Ek9wP61oS6ZZ2t9rNrb3yTXvlxzS2+MiOIEYX3A5Ge2RxW8buPbl7Gc5Lnt3OU0S+nupmgklhihlj2PPKgLyAcfKg4xnIyema3vC9zZNJFpBupDCpZY5vLGwf7O71H+TXOa1aXF1aWaWV2qWhGUByxXjP3hj5Tjn1q5ostzd28sENu5eLKhiBtXnHJHHvxWOIW1WMrm1PZwkrHf614TuLrS1sbTaICQXzKeeeeCOntXOXenyieXT5408yIABUPT3J9K0bLxibC6+y31zGFiQFnI2pknABJ6Hr+VZmq3l3Pei60+6j8li484ru3Y7YBxntnPOK55VE/eXQqEJ/DLYw57NNGlPmhRjCKB8rDJx8meMAc8c5rpPCWrbbmVb1Sdyf6pxkBM8f8CzzXIatJdT3AlmlM1zGuQkvyrGfUAf55qLQr+4/tO1ed33syrseQNsJbBGB/s85zXZTnKvHZJIzqU1Dd3bPUZ/E0KXsun6jpkjRyoY5JiR8ydCD7Y968/s/Dk3grxa1rpT2lp4YEbXSWZkZpZZGON7MTnHYAdq76608ae9/danqUV7bS3G+JXQKYIjjEecndzn868q+JN9qD/arrRJLie6aVIhsUsBGM4AHQDPet1UcWqcPtaPsc1OmpXlLodU3iW6+2To7OscS+bKkchCHPQD0HB59q1INbSKO3KQpGzTKrM0hG7cOxY89uc9jXmPgOXXTpLS+IrOO3YuIZElAPmwZwd2O4JODWx4q0X7TAkkbmG2yjQQDkAAfeZR19gKzqOCm6Mn7191qjdQulPpb5np9jrNve3DWVwkUsxjISVHGSueOnSqGuaTMtlFEJIzcj7ruhJI7cfXvXK+F9P0vw+7k2620+BM0jth2A/iYZ+UflXZX8eqar4htNW07VLaTw68CMlvt3lz82WU8bTkqO/TGOaTo3vFuy7/ANXM3PlacTnmSa005GurZ5p/KEbeSCQzHrgDnn37Vzgs5IJI4/tEmlmUfNLPEV3FeAMkYQYxj9K9R12wbTdKmvrRyLgx4MjcrH3+73Hbv1rib6LX73w1qEeo2dhdyNsNsCvlb2znLckHHY8Zp4elbVzsvu3Cda+0dTLfwRbW5Vo2+17FaRkYFjIw5JJ9T2+tXNL1a/1bwfJFbQT+E7yVSgOQhjweGGeucfWrGm61daXotp/bFybi4tubgRBQG4zgAfewP5VRi1b/AISTV5bI2q3YmbemwFigz8rge2B19KmEqdKfs7K9733/AK+ZrKNWrHmeq7D9Ou4zokC6mG1K9WM2l5dSoqMef4wODjjnk961tC13R9Lj/s1roWGJFiieV94LsOFFV28Kan9om8vULe1maNY5GkBlMmODIQg2g47Vx95oyeHNQht76NL+7iYzMYkLlG/gIOPlyOpNTGpOpUak/d+7XyKdOny6LU77XvDdn4ksJodXhkkCtveIOQMY5Jx1Xv6VzfhrS5rKHU4Lay0+x0xFIsHtolSTdkfKcfMe+4NkdOa1vM8UtYTT6Zeac0txYfZoobmX9yrsTzuHUjJ49sUzUnih0HTLI6gr6haxfZ551QKJJDjc4Hp1x7UpJxXLHW/Ts+5MZN79Bujana6JrEU15Ibmdl2xBo8NCSOWA6c9zWl4s8S2l34ZvIPtL/PGGhniXLCRTzt7Z7VxtvHNpsk7I0d5E+3HzZZjjofTnFW9G0a81GWR57eNbbfklVxuHce2DUxoOKafT+vvNJyjJqTMz4O6A48YfbkDGLJPmscMvcpx7896674m+Lj4YmsI4re4ubiaYRhEUEMvTHPVjxjFX9P0K50TT9Qv7O6thMUJt/OIjijOOM/1qjo1reaFZ2lz4ovI9a1KVjcrdxcwwA9AvHI6/NxXo80Kk1UqapaW6v8ArqcUm1pHckl8M6kY4LjWNYurhJ0WV7W82brd+oUbAAMDtWHql/b6DeQ2YaSeIxmYSsclTu+6Fxz1HHvVrUtTk1uF9Tl1ASRwO6pbw/IykDhjzznnnp0rmrya917VRcathLdSJI5wfLkChflbI4BI7jg5rGm2vfla3Vbehry39zW/c1oNXlOtXEEeWgg2pvBP72Zl3kEjgBQR+dUZ5TNp5Fy07CdA4dlG3l+Qeck4qvaWhluri30u/f7M3M0Az5jlhzjuR059zXc6Z4D1rUJLdNSkitNMjRdsed0px69hxiuR14Td4Q179DpdN0rc8tNDiHtbK+upLq7fIeTCwCVtrbRjzDngAAHpT5Le4mKxafceXEobJQDjPpnrx/OvYbLwfoXh+28wRxC2RT5r3Pzkj03HoPbFeb/ZbZbq5mFwhsmcuNqsoI9gfwrGeIqxnrK9y6apTT5VojU8baXongDw3YyWul3WoX9zeRwRxwMRJPI3PzNgnaME4rvPBvhLRPClk0eiadHZtPh5iOWZuvJP1rZu3RIDK0Yl8shwBgkdsj86dLcxxzrCSTI3IUdh6n2rpUrU1Tjt18/+GPNbcpOUmYXjwwLowa8O20Vw0+0fMyLyVB961PD0+nz6RbvpCxrZlfkWMYC+2KxvHHiXQNIjtbDX5sHUH8uKNYy57fMcdByOfesK51KwsLu00yy1mTSgpEiWkVvlpkPck5x3HNbqm5U0mmt35WIcrM2vFnj7RfDV7FZXk2+9kI/dJ/CD3J7cc4pNW8SXsPhyHVbG3W7N1IkdrBCpZpNzYUn2xyT6CuM1W30C+8Rw3WpxwSQQ7opUZCZJZDjBDDsBVrUtO1zxVdy6Zp9/baboMCBEFqxSeNuoOQeDjjHTBpx+rtxSe29/yRUoVYptr0J0MlzqOp3V7fafLOQ0VvLHb7JY3Qkcg/ex0zXK3l1NJNMtxNPd/ZNr7vKWR5dxwSpPAA4OB710Uch/4R+7gt1eS80+byDuwu4jG5x7kfrXL6faXEga4hV4pol/f7zlH56gemM0SqcjbaTS+X9aGlOnzJWepkXX25dSv5XAmht4vOGBjfnO1+vQ7SOlOtbD7HbRxawiq1yTdTnoxY/dQD26CvRPCeiWGvafLqN/EjRzRmzhWJ/lZA27dj1DdPxrR1DwtpWj6Hc3+pTzTypA0cUkjAMpJyAv+1nHNcnt5yhamrLX+vzOr3IztLV6HI2fh3yrd104RSakwDOZIwY7fofXr7dTVjSZ51jNvLaTuJt6TLJt+YE8nIPA7jFWbXxPaJZwwabps+G6CVhtY4yc7SST71mzeJpJb9lvQkLptc2sKYIQnAYkjkfSqozqVYtW5mvwJqQUHrojoJ/CCz6GFsRGIf8AVyRu3KqD1zWXf6auoSW2nuQ9lbyKfKBKpM3ctjlsZ6dKqapqWqN4SdbGdTLdyHkE/In0Hr+dZejzXEL26ag7XOohM42BI4z1PB6Z/OrUpSpqTlrr6+pKjyyatojT8QWsEd1c32jX1vm3UwbcErCeNytg8nIqbS7CKT7DdF1uIGlDuAisj98McEgVoaZoVlpQMaOJEv5Gu52kG5izEALz0wM8+9S2BurC4u3treG+hAGMqVUEKSFPqxAGOwrR8s17NNtLbz/4Yy5pR1tqzr7XxbplxvhulaOaM4dNhdR6cgdxzVm1/sTXIpBa+VMsbYbblcGuAa9kl2WiKYLy5O+RlXpxuPIBGTgj8Kqw6roejPHqE6XUVxJhxGu8yNyD8ynGOcdQK55QnBczWhoowk7Qep3+rWfkqysxePPyIEAOcevfFQWsirFJFd+UERvLVV47DBI9eeKoPq9xrVkt0s6WyOCfLChwB7t/h3pnhyQTxRvdTxfaTGnOwchhn5vUVE39kajpdnFaloWsWuqazd6jqK3lrLJHNZ2zpgw/89FJHbB/KjVtPhuBb3ssaSReWZJpHLbVGOgA4AHXn0r027SLSr62QbmnunG1I1LEHgH6Lj1qt4w8HDXLc+RKsUoHMQGIpDnIZl9c1dLSqpyCdT3OVHEeBNQSea1j+1ItqziJZpkWEXB7GNT1yT2xWpJaTW3xUnuHRfIktGBJ78YIPbGcV5hY+D74eIZbzWNWn1OW1ujBbNASsZwQCcdgDxx6eldhbarfvqswmyBBbhTLK+85LMPvd87c/lXo1VGKnUpO6af9I5rOUoxlo7k/2GPUruZIRdJbGUZTPCg5yB7CrV3rS6NDHY6aI2byy7I5G2AD+Nu/0XvXD3mv6hLMi2koht55MPLGhVl/2j2IxxXbW3hXS208Ja3ty9xICzS+eDyRzkV59o0WlUWj+9HY7zV7/wCRiabG1+Tc3QSdLeTcrIgk86UjIYj0XNGoaqfMQyGWwtJJS0kSLzvU4ZgByCwGePrU2m6tZeGfDiCJIpb25hL29rDhii9MluwGeT6nA5pyW3mafB5ljf3GqO+8XLSLCMegB5VR7DnNRRkqtZJRSRdWLhTbcjGvFmvrGSd7h1jPKJO2WYc/dIGT2PNVdKtoI7oRyFhxlkMhBY4yAMc+xrc1HIeNLi6t5rZlMz26R7X8wMQFyT8uOfr9KpW97GlyBptslmglCgqAMjvz745rSNG7lGKTV+un4C9raKd2dTp9/dX+libWFRVKLttU4zMjH5x6grj3zWPpVhdXEsf2Zpv3bthwACVPIHuR05qxbWKa5qkMGm3Mc0XmghIfmAX3IzgA85zXoWnpo/hrdAbpLnUT86Q5yRk4wB2Ge9dE60ZL3bO6+45FBwet07/eUfDvhqJL0f2rMbjUTGQ0cS4WFD0Lf7Vch4ovbS18T6pZpDcTbBHFG6J8q4AwAenB79zXqWrTvpWgXkwIS6mDMuO0jDjr6V5DcaRfwWSz3V45kYB+EHBz1ya8/l9+MYnVTndSlIyrYreTW2Vll+0ziORHOXeJSdx2g8L24657V3+qXz6JqGkaP4Z0qbUZpWjaZi+xIIiTyfYV5EVBnnFnqc1vqLFSZyASiq4JVQMcHvivefDdwLuU4khGpSQLvdUzlecLn8K9Kb5Hd3cexzTtZWtdFl/Etla302l3D7pQN2xhkbT0/P0rh/HeptcrptizbLVyzy5HVRjaPcZpt3o9/f3kV1ffZbXVDIY5IonyJEU8MATnoBmqfjl4tFvbO7kluhNdnyIUjUsgbac7uwXvjucVjKilOPI/11Q6c1ytyRiGTRNOWO6ubl5LnGCA5dsepxyBg9eOleq+G4dAGg28uj6jbWPnAySSRSKPMJ4O7PXHSvKmtTLAbeO1VbOJVluwcHzW42o/sTyfyqVriBpc6hHHEX2xxrGoKRgD+EdBXM6c1O+jOuXLOFrtHqNxrWk6XbyDSZYdQ1IghMuMFhx1HHY8CuA1PU7u8tZG1oQsZJsKi/K8uQQR6dM1FpGp2djayXN/LKqxuXykPDgdg3PPXPoKwtZubrV9RuJ4oFWS5HmRSKMbMYKMmDz75HP0reEV8fNt17PsjDlcXyW3LVvdPILYTXLeRbr8jiVWX2J6ZIII9RTr5re+0yGSWeaBnn813IG8rngD0zx+dFiZrXWJRc2Mk8XlBSsZBLsxBOB2I6Ae9XZNH1PRdSttRv7DzDOxS1tjkJDz8oY9B3Yn3GKzniUl+6vvv39TeNHVc9ilBcL9thhghk/esw2hNsQ47s3VhwSSD3xXqvh+8e2WCyaOG4JCx7t3APf8K87vtIl+4qmVpDvCoSFYZzjrnHXqaNOggsb5yHji+0SJJIkjk7McEYPGPTHeuhuFSK5Xsuu7/r5nNKMo6Pqd94+0jSNTsLe28R3UUFmsqtGnneWJHAJVR6nvivNtQ1qXUtQOl6RFt0t2KqPlBIXAwT2PfHtXUeLLPT9b8Padf+Sstxpt262zvnapKgN16np+VZtppL20UstnFHBcIwFxHkbiTyGB/HOKzVSHLyvfz2T7jhBp8z6GALJbW+kkL7gGKmKMBU565HP1OTXSaR4YsdaeOezmljSFlEhxmOIAdApBHSptW1K6OkbZUiVgBvurgbQD2JHfrXoWm2+maf4aS0N5EiCPdJLvClmxksa56lX6xPmnbTT1NlehD3epH4b020tdQmFtbxfIoHnMgLt16NWnruu2Oiwq97Mqs52pGD8zH2FctN4ifdFpfhO2W4k8s77tvlSIDoQDyxri7h7i31CB9ankneBUa4MuMzckMBnjd7cdqaTqS5IGLh9uoaXiHX3195hdXDW1nD8wiUgxnHdiep6cHgVjCxCPb3G8GBnKsgYNHIcZzjt+FN059MvLq9sbeeO6itJFZo1J3xL2UjuCDW14etTe6gYY96LAd6x5D7fqB3xTnCNFqMbub7m1OTku0UUvC/jV1nlSVjcTRDmWCLKDPAGfu+h6nniuu1yQnyriW/YRyRmV/kKeUoGeRnNcfoOnnW4ri9t459Ls4dqwzhgmUGCSwPABGB68mu91eP7NpctzJbJcyiHOMAq4Pb3FdDlH2l4vc5JR2VjzWyu7PxHrusarNqOsPYrEljZQyxr5YcD5miBPJyM7jjGahu5be5lm22cAeC0UPfGZnlMYONhOMZIBGR6VPfwSanNbTgraRkFVjjACqvpjj9Kh0yJNH1ac3LRzhYlhESkCKMu4A8zqOMlsdfXrUYnFNxsk0tEvTY3oYeMXzXu1+ZnaPqQu5JLoLH9hVvMIdTzuOFHHPAAJ+oq74N1pDd3crXOJ528wIHyUU4wMdxSXVvF/Z1xYwPJP5bSQteRqERoiAxxjjOMDjFUbPThZ6DLcyw+Y8jr5IMhU7hyAMemR+VctOnRnywbs7u7OmrKaUmle+yPQbOe1u/PSRY0u2k+Zgcb8fxcdcjFef/EiCTTbYb7yWztbl1gneKQtMSWO2OMdy3H0ArRsNQfTrlFuNjSTDzWkBxtPfJPAArR8TaBp+oLZ6vPcRiCN1jELhSLeU9WB9WHfnrXVT5oVFdX7foc/u2etkVPBOo3GgW82nQiOawiKm3GTmIEj5ck9eprv470395LBd/6Ta3A/cgnISQZyuenIOfwNcncLbmfR7aC3+zp5kjNHIQC2AACfXk5qXWEa2tYruyuZoc3C+ZGG5D4OG9vSuSNOqm7/ANM1lKnKxsy6bp8MgEqNaxyAqSGxnAzkDrxjtXJX/hGVtUS4OoNcW3G2M/dIzkEjv+BrYuNZ1C9SCK4WJXiVtpjxtdemd3bNV9H1hzdXawxtLDaBY0LfdeTPOB1IX1HBP0rrjCcNIKz6mHNfWTv2NjUdOn0vRXbTrVrmZEHyR9mOBk5PQe1czqlhcaQ9sb5CI5iMKqkklj1GO4960tD8W3NzquowNcWjEIPLRv4iPvg+/wBK0dZtL5p5lgjjaRyH3hd2R027s/LwSOeKzhCMHeS0LcpfDcakObS2eGZU8pw77z830J75rU1BI7SeGSRr8CRMR/ZQCkqgceZngEZwc+lcXqU0mmxtcyvdBoyMSMgKxt1K7f73H5Gup0jWEvbC685kltHj8+SFlMZZGxyh9v61pGDglOO35eplN8zs9zkbnXIvJk+zXyQlyxMsSMz7s/dyDnj1I+lcpqHiaxMCvHazSRI5Qtz5k0nOHBOTgfzzXpzeEfDsl46RzXAbaDFK7YG0nJX0PPHNeZ+PNM07StQW1toRO0M/lJDvMYMnUEsOo6nA610RUJWgrtdRQlrzbM6nwxdTQW1uVty9k0bSyGSThSDgqF/H/Gug8La5KtmYImhfbI2Jk6FSSVwO3GB3P0rAs7SeTRYlkguJ5xHvumtzsDoP4FH9RzjvUfijxDDYaSJLSIQbUMeIkJAORyB6jpXLVhzxi4Ly9WawkuaUZdfwPZNI1W21e3aS1kRpI/kJP3h0zmuN8XfEGz+zX9ppxLtbP5VzKrjCD+LB9QP51y/hm+vIrCN0l+ypLE3mREjLnaecnkHn865Xw74XOn6BfSOrpc3V5cfaXlJaPytx2MuOMkYFFLllGXtN1Yl07TXLqjdS7sNUsrDEMgZWUK8DH5X7Ej8BzVzxVFf2Y0BLDbGN3mXcYQYlQEDaW6DAJOM55pPCOmafZ28c6xzxTxANKrSF9/PUrjgVbGnYk1OdtRkvbY6m8sqxAgxFgMxk+ijA4reLSdoLbv1uTLe8n/SMXThANWu2ufOQqSwiGTGS3zfxdcDHSu38LaLbeKLQz3CBLKJyitECjuccjcMHHNUbW6ttLuJlFnHFblcxyqQxcdTjnPXr+ldR4N1aG48KTTQIiTebKvkNKBg54ye3GDjtXNiPere8y4yapXiZeq+F/DtppcmrWMUNpJHPuWZ0G12ztH4DPHbIFZ+upF5Stf3E8qCPIcIvA7gEDj61LrmsLZx6dZqBNptopW5YH5t/+znggc9fXisLVzo2q6hbrps8satGMCMmPn0YNwaUEue62KtJx97UyrKxs7+5nzK3yASIw5LqTwufrj9axL9ZLS5W1ybm7YllY4Kr6AA9MDitjT9Tj0PWNanS/L6fpce24jMI2O7AYUuv3mGfuj1rO024g1fVJdQnuMjp5cXcHleOqjHbr61s6cqS9o1ddPIcZqbcUz1PwdprDw/JcWVrbJqNzIYJbhEUMq9DyBzVrw34HfR9eF7JNE8CLwOSxbt16AVB4cil8NaA8jSL+/8AnjgjPCseyjuTxmqmp+I9VaznluJUtMNsERbGBxhsjvg59M1gsQ4Rt3JlTc5Oz0L/AMQNXhuCNLhKSTFgcHI2kd8+vtXn08ks0vkT3cstv1YoxwhHGMZ5NR3XiO6l0kwRQrKM7WnQ8gZ5OOxHWqENqYpLkeYZ3kbD+Yeu4cHjnpRCi5ztJdPuLuqcNH/wSvpmlLJq8LLbthmPySkMPvZPfv6DGDXsvgXTLOPUr69t5A0oVYmjV9yox5br/nrXk2k3F496rAxARH5Y4SDjkdeOa7zwxqUHhySa61C4ijguG8uNsElsnOSB0xzXY6ntW4xb2svM5qsHCKb/AOGNTxX4Ls7u/j8R2+9dWso3WMsxKOMkgFexBPWsC3k1xfBMbeJY7aLWEm/dgIXWXnAzgfL9e1b+q3d+2tT6da/a47W5VZW1BCuzAwdq5z1HcVdtnlubk/Y73zwpIMQ2tjjGCe1KV3BRn/wUv0M4Ozujk30PU575bqytnt7SRMSK+CG49+OCKVvDUc4IufK89uY1LZB9j7c9q6HxG2oWugXklxE8EsabUKS71OTj2wcc15noV9qNjp9taXCtPA0jyJgA7VYk4J9eaxjhYqLnza3OlV5ydktB3jN7DRrOC2S/MswY4hgI3AnAOeeAR1Jq54O8Nza8rR29isVvGwc37Sbju/ugnnIH4c1Q8LeCLG58VwzGV/IlkDeTMmWI5JIxx04J/rXuUcMtlp6wadBb20aD5EU8fhU1aNOHuRk33vor+g/rEkr8quVdG8PaboUW9yJJ3+9NMckn29K27i3gu4THPEksZHRhkVQgKw2yXF9dC4kUFGZQNvOMgAfSpLPUFls5bh1CxK5VOMZXgDI7UmrI5pOUndnjt9qdtYalexXDXZs4ZWjREhyijPABAGfxrLHiWwmkl+xxStKFyY2hK9D0z06du1TeMtN8xbsRM/kmdyzrJg5JP8qX4f8Ahwxuh1S5WO0U4kaZsDB9WPUnpmjCU48jm99jtqy27HW2ckxs7XSvsuYWtTdvcSDCrM5ZUA99vP05rlNGivNMmuY7hpJihGM4bn8BjFdl4gOj+NdfsbbRrq9a68PXSzSy2qHyMYw0Rc/KSRjpnHNcP8R9Z1ia4uNE8BWputVQn7VcEhUtR0PLdW7d+ldLpVHanBWclrfp53OWFWLblIS6kl1R5LnUJE8iDmKFyNuehOP071cj0+O8vLe7v9wtkRRFGxwMnGWx79B6VJ4a0cJpWl22qHzLqFAs0pGWbAG7PsTWpJot3qOpoumSSmJHBLYG0cdMnqBx0rm+r037i05evc6XWlF36P8AAisr6+8O6oywPvwpYFkysyZ6bgPlNL4/1i31lbM2luYZJonZi3ylcDr7/wBcVoeHvBcumR3a65ejULq4fCFXEYRegA561XsPBupXcWpLq5s5WlLww26q8ZWEjHLMTliO4ree6cknbt1OdON7pu5xGk61ays50l7d7ib55riJNu/AAIJ/EH0rftWks5w2nzvb3D/8tEGM5GCxPfHYetU9S8MN4L0y4TQ9KF/JboFSIk7yCQW6elVtQnlltELxvp6wKA8cnbK5OD3606+HjWnz09u/U0pVuSPLI77xD4h0CXQ7WwsL1LKO8JisygCOzYOGRTyfUetcbDbapb6VoltLrNxqaNcS7ZmDExxYCtuB5ODnr0zW7qPgQ6rqmq6lZTWEl8Lpbi1jcLILdkUKuAD8pGK0Y9H1aD+zr7W7p/OszJlIgqxuXGPmC9uvHqc+ldKdOnDlg9PxvZ/M4FzNps891eCztLhSL974KPuQzGQ4POcKM7vY+tXxFqGvWdl5lrFBZhCyRAAGQj+JgvU1peIon0OK5srOJWuTIrR+ZHv8+NgDt9Bz+VU7My22nzvLObd0OVtk6gsPuL+I6VyTjD2KfVdv1O+Epe0069/0LPhvwtqGrjU1kvns7GcLAsbAOGYY3MMc5xx2q7r3h+fRbaG6F5DcWuBbtuBAhHJLY7kn6dBVLQ/FWvafoOoTb7aGztAyxNHHuM8xPv1AOF9zmr93qt9rUMkesy2irEEDxxr+6dioJV+5+boe3vXn01Gabtq7nTJzjLVqxzAvBZ3M/wDZbLcRyjDPIgJbjn5un4Co9b06bWNFFpCVkncl3Ez7Y5PRcDp7N1BxWlLDdX88MdnZ4LMMFwCgHoOvGPSnyaXqmjzx3Fwbdo4vkClRl3Y8bFzwME13UudOMo1FzR1/rzOeo4NOLjozau/C9nZaDaS3c8lsLezVTcTzlxtHJJc9+f0q3b6Qn2N4GlEqTx/fUZ4/vAd6Sx8WaddaMNPmZrlUDRzRsg2dTlcHn2rVstUsp7RJLGKW2giXGFYEgL3CnrRKWmujMlzp+SOQsNP+yaksEqCx1BYSLaJgAZ1Xqu3n5fc49qw0ntLTWLR9Qu7tb6R1V5IwSzqT8wKc/KBn6dq9KbRdJ1vVI9UaRLi6t4/JZyNrqjDOGHfqDn3rg/E3he40/WDNpMKzup+ZFYlgmPun68HJPWtkoVU1F6tat9GuwozcXr06Ip3lsls3l6dBDmNZJYLpjnGR95ie3Qn/AOtWzoMd6uhWaardCS8jjH2m/i3L5jFiQFUY3AAjk/lUUOkJpekpqWtT3EcEkotjAYsfM2cKOpHpnpg1WvtUnNz9igQhSfLEag7nAxkA9uPX3rPlqVoKKV0u/wCnka3hCTlfW50NtGdSt0sDckKyloQ3XzM53O3fPT2rnNPhax1uCzcvFbxGURlczLK27JLNggKp9e/0q48awT/ab3/RpEAkS2LbtwHGeuBgelV7/VYLS2jl1W6+y2BzIiAAHk52qByBk8k/1rOnWlQfsOVyT6dRyoqr+8Tsbl/d6bqa3NnruoRWUUsJjcbwonQgjPP3R0Ixisi4k0qO+N+tiZLWPAiMzE7nwq7iP4VwOM8+wqGw8mV0mdG8pijbyM9f4vr0HsK0tV0e71TSJ4La38uNkBO5wGPPQf4mlT9r8LlypjkqaadrsoeKPEFnqU9ja2oxLbqJhLDIURE5zn1HX86wFltr7bqTRvf28TlIFhyU3Dpk98da29I/snRlOlQwm5YwBZ3uQGDJ3wSMFa27vWbCx0KKOztBMPOSGARxBE3SNg7emeMmuupFJqnFO62/zMYSfxW0e5yFhcXdy0dzdWxCJIFICBh1J4GenTirGu6lf2mjPBqMd1c3EsbtEkduy7wuTgDpyABgd67fRtE0+61GS3sPLMqHfLFK+1g27Jyv0wRXT6/4Za8tIVs7hftluS6pI2FYHg56ke1Ye2u/dtYp8sWrnmPg9dRttJtpNZE8uqXUYeWLaqxw56RoR/dGMk5JrpNO8LXXh3TAdNvrjzLyc3LhlDct1Vfz71iTajP4c1K9FwYhe2xUPbxuzgL1UqcAYI68fSneC9c1K8kmhus+fdb2RCQdjdckZyoOVwa2nSm4yV1Z22/roZ86upJFSW0lTVLtrpFLwviSCWTbuXP3i/HYH5QBU2tarZTWVsIQbaKBh9ng2lVlc8ZwOQoGevrWvLZR63LNBe2pN9blFMlzIdjnHWP+9jjn1rF1fwRq13rC3UcplgjjOA0gCxnHoMn1rJ0Kcly25X3NVWknd6mJe6pBcOD5kiRyOAxfLBhnAYj/AGTx9K2vhzoN890zXz4sYHPnsqYV9zehJx1NZmkf2bNoWt3WlwXmsXWmxiOW2htnhLsxxjc4zjrnArp/AXjCfUPDDf2ZZeZcQtta28sxKZMD5VYkbsdCT+VdHs6qjKKjaOm+9/0uZTqRTTv7xt6/4V0TS9DuLDSrK3NpfTyXV0khLiSR8HeTz6cemBivP4tNsEaS7lM0KRp5ccYJ5IOB09PavTbVjq15b6RrEltHqcMYnk8ghfmHVQD25A/WuY1u6g/4TE6DLpBidowy3WcR5Pb9OT0rmnz3+LTdl0pK1ramOnictcMYppPNtNyiJxxHnG49+en6461Hq0txLqsAS3nnlmQb1Xo7MBt9M8Dp+dX9TshocEVxf2ZLy+XIjifBDfN3IwAP1yKmj/s69soZND1k6frk37mCO65WFiPvkfxcE4Oa2UKcrTpxvr1/4BLnKPuyfToZ1vbS2ctwjpFFMQGyy5Oe/B7YyKgtdBuP9HkuC1ukrNsnlLBSvJAIz07V0H9p6b4U1LRdC1vVHv8AXrk7GnW1aQyODySR90DIrUWz1Cxtbq70bUvtn2q4AE17kxQICSTt7nt+FL2UrWk0l08/mDrJO8Vc4m90m30Gz/tqeKVUt5WWCW2QvJMTydijjJ6A9qsarp9rB4cutR8Y6m9lYMyzRWRQF7fJ+6xHfoOO9aWteNXuYMWf3oyIIbkuFV2xhmVOvBB4ridYt5fE2h3FtcyuInlTdJggz5baVUHkg54qqdVw0tbl++3l2B0nV95u9/zOg8M+KZtUhF7BcSDSthZGmOCFAwp2nouB29O9XNK1fX9I8c6HBplpCNEubVrq9YRgeYT1+b+8Dj6ior3TLSGzX+0DJa2VkiqbKFxmTHCKcde3ApdQ1/UbOC3j0jSGubyUiGGBR9056DPOB69KwjNyqN0o3TXXz2+aNpwjy2kz0r4hfbJtFgaz+zGAyBpWkJPy+gHfOa8u1u40y8vms7W533FoIpJ4kJJiGcjJHr1INdf4Su1mt20zWNRs5rxObq2WQM0LMeM44GOnGaxvE3hSHw5cSyWel20sOoz+ZdO1yUUA8Fj34HQdOtaUvdlbr0t/wfwMNlZ7GHpd6P7RkNo8hdiYw0z+XjnqOwWpNRvNch1X7CNVnePqjLzvICjb6BevTnvUl5oMkTTrYQyyeYrKJc/w5BG3t0zWMscEmvjSGvbqDU5gZ4reRdsq7VOQvbnHfGcYp/V4Sftov4Ve29zT2rS9m1v1Ot8F6xNceIpkmuZpLNiLeUeZmMkDhgOzAnBrvPEFxFpmglIyy26LtccsTuBH1JzivONB+2JpEV2LS2SUSR+bDG5+eU4yD2BPBI/CtfxPrItbO2GpzwmHdvIWT51yuOfUc5/GuKo+eTjTi1fobOFrOT2Mi41K1a2tjqSyxFo1luEjxuBJ5xkEHBI4960prHRJbO0XV/PbTIf9KV5DheD0cDrgjjHJrn7e3utZu0tbPVEgferCO3Uu7ryCCRkA9D6cc1veKbDT57oXetpezWSxxw/YbSPdlgSfnx2yM8V34enBKDg2nre25y4icrtSWnQmvJvEFvdWGpvrNhpvhO3cvIlrGEa7JOV2jHO4EDk8YzzWrb+NrW48Uabo1rpMqS36ec10IgyqvIG5j1PHX3qn4k1zw7r2jW9jqO61s5iIbeKZdjlsYUheo7AE1d1CKPTNPs9P06dVjhh2mScfNuOMHPbFVUlFRvUj3Xb5+buZQjd2iUda8baFNe3unQ6bdwCDhrkIIgT3AzzWZ4dW6F5qC3LX96bgIYhuACDnaoAPB55PWuMv9TtXup4rcQXWpTZidpAWAbJ557gc8dK6bRLc6Rp8Cyu8mpQuskjhtuCpBCfTHWmoSbcaeisr9bl2jCHNPVnW+HPDdvDBPcRTtdu7sjFlO3cD0wf5itbw3rFvqo1O3urJob3TH8uXc+48jKlW9MVSg8W3N9od5dR20SzrGfs+xsqxI6j1xkfnVLwPfDUvDmrajEvl6tdqVm3HKiSP5fy5Bx7molGUlOU+mm+z/wCGJulblOfsodOv9bi1Lwxe6Vp2ZijfaGk8xyMkkbmxjA445rrNQlt5YotRuU0p7CIn7Rcysu0dlCsOAcnGD61iWGn6I13bWmuabZSa9cxLdTLApVZAPkIHbOD0FaHiLSF0+xfSPDejGGyvIHlEqxrJGsmMjcrHLE10VHGUktfn266/kZR5oo5fwTp+lfDzxdbWF5fTzapqS7pYYFaWNHPOCcepPJ5rd19PE9p8SIZrS38zw/Km6aZzkN/sgdiOMfjUbaH4fbxVo3ia9uZIrpIikUMpAbccjdtA5PYVznhXV77WvFOt6jperapI8Mjo9ndWxjt0jDY2g5OT+vNJfveare90r37vsK/LaKR0Gu6xpmqW2oy6ZqkJuNOwbh4TuKNjAHpzgjivOp7y7tmuBEEN1McQQKpAt8jlsd8Ag59a6ywu/D3/AAkGo6f4dMNvbW7GXVoYIdsTS8gKZTxnPGOg5rU8Orps1451vTFtr25jD+UJCY1j7AP0LdehrHE05Ri4wWnZ7/M6cPVineW5wFq10be0t7ZfKjhZtqSnKyyL9wn2zzj1q54T1OLVpL2OzuIypuD5/lliFkC8qMjn8K9Wg0/Rl1NoZktEnZGaO1mxuI9QfTnrTvsWhWV1bww2tkpyWaFfulj1x6n86zqScqbitHo1YuNSKlc5/Tt9jMLuBmkhiXapYfLFng5xWFr+pw6k1tbalMYGF2uWcFAeSFO764rP1yVp/E17O15IqSKscNqhKogU5bIGBjgfrV5xhjBryRR2Vz+8lZYt7lEG4EAHjp1+lctS1Nc3Nrpax0wi29tOvcauk3s0szIyTzXMryIUUYVQduffoPxNQ61qz2sLWVkd08xS3hZyAAW4+b0wMkk+orqb3VLKyv2sNLdNPsraNYonMe/dj5iSeqnLcA8HrXNy2Es8L3zXPMcmd1wgcuTn5jnjGM1UazUJSkrtkqCco+X9ILi5uLuJtHj1a4EoYGcHhFTod2BkHIGMHmurtr/WL7TLI6QII7gwiKS+n2tLIDwGHYHjv1xXHR6RBFqFw2n6h51rzJNcxkFXzzjPUtwBweKs6hearDYxyaFC8NoAJXaOPMhb029vatbxUkqMklvZ7bGcouSvNO56D4K0S7i8LnR/F13/AG++9pGkuE+cjd8ufXHTIql4y8HxSM+oacWjl4bdFwQV7cevQ1yGgeJruG0N9fTTI5+RZbqXMg/AcDvxmt3VvF11cxaWmhTQHXLqMymwbPzw7seZjGOx4OOMntVUKk61S8fPXp5mVSn7FanHCwvbm6826RzcSNvmZw2VIJ+VQcfL0OMdj1qOGC8a6vpP3azPNsGYd2yLbgKQfzAHevVo7qK4uZobjSYGKRLm4hnAMz9CFQDOM1V1y3017mz03zDFdzqCD97ao6gdvbJ71uq04ybUVqZpwkkm9jznw/riy6p/ZVjpi6gYLtbUsJvkjVQd0rnHGOR6VveKZNZtrzZ9rjFjeTFYpIotxjVFzt9gcdTUz+D4/AOhTW+jI0txqVwqsq/MTjJUMTztHUnv0rqItW0y1Nto+o6jai6Cl5YJMb5f7xUdcDpmitCna9NXX4+vkOFWTleR5rJbXMjXEl05itjGIlkTL7TyTwBwOn+RXReENIudR0ZrhmhgMUf+iSzZlcSAbRIEPJ5Nbt7cwDVbtdDu4bhrCFmuNKtwrSnK5Tr05/nzWXrXi620LRra9nlMcxcKbOGHzJGm/wCeZYD7oJ+nHFVFSceWMdW/6/rYmU7u99EbfhS8sbC+nuL6GJdT8lTfXEZOwNyNwB4UHGcUeMVnilg1vSLgSQuyksGJBwen0x2rzfxp4jvf7Q0zSE3W63SCe4giwA3OMvgE8YPX0r2sabHB4bgsLSEy2ohAHl4DHjqM8e9cNaFpWfU6Yu1pHL6vqia7pyJFZpLdyL+9EafPuHTbnOcelcfrt1qOmaf5GgxsdUuMq8ptzK6t2ABwB6c9PSp9S0+902/HmJcLbnLrIUZAh7j0z71as/HOqfao4YLu3kkYFf3igkY9++e3NZU8R7KSctuxrOgpL3DJ0zw38QNTura9ubSyguYITBHcXQxJtbk9OmfYV0l7D4j8N6M0t5ZRX6QKHZrabcVA6kggHH51M/i/XGQOTAIQCjBRl2OeuO1S2OoTnUorlXmnuGUIsX8JH8WRWlTE+1avFW7GcaMoIyPDfi2W3t7uXU7y5v8ATb1DL56RjNko/hcDrnOBgdq0LjQLXRtTuPEltdX+oytCLdLWNwsMIJBPy4zuJ5JNX7TQI4Iri8tvIsxlt+1clU7IQOCRXI+P/iVD4Xu7TT/sIf7TGPtF4ANoOQAu3n5sdjzXdSbrTtRW+/p/Xbc5JRUF7x12nWdrfX58UweUNZSAwCFp1kjVuxJB+Unpz6VQurHUvFsbDWbBNKvEQqWJLZb1jfoUI6j2HNLceDNM0/wvd3ngu3tNJ1zVI4mab5lHUMTt7HBPbvVvR9IvIdInsHv7m9lkBDXTvgjdgHaOwqJyik5J36K+6/NWKipXOFF/ZLLLoeqeJ4Llo1YR2yfvVGwEkjIOWxnjNc94M1/R01qKRdF1DVriW5LNcFtvl7cAFuwAAGAPSpNV+HV7Y3V4PCekSC9kfy11G9LMsSkfOygDGT0r0D4feH9Q0vw1FbzvFqN5EConNv5XOchsdwMnk4PFbc1GhB1Kd25edvnoO06j5ZPRGx4otf8AhJtCD6SUsbmZypuIUBmVQcMoyBg9OtXNY05bLw0tlBN+4t1CyySLncAP4hxnIzz70+SW10OGzsTPGLy6+aJS/wA7jqSB+v51S1bxA51+PRJdLu/s17btdyXZ+5FsIUL05zwa4nzyhyLZalq0Zcx5XE4Sb7XAse5kMRmuA20HAyqrjj1ySCa39B0iO7k09ry6S2cByJAvXA+TnPTknv0qJ3hutZfeyLYXBBXLf6w5649+cZ962rvw/c+J4msNBjht7G1dD5rrwWyDgf56VFWrJxS15vzR0Qik76W/I5vUL5f9EtbnbdRQXReR4FIRmC4xn1JI/Kqd7pWm6hd6dfW7XsKW7ExRiY5lZTnBHPGSPr9K9Zi+H0PkyC6vWRHYuY4sBQT1wSMgH+tY974aKTRQ6dPDePCT8sQ+cenHQADjrThWcJc9tf66ES5Zx5FLYx7KLTtP1G+1OWGKDUp1ZZWDAoxUDOMd+BkGoLfXRriN9sQC1VtsLJIz707E+nU8UzW9IvY7m3t301oopZd9zNKdq+4/HHX/ABqdLXTEu1MV1KIYlIRY4yqBuvYc1EsUnLmimnsvI0jQ92zd0X9PuJSVsLDTmigQZ+0mQsq+gG7OTWt4j0l77w9JNpcVvLqybQZJgqsVHo3p3rlJtWisJ2hZnZ/lwrgA98k885PTjtVrWtUu9M8AanqUaSTyNhFXaSDuPTA7VvH2nNFRV2/xOecYcrk9CjCLnTdIhtrZGVEJubiXfuLuewJ7Eg/gK5yx00+L7P7Vb3DRBJG8z7QwA2Y6nHXHt071QsvEOsxRW2oeIbBXtJNzxaeseLq7bseceWg7k/QZrq/AOoah4h0fVry70RLDTy5jj01Dl5VBzIxbrn6AdK7KeFq4Zyqys5X3v33Vv62InWhVioLY6DRvBFobvTLq089Gtdk2IH2JNtU4DL1IJO7qMkCurtJIRf3EcsRQIcF+nOKwtRtM+DdXt9M1v7LcSJ5UExbcYO+0kcjjArjtR8YX0ut6d4S0xHuIbWArfX7EhWl2/wAPHzEd88dqwcXK6Tva/wAlvcE3J6kXjrW9KW7OpajpVhdXdvMiwNHKxyqMdpJ7gEk8V1N3qwudC36hdrBeX0SukbKCYmb7qkfjn6VzWo2un6TBbiVYri5yxUXScZxw2B/dx071UsNA1CXWE1e5eW4BYlBvHAwMOQe/bHas5VaWI/dRduXq/wAkjaFKVKPPLqWdM8D6RouqG7tNTk1XXHhLzOy/ut/onv19a7iwN2EKx2HlK7mSSaUKEYYyGyeuD6cVg6E1lpi2hvbsyaruxHhei5OS2OOaLTXbiDVGWcCXTh5m5X2iOEbuOOuevFV7So5SipX83pt2M3GLim1Yd4zuLeTw/eDbdTRQSxqsdqQGfqdxGMbd3PHoKv8Aw2uG03RLy91RiYBcdSOSGHIx+VWvDGqNdQ6gsgJiEm+K3MQXyo8Y5J5bOfeukNpI2nWVs1jEDcRGOZS5GzI4yvfPfNVGbhS9lJat3IqK8+ZGfBpdhPPba7YiOeKYKYLhmJZVHZc9KZay+IJtYR9Qa1Sw2yLvjdiQd3yAD/dxk+prd0/TbbT/AApBZvIiwRR/extVRnPArn4r7Tr2xuGsNRiWMjYl1GpZt/8AsgjaW/OpTu3bVLTUnY5jxDoMeu6v4X1PUbWS11cMsiR5LCKNTkhgOBkDr2q34bsbLw/pOr3UssUM+p3MjeYxJdlduAe/rjFWb3W9Rv8Aw/cf2Wyy30bB0UAcpkAgg+559hWd4j1aXfcSPYubWzUu84jLKvAB57VUK7qU0r6bW9NV+YOk+drqYvjnTraLQDYaBbRQQvKjSbpGBnLDGW9DnHXrWxpOgaVqHh6xs71JPOssghJ3yhOMgNnoPTtWNpROqaGuqWc32iUjyjbscIjlsZzn07461ShutQsNNn3kGTDR4VsAEn09c5olianIoqVmm2+5pHDRbbto9D1aBLIfZozbtuhURxXDkFtv90n8OBWdd+HoZtUtb+5laS5tZJGjeJtm+PB2hl53EHPpisCHUYdI0pba8uHnn3IqEn75OOn6/lXR6PfLdjyJrhnYjALAq3puwfQ1yQxNnZuzaLlQsr7o4DX47v8AtDfZxtbwvneLpAQM8ZGe/J/OjRrhZ9OubaONZZ3+S5u53yQnPycdfYDpmul8b6WxXybg7UChQoOGlb0Bri7awGmtFDfZMhXbEm3qvqR0qpJ1o8rfvI6ItQtJbF5rabUbrULtLKRY7mReTCT8qqACpHIzgVq3nhy7t9LV9Vka6ty4aC3RsRn+6XJ7/nir+kX8V9bC2E7Wyw7ondOC7DsmeBioJtRnwdACMxmi2RStyIsAncc8k8frXJOpKyUndI1gtW4q3cz4oLqG5iEclvEsgDbYoRt/8e5JAxzgVoG8vNDv9OhYm/s7seWkONmzcSckjqBtP6VgapLq3h7SGm1CWOK3iKjzraEyl8sFB5ORnPOeldVDr+k23hiJLjGoahG6sY84eF8HBOOmR27VqqUqsFO1ntczlUVOXK9Uc7J4Pm8QapJGLyRLYESuREESMA9Ce5NdB4r8HySxwr4Ont9Pu3Mcd3c3AJd4lGAi5zhcZyO+aw7TX7u8vrW2tVNrAYHlFsxP+tBG3n1wW/HBq5aaxfxQSnUWe7upmCWoRvuN3O3oQOc9a2oV5U03T2j/AF8zOvSc2ufqbF/otlZeKW127vfKs9NhLeSW2ImVA3lR6dBXL32sW/jCX+y7PzF8LrFvkvLcnNwAflVSOR8369qv+MJ7pbDUGt7e1m01bNbS9NwAfOkcgLk55CglgB1OBTLaOOa18LixD6dBbL50enwj754CFiOijk475r0qUrUlWk9enlZX+88+Uby9mkb+tXmuwa7YWuiW4mtoov3skyFkhjUDI9WfHT+tN1SWKLxBputWPhSO/v7qFka6aELLEoHRj/DwTV+z8S3ai9nultHitCyzqWYSORzkEcDHbir+sxDxd4LuDYX1xa2t7gb4gFlTGQyk+ua46VeMrJqy2e/42Np0nANC0Lw6+py6nZRJp+q3h8y4aCcMZsdsnPAPUDFLceHbbSdT1W+shcNqF+iGImTMamPONo/hPJz65rg/D3gHQ9M123vHlmgTTolijJnDIRk5JPTJyScH61q6rP4si+J1vHJlPBcFuzhI4xiUkcbm7c89e1bSp3m+Wd9Nb9bdOt+hlfRXRzXi7Sl0jUmv9SWEXF2iszfU5IC9u5x7113gjxwsGnpbTpLJZxO0aOx+dUX09QO3tWj4i0TTfGNtp95bXCTRruEUkbh1Y7cEZ7jjHXIIrkn8NTC4E95v8qKQKsO0rv57j+7xWLjGUdfi/rQ6VK6s9j2y1nt7y2WS2kjlgccFTkEViN4M0Nr43RskMhycdh9K87TXNRtNQki092/dpsYKQnXnhf8AZ457V0Fh401G2tyl9aiZwN/mFsAp2OcYP4Vg6U1uhK6+Bm7eeCtOuLV7XLpbSSCSRATlsdBn0qS9NlpL21vbWq28MR6iH5eRgYNZVn4uuL9Z0tTbm4jQtt3jB9PpmsO+8SXL6dKNUukErZ3pACwQemefxxU8kmtFqVFu/vPQr+LLXUPETQabouqtYWxlEmoXMC/O5B4QEnCqMcmqWmLpNlrjXGmWF/rczTZmvbgbYUYE/OCwAbHbAIrVj1UwafcABYY47czKEGA4HoPy/OmRpLFo7X3iu6WFsArBGCY1DH5cg9+/tW1OvONP2aXl21+WrCdJOXM2Ztld6hoXiq98+8i1HQLg+YJn3PdNKRyB2A7YAxxVzS9Qgn1Se5TUL5IMGKKIsAqk8E89T6VlvbpbkyszMHm2gZMixjGfwzjv3+tRRw21l4juLZ2SG2XbMWMZAjLAfKMdSG7D1raSqNqTa1WtkQlTs12NPRU0/wAIzasreJP7U1JU+0eTcy5YBuFbb0Uc10egeIpL/wAL2twNtld3P3mfouGxtHqcCq3h/TdGlXVtQt7JPtk4xL5kfzTDACnBzjG0cCsn4eahq17cagNXsLoW1qT/AKVfIirweBGiE4xjODzVTaqQc3urXvp07GSTjKxs+NNP0nTbnTvEt7bXmpalaqIokhfjqeSMe+PSuQ8X+Ob23Hlw2xt/N3M/mHzCvbacdOvapLnWJI7i8mtBMbUFnaRjvZiT93aBkn6dKr3emyXjG5mtZxIV2B1CsD7Y6fnWU3aKdRXj0d/w8jejBczs9exF4Z0tdb13TbaaORZGHzOjY2Rqdx49+n417zHBb2VqI4o0ihQcBRjFcn8OPC76LZteX7+ZqFwMZxgRx9l9M9zXJ/F7xddwaidJ09Z1igRZppYYy7OS2Aq+mO57ZrCnGpWko3u2OtKN7LZHcXV7bX9w0bTKywSFZNzEJjufTjrVvVdd0jQLdPMeNDIMpHEBlvfArwvQdcaJpIIJC2+VNzSuSGcg898Edc+1XNa0ye4u4GfU3u1TLSNuCswPUHjBA7dOlZRac3CTsl1NJUdE19x1us6/d61IyYSK3KbkWGQkn2Jxj8K8/wBSk1BLkxxFlBOVK5PPHbpXcPpUkVlH/wAI81lI8IXzUuGIwDjB47/WtHw9fNqt7Lp2pJax6hCA5jtI/lABwcseM11UaSs5r3l+KM51bNRtYwtI0G91a8iN/Hb5KruZsAsB2/z6mt221efTLu6ttQtolaFTLAsB3LJHwBuB6Gry+FVfxbceIRPfyxiAQW9osi+XFjlmAB5JIFcZf+OrnQvEOoXepFbvw/Da/v4Xg2SxSZxgDrk/UitqcedP7Wn9IxnK+iVin40vI9d023h0gvZaxJtkkt5PmcITxyOmeuPSt7wR4dHhXw/cT+KtZgSa/A8lfOII9cFu5yOBWhbX+kXej2uu6lpsdlNdRoQbtQZYw2PLQn8Rx7112tWOkwIdZvUjnNogaLf8wVwOCB69P51csQo0/ZpNK+ve/ZMnkfNd7nAeKpdP0rR7extrWVHjbzJvLbIR24DH1b0qpaeHr271dItPLC4fa0kkygbF4zux1+g71nWuqyvq881xHJFbbUuZpZSBu5POT0HGcYrsvCevW4unv4o5JLSRRHFIMlpsnOQPyrkxCcFFSvrqzqpN2bj0Ok1fR9MsdCuWaCKeeOIqZJQGZmPRj75rzxfMiubX7PuKJlh0O/jpg9ST3HTFa3iPxhba5cC0tkkFlE5WZwwG1wO/Pb0HrXO6P4tjsbl1sIWntUOxlb5SobHbn69KKNKpzOSjfQlyXJaUi2sy2euPplzKU1Fl3mNYtqbeASWxyc/oazvFWv6BpqIt6LqbVZ1VRFAvzuc4ADdAx9T6VH4w1LW/FPiWHTdOga0txGHluLYhprlM4AyPuLjqetO07wImmaidY1KdblkYJZw4z5S9snuepzWznBqEpaJa26hGDV7vcTR5RcyzTa9e3xhtozO0FpcqREFy371wMscj7owPrXW/DPxVeeJ/Cser3OnHS0uWYR72LEop4ZT15+n49Kh8MWlrqFleyvak2Skl1RMCT/HNLdGXV9Gtp9At5prpXDWcB3QKHGRtl4+VBg5HtWs5e0unG23y/wCH/QxUeTZlrUvDUmt+JrPVItTmt/saeW8MkhaEo2QSE4yx6c9Ki13wXp8Gu6JqOm6RfXws8/Z7COcRQQtnm4YH7ze2fwrQtrufwbpLx6tqDa54guW37UiCLuxwkajkKPck1i2svi/xZZ6mL7Uv7CijlEUaQQ7nyBkqTkdiOhrONeSa5ZKy06pefmHs762NHT009GIsYo/NQurujbju77jn1xkdK5rxS07Ww0ueEeVIp8yRZB85I5JHv0qWHSZdO8Ixw6UrCRgxQFjvdc5bnufSuMmvvssbQoWSaTY135gMnkZHAJ6Fj+QHWsVScrzg7u+hvCSTtI1dIjgsbKazwbRYAGZHkUo57bcHP06VpeHdAv8AU9Pvb3UbuOPQ0JlS4PzSEDORg/T8c8VzRJk06CWwskjt937+6kCqCAedowSfTtXoGr63Dd+HU0m2s3toLm2Cs0zYO0Yygx0OMV5tWcala8lZeR3RjKEFGOv6HBWsMV/I1xZalbXV6o227SONqYP93PBx1rqbTUmguNOR2825jYnKr03AABsdBu9a5K+0/TROIYFSW4RgHhZA2Mjuw+YfXNXtChs9O8QWIWJ7ZXkAljUn5yOmccOD781pSjV5PZ8m+t/0FW9nd1ObZbHb2HiDzmvNK8WKGv7aRW/cKSsIboAzY3Hvnp1xUXiXRYpHheWQSLIhdLlR1T27A84NWGglu76Kw1jTxcxwoJjeM/7tmySU4OcjsKuaFq6eKI761sdPnW0tvkXeAEkHcL6HivRr018UNPy17evY86jUa32PPdTsmg1D/Rln8pZkJCsFCgkZPODt6k9c1Jo/iH7b4nupAFGEbaG428KufT+Enj1r0HWfDEuoaS11aTC6aBC32SW3DSkgZKBtw5PTniuRt/DE+oWCXFxYXejSBuPtZiilU9QAAxBB+tH7urTjGcdtG/8Agblqbi5NPV9C5biTUongkm/czZBdOgU/xA+w5zXn9/GyTm20qdriGS5YmRU+9jBLE+/H4V3TJPZwPZAeRG+S+913MSPmyB0HfFc1MfK002unXkMV8pMnnj5xEcY9cY9q5atVRT5dNdu500o3dn/wxWt9TltNSY3EU0b2UYZ5iQykArhUA5yee1dhcXiRyjUr+KKDUbiMmC2AA8pSM/N7nv8AlWn4L0fRrTwiEu5o73UpozJNdSEnD8kYB4UZ7CvP9Wnn1WxuhpRuJtUdWY3csZVbbHAQZBJPXkDFctJWqKUnpI3m1OL5VsdNDJaXugQ29+Iry6M/2qOBfljUKMHgddqknmr2hyy674jjvNPiikthL5NwrfK0WBgEfQYBAx2p+gaVcNO91dx7/sWj4LsMCSaVgWJI/wBlAPxqz4f03R9Pnt7vTxczS7mdmvCQoPcD5QAeBg98V6NZx9kopu+/lr/SPPptucnbyLfifSJbHRDDZeT5cs29pCMM6sc7cevvWb8JbuS0t7rQpoZAMPdFXffzkkj6Zxx9a6TxtKNZs5rDTV+1z+YY5ljlAEQA6k+pyOBzVPwAtjZy6pqV1bNYmzi8m6mnIAJHzZ/AfzrCMltb/hzSV3TuzifBmhan4v0HWZPiJb3cGmfaElsrUt5HmBckKB6HjjvVrwvpvi3xT4r/ALe1WOPStEjM1mdMnd8Twbdqnb7etb9zqek63rkN9ePdNbxA/ZmKSYBb6AhcD15rZOj2mrTTTBrq3RAHDDf84AIydw/Qf1runjLtqC3/AA9P8zmjQa1kZvh34ZWnhyw1uHStbvora/ULFCG/dWY3Zyi/XvWZ8Pr291XRPEunJHeyS6ZOILKS9bElxxycdhngcntzS6ZovifSfEV9qa6g4glBVbKeUyQgdA3t0yAPfNa+leLpdQ8VXeixaZLZ3qW3nLerHugkIxkH0OenrilKrKspRb5no77W7i9n7NqRz2qWun3Gk3M2rQvAphlhlbpMingqMDnnHNcj4c07W7wQadaOYdEICW0RYh5Iycs7ZG4HP0zXZazeeIdM1HWL+TSLPUobaFpoI7YHLuR0K5557Y/GqNokujSjW7nEOs6nAjzQTk7Y3YDMadMD/wCtV04yo07N819uuv6eo5TVSV46dyvcT2FnBcaBoPloFXMkrqZJJWzjIPoCPwxXV+HPBFze2ySa2DCkWGicHDlf9odPxPrU3wxs/wC05n1OfT7exEDMgigJKyMe5z6c8etdTrWqNLPLY24KouBNLkf98j+tY1anLP3VaXe+v+RSu1yp3RyciaHqXiS70S0n1MXcdsYhL8phjBx0BHU8c/lWVqGvQat4k1Hwz4g0n7I0RARzL5qyqFBBYYGARnueldrosK3GpIYljIXmRgnYD5cn19K848fWVze/EG8v7WKcWwEdtOcZEu0Hp6dSPU1hKUY3ktGlp6mtOLm+SWpe0a7R3mmltflSQ+WsyrhwPusPQYFYviWWe+1CS8MLoWKyFIsDGDgNyegHJq1a6lBE+1baadmdFCsFQAZ2kgscHH44qrZeTrd+bfzllkslMEoUlXXPOMkDI9/aijze0c2nypal1FFK2lzr/BU7Q39pGtu7C4jeSacEbUKjAQfUEkVh2Nqtt4IWTQoRZtK5uZYZmJYsSeCRzkCuv0/SZRoEttC5jdYmQSpwVJH8P0z1rlrrzprW1v7DUbe40dLdre4QnBkmUYOCfwP/AOuujmdSGnl+pzJKMznJ5RNPDNaXht5A7K42EiUY+U+mQc813HgSOfVr9IJZA1pa/vJwkO0Ox6Ak/wAhXGQW1w14Vm3qjBHRJLiMouOPlxyM9fSvWvAbS/2ZPcMigyTbQFOchR1HHrWWISjJQTNlJuDlY2dUvik0dnbuFlf/AFjAbjGv09TXkvxn05odU0i1FxJFZXUbrO+45YrzjI9c/pXZQLfWmtSSz7g0jlj5inBz0rf8ZeHbfxLpBtbhF8xGEkTHjaw9/pWMok0pKnJM+bLLSsa2lwsyR2aOkkSu/BAAOPxPP0FdmiPJcNPCp3bdrsjblxycgH8a0dZ0JNDCnUoBbRBdu8IJVIz2/wBr6+tZJltreH7TODb2eMW1tnc8j9t4HX6dKtVYuKg9zolFt8y2LlzctaIqibyLFSreewLNM56Y46A9DjHf0rRtNcksp8zlARhWndQWkcnhc8H05rLku53kiu9Tt41bGy3i84Fj0OXx9cYzV03yaqzKbeLfHxuCghemM+p61NCnB6NMVaUrdDpvDketzapLI1wkmkyputiwG9B1MRPHf19K17uG1F2q64LRLmRV8ueSNQC+cBRk88YGBXG2Gr3Gl3a+Qq/YWHlyRSfdZs9c9uc81uazpY1e5hn1TUlisoHUQIyhirnoR79Rz6V0x9+znpc45x5H7uo2We5u/EUtpqGjzRwySgwygB42wP4uynjiuh8VJDqNilozr5Dkl8Hn7p2/h3/CsvxHFreo6fo1p4S1NLeyLK1zflgzMgP3V4PJwaw9M0vT9H8SeKHE9xq2tGL7TKjsVEcO4bUUDgYx25qnTUo3Ts10+aWvYmMrPU4PUfDL3viD7Ff37/2BaSNc3EbE/wCkvwcYGTsXjgcZzxXYNqC2l9DDahRb2yEZQL8oxnODzt7cetT6NfLf3DKlgrOshZjFMS6R5+8w646VoPoUH22+vJImZWjVhJs+RxwCpPU4xntVVptW9srtIunZ/A7JnL6VbW8CtfSWpjE5kCxSjkjJ5x1BIzjvWY2n2YuPMBvPIiPyJwglY/wk4+bHr0rtdT8R6borRf2vKkIVfMjVlB3jHX9a42O/fxGZdTuhLDpbTM0TbCoMajOAfc/yrHnrSTmtE9DXlp3s90dN4FDaNoM969kzT3LHdt6+WpOAD3rcubK+uoIrm6ge0togZIxuzyepKnkHHHNcnpHiu7/4SCFLuG6tdOtTEySNGPs5hwSR9VAznrmurj8faX4r1VNG8N51CPObq6XiKJeoGT1Jx09KqthqkXdr/gEKupPTc53xr4pttJ1Gy0e21ddJMFudRvCbbzFW3B+Vc9nbH45rubPWLePw82pwOAkyqY1xtzkbh174PNcr49XSI/D27X7aG4t5ohCkDr81y6/MpBHJA2k4rE8XPdaraeD7Gzt3ijlthqM0KNsPGG2Y/QVpUUZUY6W11f4vzM4JupYseHItRsLmTWNVSScTuUeaVxiDccrsPpzjA9RXXww/Z5XFpOkZli824Vfm2YGN/XIPQfhVV5ItYU2FwbqGKZcgSr5eCBxx7Y71cgt7We1aXUJHt1tkWMyFvLMjdyR0YHC4FefUqOo3KWh1pciscjo91bePPCF7aXMN9YK8r26nzB5kfbHTIxXK3/gOTSpEgtLa4mtoIgFlOczcclyPoOK7S+0CGHXzJZTWf2K5ka5u4N+GeUY2MOcjBB6V0GveMYfDGi2897ZXNzE8hjDQIGAHq3NehJycuSls9bHHTl7NXkeSWd/PqUv9mSp5clkgkljEfys2eAD3q9nUp4o2vEK7JjhuoJx1x24yMe1ei6hFoms6Z9tayeytnVZjcwFo32nHPy4I981g+J9PuNF1W1vdP1uI6PAiPLFcKGAwMj5+rZwc57GueNCD5lGyv3/JHQ8Q7rcwrPQ40kmv7uRraGQqS+0Bjg9u+APWr66jBJqUMWkxpbJbuPmIDSXCNnnJ5xn8ckVj+KNSn12COR7myFvcqJFkjhYhk7DJOR0pmi6Peagi2sDLcLLzb6hanJtpV/gkXJwDjqD+RxWE7uLlJ6v+ttzpUVs9i1LrVtDrUOnX91cNdXuXileE+UB2G4dCB24ro7e5GlrcJKHnZVjW2C8l5DkbVI7fLknpgE1v6X4JupbFDrF7GbogFvsylVz9OmfcAVS8U+DxpunXGpWuoXn2mJNsPlxiR1LEBiqk4LHoM9PzrtrYiNWlZKzOGlTUamrOY0bX73S9cy91PPKzANA2Sxz1x7fy4rS0LwhoCpfXEcck0t/J513585nfzN33Sc/w+1c/qFxHZQJ9ltJLO6cbpbq8mVpXJ65AJOT+natTwZp0OtXcDJNc201sVuUuouEl6q6MD1BA5+grnhiNE6b5U9H+n4m9Sja7lqyl410aDVNFk1aWD7BHYRPBc27jcqqp+WZcA7hjtXEwTWs+lQT6ZKbm0kAcKSVaXJ+6q9QSccdq9z1q6stM06WS9EvlzEqJMfKP94nt+Fef2vh23j1v+1IruOSxQExeWgVQxyCT6EDGMe5rbEJ1aSi9Nf68xYaooSbb2JV0lbTwLcWlzcSpfqDdPcLxskHIVSRyo6Y781k3kF1ol3BFbTwzRXcSvA0PKyIRhsn+9k1patcancWk9m/lMvm5tzbx5YJjkHPXPXNbXw38JTQatJcXkCLaRYHlkkh3HO4DHX196mVCOHvytbW+/sNVnUjzS73NLw7e3ms/DfW49MieKeP7RZwliCzNGuA3Pqc1yF94k1TVNG06LSRIfLtknmjRfnV8jg54IDAg4r0fwzLbzW91daN5b3M1yy7Lg7FjKjadoHXP9atz6FBcWjXUdl9gbP8AqkHVR32gcH2rS9OPuOOz0/4JyxlLm5rnm2oWN9p9jxfmzjlmM1xeNuVJmYfMFxzwfT0rq/HVtaaL4Jh0iS8jhlmZZZJ5iQsxUgtubnknA59q4G4t7TxR8RYY11S5GjaMjG5DSAJclyMLEFPsc5Hc16L8XdGg8ReEI7mI7vs7B0+XcCCRnI79BTVONFwhJ+e23b1G5urK5k+EbLxBdWVqHNpZwwIskO9d/n85yQPu4BAB/Gu/m1O206GL7VNjdlBgF2ZgOQAPp3rzu01+yi8IpbaBqMpvIHitY2JCsJOB908bcAkjpit/V9YtfD1vpI1KbzPmLiTAwx28seMAHcTXB9p2Wr/rY6Zq6TZheIr66vrSe8hdxHhhHArhWXdnJbnlgCOK5LVbrxFqmj6RpFlLqMdtel7s3lmczFVyMA++0ce9X/G1rfeMNbs7bw8Y7fTLqMG4ueFefGTtT04+82MgYArdlXVvD8+nWqXB8uNfLt7dX2xKqoQDtHVQQPeuqi1h/fdm+3b/AIPkTUi6i5FoV/hbZeKdRutTv/F5lsbSeVBZWc6eXMhUZ3Ej17575q78R4LlZIXtxCSuN7Tc8HGeO55qr8Pn1QavrGqa0LqO6EIM9kzb45iG4mh5+XqQR9K6DxFLZ6hoDa6xJtLSORZFA3nC91A6nII963qvmqc0Eum22239bmFP3NJFz4VSP/Y1zFIxIWbdHnqVIHP5g1ZvNJvmvrmS1giRZJGIYnrkdSPzryLwh4k1drqO7sbS506zijLW8uoMQbgEc74xk7ehHTpmvSNQ+IptYLJYdPF7cXHAaKXbGGA5zkZHPbrXJXjKg25m0Yucvc+42tcvo/CPhxpLaBZbyQgImcb5D/ESewrzfxVILqy065lmkSdJPMYQglWB4JI6881s6zdR6vqLSalICHHlrFu+QAZOBx/+uuReLU38UAvIv2MR+XHArYVVOAOAew9aKcuR87dvXr5FezvaNrtgk8jHyppo7iyabzbYJEVZcjCxt175OeOBTtKt549fVJpIpJJpEVtj4xg424HJ47n0q14m1TRPssWlQ/6Hb2jrI8srhGaU7wS3PQEHnnrxVn4fRW8Vtd6j9lfy7UGQnDKpOOSpcA4Of0rVVKk4uo2mpaJA4xh7sU1bqd1dsbNLKKJUebzWCgnLbCvz5547e/FctqB0jQPD50i2t3jgEshPmLuLZY5OD6jAB9K3vCktlLC2rRW00U10GZWmQ55bHB/X6Vwxv7XxLc3k0aTxT20zQeXcxA7cdNv16596itGpZqOiW5NHl5veOfutegtZjd2thE8SsY2nuJgjBewVQP8AOKLbxXrErKbIXkNu6LgC4BySeDweB1zVsWd7c6sLf7JCtuAx8txksMjcSOn4VJcw6VbTyRWQmDqNjxom5VA7DJGPpmlVlGlZyblL+tzeEfaLlUbI9N0eW91zQG+2LKLm0YB3Y4Ljr17kYrp9J1dbgxwTZWY8AnviuR8IPb2Phciwkkd7h9srSfwn2AJ+nWp5pnEEBDOskZ3duSP4h6fjWSlzK5jKFm0dnq1hFqVhNbTqGV1wPY9jXiGu6HqGj6u8928jjeIonEXmYTOT8o6Fuma9x06aWe2V5o/LYgEe/FPvZobe3aW4K7F55xyfQe9HwyUuqIhUcU49GeFx6XJfzmWGVIW3HYWUMUQnJLckBj6deO1a6eH4YLuGCPypYQRIpz84Y8Fiei9+tVL/AFGVtSuZIbOSz05GwsKAEnjJ5HbjsabJqFtfCK3S1dHmTfFFNKFV9vUgck9uuKqhVxFSVo/fY3rQpxir/cO8Yabo+taXd6XdO7QBkGy1wqrg8YbqR1GcYNdL4egl1a3m0m5t5X0yW2a3edZcOhxgHHXOP4qw7XyLm333CyxzxsqOEZcDA65HaoJPEV9pHiCOFYUh0xow+c5nckjBC/wgc5zVScoy9nHZd317oi3PC73ZtaD4W1jw5qNjo2i3Lf2DZwMpE2NzsxPzYHeqUur2PhfxW76cEuNV1+RkeViXRViXHOOhyfu+9dF4W1a++w3EGsX0N1LJJMbeRTtZogMge5xmuV8OSTaZY3U9hpzWGn3EhlT7Q5aSTjl17jjv3rtu5KTk/wBL37v18jl2a0Oih1bTNO8V/ZY7SOHV5oAZdi4WY7eQPQ8d+tUJvF5uNDkisrcC4kleLbOSvl4OSeOuKzLrWNOS5t9TGnxy3qPt89SA5OO+evB6Umk6LYa940vdXupLi3vLGJJI47ZdqSROCFBU5GQQeR1FZunGcbzT0X5dC1eLKXm6R4kkspdbgjuROStu0cbI24dUKE54x3xipb+213xKkeg6Jax2xtrgPfyh8wJHkFYwejMw5IHTHPWszSfAfiTU/Fg1DXdYhsbESFYkQqZZFPVUUDC59TzXX+Ml8TLbaXpnw+8mxtUuAbt3j3PLHn5sHGMnnOcZ9RTnTgqqUWmumui9f63KjUfJfW5pW/giexxNHqcQuRnZEyZiXJ5AHXGMiuasZ7PRfEMdparDbSSSyRRRwQgB5H4PHQcnJNdjfatFoFhPdXtwkt0u7yrdZhhRjqzdOByTXEeHPBdxqnjWz8VXM7Q2sai4W2c7igxu59csc/Spo01NudV+7b732FKpyrljuaPi1lh8f6BYXiweRDGRaTygs7ysSG2AHjaueT6io/HlmqfEHw54itrhX0+yjm0u9QNjYxUFc/mM/StpLXS/D5sJtTa4vNTu7lgs7Rl286TkgAfcXj8Kut4W0vX9K8QWNxExTUHDzoTwsoGAy+hyo/KnOaUY26Jrbe+j/N/MmHuu7KL6rB4hvZtPsBNMsa+YNh2LgcBg3fk9quajNC94rtZpNIR5ccrqNyADk4PYcnIrjdEa48HWDWOtXEkYs4nZSIypZN3BGOoAFLoXjK31XT7m5sN91NH5ixwrGQ6sefrXDOk435dUup1pp2M65+Gmra98Q7fUbqPTG0azijjimaVnnlAAwzHOCcjPTFextounQabHbyqpji+cM+OD3PPFch4g1xPCmm/2Tol9pNxrkUGLXSmbEjhRnCjJO7A4B61lR+KNY1jQtLbVtKiiN6PLuo0uPLlhz0YKeffB6Zrvkq1blk9lov8AhmzgThHQZp7eMk068+0volvNJegQFpQUWIj/AMePtjNHjzXbOTwjq8MumzSzwEQS2qx/NIOOR6DnPsKyL7wfrWsarp+jNLBdeHVXzvPucrPFKM8rxz1Fddrh0e/uD4aN6X16O18tJFBJ4AwGbuen51rLkUlLTv7ulvX+tBQve35nnZn08W+6zCTzSOpiRYxlOB8p+nQr7V3Xwsn02CDVla4iiuC+6SKFQpQD3HXpXl50u6szPbuskUSPtYj/AFr4+8D6fXrXSKuj6U+nS2ST+dvCyYbb8oHTg4IIxXmV416sk1HSL37nppUoRcHLV6nrEHijRbJIoku3dZY3uEZucoME/h8wP41wPjzxKNdt7SRQ39ikeYYgxDyEH+IA5xXLTIDPpi2TtmC5uolLLkCFwAF/MqPwpZ5LZI7Kyw9zCkoyrgAwkn5kJ6HPUfrWTjVkm2ny63sVCFOm9HqRarqumXGnlrXTZLSO3U5IYB5skfdAycg+47113hqCbRtH1XVglxeGVQiwIpVn5HAz37E+1Rab4QsH1KaOxEsoldJJWm+cRgY4xjANdhbW9/5d3iHyLFRtgSRuWwev1/8Ar13RnBwUKbvFWbv1OOpdNuW7/A5j4jai8+l2y3TPEoTzPJZRycfxAdhXM+H4tXt5S7O1xbzMF2qAIgB1GB7V1PxS0hPEOnae1hdWcMlvIRfyb+kQHJGOOvY1ymoy3Vx4WS28GGCNYG3XCSJukaIghtqjgsSRx2zVQc1bZx136FckJRtHRv8AE6nUmhNw2kPcrpcTRIZLq1/eTs5+8i9doAxzW74f8RaTaaVLp+kxaibO0XY90672XPG/HU888Vw1/p9zGvh5b+aSHT76NYnlkfawOOQR/exyPoaj1Nb7S7y4XwzMs0UTgPNbsFV4zjKt2zxnjpjisYT9v7nPZ6NL/hyp0lBXtc9C+H+gPpMs6397HfytIZre5XgurDnK/wAJ/rmuptLKe21OeSM7oJDkmRiTnOePzwK868D6w2oyyzRyW5S2yVYth5OQSV9uoPr1r0HTtQfU/wB8qyWhhdkMMmCJOPlYEdjROc5Sbnuc7go2S2MvVtF8PW2u2uq3NpbQzxsekJBkbsxC8HGeCfWr2mXlnNPd6VKUDFmxHuABU84H59qzdd119Fit59SuoZwk3lTRwYypcgJkH0P41Vs9P0nXPEEOuWt6Rdacj28kacrnJOfr1rVpyjebfl1JT7HNat8Nb211ie+0WaByGaWFZBtaNmBB56Hrx+NQ3Phqb/hHfM8R3a3KWzbI4xN5jAEcoT0+ldd4Z8b2HjKz1V9ASW6t7aQ2zzSoY43bHO0nkr/jT7zTre40HWNPuvLtVIzGQeBgAhsc8Z70rSTtPR6epoqj07HL+Goo4byL+1oBbshZbMg7fLXHPOcDj881rapp1pc3VtcXmrbbTzDEzFgGJ54Ldj0AHvWN4e1HUJootNmaKSIN8t395tg4KD1OeM10HiZdMvIrTTGe2jtHPmOqRg5wfXt39zXHOm4ScW9TrU1JprRGNrESabe2z+FxJLOsUySLIzu8h2HauW9/arfw8WTQfCiWniNvKnJVfI3Ann0HXJJ6VjJq39mTkrcA2wDRWrN8jRoMZJPY44Ga821rV59S8Sq8i3F3ECY4/KBPlAclmH8iOa76cKjiqMklfW/p/wAOczUZNzTvY9J8baVd2t2bqykupLa6barwyBHjZTkKwI6HGPxrDtYr6K8ju2hQs02V34KoR1z6HtXQaRcXWr6NbWa3vnzcSSzyRlGI9CDyCf8AGq66ZImoZkmiuI1Qo8AjLYfOQVx8o+prKXPWTozdrGkOWk1NK7ZkzXd9J4mitYrMqjyLhthKt6knv14rofE8EWhywLcSpHJdAqn7sv8AOSBzt+n61pWzL4dsZbu6TN/KAigyFzEPb8TXHSau32me7muXBZiiSS9jnHGenI9KpWmruOy6dfmLVO0XuYlxaW+hs9zepJMGkxJOUMkjMc5Oem0fpXb67DdWOk6ZrlrfBdFsxJc6jC4LNcjaFWHYeoOe/SsmSeyjgaSaOAtGcM0pLMMnDEY6/Su88I3+lato16LC5t7m2XG59uVIHcg9D2wfSqp1laMuXbTbTX9Sa0Xqm9znPCVvqbXOpPdmZbO4hS4hWZvnVyvzBR0CjKgDFT3EMEcskwkmjcr/ABIDlR3LY/wqv4vs71Ndu9Vtr17aGCCNIl6+YTkso54HTJHc+1YM2rxPEkX9o5aVS6osqjD55TaDke9Y1r1at4NbIuiuWHvdzU1S9t5QhWeBrjBCecuzflSAM9MGuRsdI1e4sWu47X/SZFIWOOUKyYY4wCeeO9dFHphtl8+5vHu7dclo2YEgYzwe+PT9awLnVDJdMLeSYxkAiSSFkGe+WIwayoVJNO1vV/kbzpxVra+h6R8P7O9fRNQae2dZ0KDY+Msw7/lx710ml6el0UaSfzA3zD5OMA8rn14rmZr+bQfh7bqL2CyklRpzLM20CM8gZPU4rQ+DMVrL4Nsbqwmea2kLOGYkgsTztzzito037N1POxyzlaTR30jpFGzuQqKMknoBXhfjvxLq3iC9ku/Ds5j0m0JjBbaBMRwx55zngY7AGvYfFU3kaFdSbgu1CcnoOO9eB3YljS4WW4YRTxiVBG67VkyBkY9STWPKn70tl0KoJX8ybR9cuoJ7ddaVPscr4lV2yVBB7YGOfwrd0vwxP4i1ljbPNa6Ai4XcCPNbPJLde4wK5y+0kjZqBH22TYPMBwFxwD6EgZFes6LeW03h+2s7yNYo5FGxf7wGMEYrplKMEp0laMgd3dS1kjKvfAsmnu0+m305tYkJki2JkAD+A4z+fNee22mRz+IUVHa4uGcSBHk/fMOwwP6/pXoXjfxtHomlyQWe27uJht+9jy17k/hXmngqefR9Fv8AxXpFh/amtXVwsVtD8zBGdtpLZ5AG4c+gFRh4OTbg7dPVvz6FylJR99XPSvD3g66bxWurzyf8S6GEpb27A7t/fJ9M5+uT6VzXxg8QtY6q6m0e7gmj8vZvZGUZwen58c5rsfDctz/wsvUoo7u5uYVs4RLb5PkWRx93PQyM2T64HNHxN0q0vLGSZ7WWZomWTMIG/IIyATxz610c7jUip6qy8jkSWrWh43pXgnUbWx1K4jM2lacjLLPNeh5UvScbBGSSwYcjoR7mvQbK707wx8Po5NQ1aCRLkLCblx5bOEJbHJzkDOaueP7/AF3xHp+k2OhaUIrOZEuLhpyC0bDpFtHT1Jz9KxfHfwpfxh4V0uyvdSSyk0+RpD5cW4NuAyOv61vOftIx9rJRTevfTv13FHRuyJm0DX/E/j3Trs6pazeGAiXKRxsQxIAZHUr94Hjv+Fd9F9p0mzvz5ccc5LrASd20c/Of9n2/CuW8L3OmeGNOtdJ027e7uLSJYZZ5TtV2AxgAdBXTzXk8umzPYwG7u4hzbwOqk59yMiuKtU9q/ZrbZdPn/wAE2UORczPNn0dtSimj17dJo88OIVBxPcy7snA7DOeOO1bfg3UdVlm8Q6bZRQLLpscUZYMfLgkPSEHuEQDJxyfpVy08QXGhpd6/46tY7KNEzbWVvH57QAMF+aU4y5J6DjFdOt9pVroV7rDKmn2t+onmkdQrDI6uB/Fz06811zqOEORxutl2vp9/mc9ry5kVLe0D67cXglu5ri4WNRG5DQqAOqL25JyT1rZhuLHQI5pNTu7a2eTLnfIFyo7hfx7Vh6Z4m0xdCjvdIJkkuz+5a5GwyDOCQvXaCDXPTaZpHiO9l8X6Q9vqOqRRvaQTOx8lm3YIAJ28fMAa51Hnb5rpbbf1Yt6aHdeI7/RX0xJr/bcxOoaMRxea5B9AB0Neb6haW3iSy/s/ws974ajWTzbmWK0KySp027zyD+VegRX11pNrB51tG91Ki7obfHlwgDqW6nJ9OtYXiSbxFPZo2jaW1zfPIGMcs3lKF7FiR09hTotwdl30d1b7thNXOe8eaBpY122vdNWzTUbc+bc3P3rhwOdq+lTXh03Wbm0cgW8xBWQMMrOncE5GG6HNcs+lxHUU1INIyTOGBYkEqxySffA/Wu916Wwk0KZbO2zI5Ko6x7DvPQDvg+ornq4yXOo057Le34HTDDK3vrc1NNkUKtrbzrM8UgRZImKup/2h/hXPePfAv9vW7PpF7Po+svOrXN3bna80eCMbh90c9qraj9ptZbcpcW+IFUoyfKdwHIOOv41v2F3GLQ3dvmaMuBcRq3+r45IHTJPGc4HHrSoYmUJrler/AKsRUo2V+hzvirVIdCv5rTxBZpNp0VvGlvPkvNdsBgsx68dMnmsPwxL4V8aSz2US3lk2nsVywzEzt3DE5yAK9N1PULeGzNzG9hcTBD5PnkntyCO3vXHJK8DO9/Hp+WBfZaoELZ7cfhXdCVN03fR+v6GL5+dcplappOlaGkcd3cr9nnUeTNECVLK3UMDjsMg88VQ1DTLIP+4un2Bw/A2hnxkf5FWNIuLy2sWtpkOZpDPHHGN6Qknv1xj/ABqK6mlt7UnybW7ZQAwVsJjuxzzxn9a5G1KXLBNxT110OxKSjeTSk9tC/o/iaWJYo0hljiClnVSF3Nnuc5x1r2LSbq31jR1dFKxPHtwcHbxXicuiz6rLE+nw+Rajb5nlBW5I5Gc5weOO1dH4G8R6Tp9jc2treS3Ekd2trMscbYgJPOT0P1FZQp88nOjt2XQmtZRSluVtYtLbR47qyjaO7DtmWMsdvToe5z161zHl3NtBc/Y5ktkeHyllBy8cZ+9tGB83GMk/QVtfEFbaHX71AkoYMojZOCw27vyGQB3qm0FlFoMBjdjJgsY34wx9R3PWitOu4yleykbUYUouKtdoj8W6/Prun6PaW1r9igQmQCRfN8woNoJz0Aqla6nIukmHUJRFICVSyt4P9fnhgzDjp24681R1W+ltok3mKNQhUeZhgyk5xtyDnI7c1oeG9Te1Sa/TS/tEtqqww2yKQHdwWLnPAG3HJPAB69Kw9nGnCM27yv8Ah6G13JuCXu/r6j9KuLiK/F3NbyrIgQxWyqNjJyduejHsRxXonh7VZb3wtbX9xpUulMwZghYBo8NwrD078dK8uM5knaeSSOWYndiI7Y4x1KqOv9TW0PEN19gggtyg3yYZlBIJJwQB6getdU8TCsuamtf636HN9WlDSWx3HjfTZ/FHhqyW2tEOoNtnkYHYwZfl4Y/U8GqfhxE0iHS/D1kqXN3IBHqbRzh5IcjBLgc5PXJrQ0zxPol/4duNZtb9UsbWYxTyMGURPuAJPH3cnr0rnb7wvZeHvG8/jyBJ2jn3fuLRmlM0r9MgHAXgGu2k3KHs56WvZa79jgkkpXib3hTV5bjSLuE6S2j2tvqUttbs6kGZE4EpBA6n04pvxJmt7WwtL24/tGS6um8hYLOcxiQDPJ4zj/GootJlXVINX1TXJBZydbUZ27iOhySPpgV0/iO1S60qORstLHHmJVXJBx1Hv/hWcpRhUU47f1pdlJOSszyS61WT+y1eC8NraRSYWJAFJ6bs9yxJ61b0vTtZvtKW6czBEBaNcAsy9Rux0+lcdqml2VzfG4gjN3fmQefHOpKvwOVB/AZHpW9F4p1e1ijsPDul2lmrAxMlxMWJzjAj28qv1z7YrklOrJuHLzddP1Z6Ps6cEpxdumug22tZTDNcXkkk0sbK4E0mEGBk7VH3s9sjIpmlzHVNVuGW3lWU4KZXDMeg/Cun+Ewn1bUtSudVhtZHtJFS2+zhhHI5BzyeuMda6fxqTBqMEkM1qLlIwJjkqQcnHA9c9zWE5Tr2m9Gtily0ZOnuclDBJYII1BmeWTfdSB9pY4/MAdhWn4dv0sIYPtU62lvHbk3M8jZC85HI+8c98Vymo6rEtwTcSf6dksw8zYiEdccdP1rWjsZNQ8O6bqAeO4juJllcopRSoYjAB5OORz1611U+a6UlZPdmFVLleuvYp6x4fuLPTrbTLS81FYpboXDXsk2ZpE3biDxwDx0NNtvDya1/pF2yRO0vlnf8i4BPznPXHP1ya1vEuoSXs8JtCLd0UgI3OVJwc4zjtzVRbmxEM8XzJdRqqIHJeRA4/wBYd3HIBwPzqnOu4S73uKMad4tHOT+Gr2cF9aniFvAxRmEnl7sE/MfQdPfmuxs5bLSfD2rXNrEga3tBMbdOJJAOmR1ILADJ965ez8+7vxdalllA8xmYYTaOPu529hk4zXeWWj2CXd7rembWutUihSa4uH/diFSPkRT0PXjqTitIOKjFN+6tfV6aMms5XfdlSUyajpsVhe25n1OKMSTsIiEVioJAY8cZxxWA1rGIltYLA28yMCG+zqAAOoJOfzzXa3mpyQQ7ru3WMSybT5TkkA845/pWbFNZte+c9jK7RMWSFvlLEc7vRl56/pWOH5tZNWiyqkkkkt0AhkigktBYyxrIqhWUKqLg5/H6VzN3FfF2keSAxkmJvLBJxgDOOg6emc11E7z6dd2zC6EzrAJreNZMhlzhoztHOc/QcVltZR3t1bSHME07gsiPkqSef69qlr2MeVO6Y4S9pLmas0ddrOn2F1b6Pa6lZ2s6QWyLmcZTOBgAGui8Ol2tvLgSGC1icqqxrt/ADsK5H4oeFY9Xt4JZrv7MbZ1njmbJWIryxIHXjNdb4LurG/0KG90uaO4trglxNHna/bI/Krd/Zp3/AOB/w5ztoi8fwvN4YuQkhjVSrOV6lQeQPc15ro+ieHdSgSPUobyO4YEx3Cz4UH+6w7H8MV6x4lUSaLcxEgeYuzJHrXjlx9nsGU3U1pp2ZQC8qY39sAscVhGUVJpq7ZtS5nDR2sZHi3+1dK0q0tklge3jG03Svibyy2MsvQ9ufbNS+HPEtzaaRPDDOv2S1YebNdLuMQPPyN+OcYP4V1axeHp7OR21XT5pCm0I8wPHYFT2J9K5PXbVrbFta2VkbUy+YQGyDwcEAcdeK0o0YSj7Oa1v3/RmsqrvzLVehxGtXlzq97Kpvw8LzAgg8Md3Ga9y8EQWPhzw5eXTQTPaQRlnSOLe8jZz8qryTxXlDW1+1yWFuQZG+buEXvjHJ+le1/DmO6HhkHUUAcvIy4GMoANuffmuidlH3UlFdnqzKo/ds9zNtbR/EvjW01bSfEE9nYQoZX0+KEoJZMYLOeNx5wQckYrUPiWDTraaOdy7LP5TMAMqc4Jx/Sq3hDRzYXdxqsOow3UfmsZYomJxknOeSMjIIrVm0rSGudRuZT5jSsTJGcMCSO4/xpVZQUkm7pI54X5dBl3qwutMtxYR7WkcAsy9eSM+vasrxjDe3HhDWobSUjV5I1jQofnjBYcgdu9W49T8P6dDaQyXiN9l2mVAdzRc4DHHPBxXm2t6T4ig16a+Vbm4n1C4llWZD5kXl8CKPjttGSemTVUqHtJcydu1+o3U5Va1yv8ADnRp9MlaG7kiW+lBYwuTvYDq5B5zmvU7TU4NCspb68IWGGLzJmVCzKvGAAOueK57Q/DFwmqJql6WileARO8kQBX+8VNYHieHUvF/iu10m3h1HRPDFixlur+Rtq3q4xjtkk8Yz68VrKmsRV5m9Ovl6foOU+SPKd/JcWeu2U9zeQrPoqr5yQzLgSSnDJjPf/GuZguNb1D4eWer+Jpn0u2inkku7WO0Ekjwb8RpgZwemT7Vq31ppviLU7LS7m2vzb6UUkjVg6wy8ZRycYcDHbiuQ8S+KvFmm6jaWuo6zaWqpKZp1hhBVY84CY9MevrVUqfNaMfXXt5b6vvbsYybTua7W2g634ftrq21Cc3XiKJrW2+0kwukKnDrGoHyEDjPoau+FLfWtPsbrQxpNtYfZ2aGzk27oDGOEYepxyffNXrC+s/FuiaZqsNmypaXhihWFvKUAjBOO49q1PC2vz6ubuO8sGsrqwnaIK7DMsQ43j2qJ1JWlG23R9NdO3TyKUdUZHiHWrnwtpqbzHJcBQvmqpCqfRRj7x5rj/Efi+9vILK3eWSI3UvlTeQrGRFI754ABxz710Xj9bttYuIZzJHpstus6SKwBWQEAj8uan0s6L4e0O3t5ZWd5S3myEF2lLk9SOnUfhXHN00lOe/5/wDDdjppxfTUzfBfh6C+jilvUnbaP9HR4ymFUkb/AHz2HYV3A8MaXFYbFywTJ3v8yr+FZHhvxJBeSSyLIqWscnEr5AIxhQM4611kGrWjIR5kbOF37I8E4+lc0Kibbe5VRyTt0OKOhwWupC6mT7UYRtbdwiDI2vjtgd64gazd6V4kvr6BUutOAlcwqyhDEq5wvq3HP/6q9N8T32nBVu57ZZ7Ro2EkgHPPABHfkc56cV5v4pjvYp9Kk0u1nj09ynyyxYw2QCGz2K1vRs5OKtr38v1B6xvK56rNpdm2n/2jp6mOSSDcgJyPmHofrXj+uTXUs81hHvt7sSfvJRgeWg52g+p/ma9Y8ReJbLRbO0tJp4YJJkCoHO3jpwK5fxt4Yt9Xglv9OmhM4YGby23Hj+IgdT3xWtNuylL/AIcypySfKefeHNQls5UgheOIEsZFlA4ix93j+Ik+vqanvnitEkVfsszNGxMSqE2AjgsfUnHvWjZXljoV0IreK3+yKuS77WMw6Hdn5tx59hWBqWlTfYnVbPDXUjPDHuAyS5IOTwABjPPahctNylflUu39bnQr1GtLtd/zNHwtY3Wn61dxWd/BNcXUYmmMS/ONhA29cbu+cdq6IasfAuiy3H9nB830QuCAu0xMceYxHQjPOa5JoTfa/bWFzB5N6UeRYmYAykAEbWBwcqWx7itmz08WVnOsq7AyFGtnjDo+TnEi9COAOue9Zx9nBubldK2jvd6bf5DqqU0otWb+47Pxzpk8msRxWkEMlpfxhjJLjbEyjGQOpOMYx+NeaXyG01GWFXe8SE4lnLfIg7qCOPwH416RrfjHTH07QrTWdPmhtNUVRb3jL+7t5cfKG7jn9K4LxhpVxHLMJ7JIra0YRyRpwAzH7o9Vb5Tmp9ndRlPZr+mFGbs4rdGHNZ2l4sUWjbFnXlZrhueTk7R9ccmuisvEssOgJo8tsiWNzm3mvFfNxMVByxHZTggd8CuQuJ4LCCWaeB32bpHlt22hGHAQD0BIz612UXhG8ZNIQojLbFd7gbm+bqR+OCR1o+pQh73M9rmksS5JRa6nH6nbPFa7dNj3WW5TFyQzfif616D8PPDWkaLpY1rXLl0jBa4dJX2pGo/ibPGD25qre6VH4fuP7Q8XzLb6TbsuVXc8krkjaqqMnJ/rXW/EKziuvDF5bWOkPqUkiLItn522SRRgqNgwcZxn2relDmahblg3/WrOfEVbK97yL/iIyaN4fsF8I6JFe6XPJtuok2qvlNyWYt/Dyc/Wue0G0u5PCOqaP4b8QW0sAYPYXdsxJtwsu5omI+9tHy9OmBivQLAXFp4YsoNRgQXcyLC1vHyqlhgg+oGTmsLS/Dmm+HpUtNPgMc0citI6gqJtw6+meMcda0jVtFp73v3vbv8Al59Tjtdk2q6GkvhV7eyvLnz0lEjPEfnDKNxVOPrge9YWtW+t63YaNe6dcX9l5ESy+XkrvKtysh7ZFafw8v8AXDYeK59dtsGK/mltUGBvjxkAH8OvvWT4f8d6/Pry21xoZGm3cKSWpOSxJALZOMFecZ46VtThUg3ZJ8vmupM5J6Pqc9qMTPaQ6jd262VxJIyyIN0at6Mo7d+tZKx2iKtzBJMb0blFuMTg/wC0D0Xj1zXbfFyz1OHQPtWjQrcpbsPNjkBcxr/eUd8V5Vob6lqlnM96FGcgxwLtLD0x16YrlrwcqLcFu+m56FCV5Lmd7dzvPD3je8svDBhsLKCK6jBDahcuCjsTk7FwN2Og7cVW1O6stRtp7i4G9ptssu2TG/POfeuVfS7i91Fdu2KCIkuHGSozjYuDwcflWqojeOaMhxz+6tlUgvzgDOPbrXNDD7RU9Utbm0ppNyUd2Os9Eiuo2W9e3S0xiSHG9lLYw/PevRbaCWHwfZRWqGOKKEKCX3naPU468k1x1hFZ2t1ZvNdMZipAM5LtGucAZJ/DFd1puvQjS302Ly/NBKA7ePwFbuq1KMb3XY5px0bW5xOrLdWsgeyRJTH98ScMQe2MiqOtW95qloZtRiVLKALlWdYg79mbJJwMdPfpWjBp97HbX7SzJLKjkqB85JJwBk/XpVuXSL2wtxe608UtpIir5CsS7SEkFeygAfUmnG1OUmne3UuT5krlHR9PMVjMl2y3cKRmQQwIzQtwSV46YB9a6JL+NvDFv9mks5ZCqg28Qw0YI4Cg9cU3w3rSR6nDbt5a2L7kMKJjCMODnvyOe9VpNNt9PGpfYmc3KuBFKXDLwPkx/dODj9azcuRtT0V7+XzB+/ZrcqHWo0kSzbzLqNollZNpwmTxtbHXPp+tadnHp+kI8sKS26lmmaad96Anqcj+oFc7Mtla6XcSTXl9bX6bZPs4B25Y9GUL3+vvWnq4nmITTF2wRgs/Iwq8kHnqB6V1Ymm42jR0v9xz0ZKV3U6GNe6+kzuLUXMLSMMSiHbFIOxG7GV+mK7T4caEvkNrmpAqFJaPf7ZBb1xnOKwdM0i61bUNL0+cQXICCS4cxBHgX+9wMEnoBx+ld54+upNI8J3DaZaC5+yRgi2ztDkY2rntk4rk9nT5l7O9/OxvUqytyvr+RlW/iCHx1LrOh2yzQrbyrBdEIQ2wjIyT2Iz+dd1plhbaXp9vY2MSQ2tugjjjUYCgVh+AGgu9DTU106Oxu7wBrlVycsox1PXHStTxDfrpmjXV2zKojTILKSAffHaqrSUVyrRL8zmtd2Rw3xM8YR2MSW9sH3ByrOCCMDGTjuK5DS9asLq3BtorC9Tb926jXcT1zg/1rE8fmaUXerRzz6jcW6j9xZYCe/ODwM9eay/h7r9prmpy6fptpLEU4kE/zIRnHD9eevTHSiGGlKHt4Rvb0OtSjBezkzejtrKW+mkuLOytUwTGlpwGx/sjIz+XNRyp+/klkWPevCyDI2D6dM/hWlr9vfQWH/Eokso2X5RCG259Scf54rk0vtUmLvrMlhbxMQqtbrj5vXPX/wDXWtSUprmpvb+vMVOK+1sdJpMs4mVbeNG3OMsXOMeg9Pqa9UtLWK+0Oeyu5XXyUDu4k8tcli2Cw7dAfavAdDsBHq6vDMzSZPnFA2AexI7/AP1jXrvhiwl8R+DdZsNQuIEluYHjF3GdwXOcEjI6cZHGRS9jKlJScr369vkZ1pqULJWsUfBul32iajfQSiELeKSn2QkxjLDgZ6jrzXe3EaCeOwYeXJIWlErAbScY2kd+35VxXia7u/DOi+GdB8NW63Go+bHGSiYV0XlyPQE5PtW7fP8A2kRq5a7jurFOLYDCgnIV+Rz3rorRdV+0ls/020OWEuX3V0PKrlmvr/XYvDtskbWsmxJ7hiFeYsdz+4HzEZ9RXq/gm7Z9NiudbuGknjjVBIzDaxAwWAA4zWFpRmmj+waleTRS3EpaO5jhUb8c7WIHT1NZXxGudag8TW0VhBFqAwq2FsrfKz4wXlA46jj3roqXrNUv627/ANWIi1DU1PGFnF/wmOla7Pfa3sRjbfZrSIvGPd+eFwfxOKiiN/oniG/HifUv7Q0i9b/RofL2Q2yDJVduc7jkZbFQ3ll4ns5tO1PxHqzldMi+0CztJNoupyMbHA4Krjp3NU/DlvbeLDNfeLpFnkiJEaOTGCH5AwDngDFc0qsYRUW00lZ26drafibU6Tk3K1jqrfW/D9vqMOpzazNKHTyoIw5EUa+y+vHUisC08P3Ut9YR+FdWtJtOmmmuNTnuVEt3JubJjUMOExxgcirrweGrKPVHexju0EUcaWSruZfkz8vpnI5HTHWuJ8U6PBpNraavpGr3FlqDfvltoMksTyAvPJA4xzmuahilF2creq08tuv6m9TD8y91HSxfEa0uNItbbw5oeoxwx3UlrJD5flsjJgn8SDnmu0vMrIL3R4kaSWEyLH/tnjDfiaxvh94kvPFvh+4sPENr/Z2rOWRXAAMwABEoHb6e1O1C38TaDZLcaRFDql5AhjjjmkKI5YjcW9MY6d66JqDlyx0d+97/AD2Of3l8Rd1eW01/TLaK/s7hCZGVZQACjqPTnhq4b4kaTrPh22ik0ZFuNNmIaQoAZDgDHXvx2q5p+t6hLf6NpV9oWoRau0jCVY5CYlJOS+8jBA616uulI2kLZX5S9x1aZeCc+nbFRXp+y5eZadtyqdXqmeEWNvBYyR6fqt3DaxQlpY0EYw556sfTriut0bWoX1aVnkjliVI44nQYEm4HJJPTGB/Sqfi7QdJ1wXMaTzRSkB9iLkBscYz256Vx1rDd6VbS2thdzO0e07AQCMcE468VwSpKolKm7yb2/Hc77ppqWisdV4iGoTa0LaxCyxlDMIQ2A2Dzn2HPP86hzd6p4qiv7q7lhsbJg08UrFViQfkuO5PXFcnYz3kviV4V1gRar5GZbaMNJLjBP3RnBI7cV1N3qGh6tp8/hfWYbu2mkt47+7SZwjbFbgSn7qZ4OwnJFdmHwlRT5+j306PfR/mc1etDl5eqH6vpXhfxF8XNLv7y4uNRupI1nsws2+3jjCkqQvGM4z6V3Ok6RoPgeW9u4JJI4r198hmZvLVif4c8DJNcF4dvLXxJpGpWOrG70m3lYWVnqBMcUzKP4E45GM9OgrcfTNK/4Q3UfDHhvxREdQtiqStOguDCC2TmM5Az0z0Fd1VPSlOTSVk10t3vb8Dhi76pEms+D2voje6FDb3MJlEqIrg8cnbzxjntXI6tpV5afZ4rqBzEjuyq2cRlv4fYfWt20trbwlZtDpus26TzRot2yhvLWXAy/ljoO+K66z1LTLq3iM17YviINKXbHmJ03YbBGT+FYTjKMbR1je97M6IVVzXnvseU3twkdvpj3WnJOYbrJZiW2IQcjI/hzz9cVX1OazsbSa+topbhFJaS3tXdzHn2yeK3fEl5pGlaw32q+0yKOc7EhjZmZ8nsi5zxXR6T4XtfD/ia91A2cFtY3EAeeWedhuRRuPyAcY965auClN+0qvfX18l9/mdUMZCMVGCY/wAEpNL4d0yC/WQQAsVS4XLLGQDtPrg1JqPirwlqmpzaLc2zyTafcpZmQjaqydQN2eQCO/5VDcXWm/Ef7Jq2i6vqEWjaZuZ7eGPYtywIOBnDZ4AB9z61XsbCM6PqmvX+hTyPLIb42Yiw7ELw+3OS2OMV1UsNThHlle60ttZt7a+RxTrTlK8dDQj8IeH7S9N6lrHMTIZcyuTGJM8kJ0zx/WtLWrG5u7Vba3ju40vm8r7Tbt/qOM78g8DjHGetUvAvjWz1PwVJrV3pN5Zoruq2sse6RyvcDHf8KreI/Evi120G+8PaEGsrsbrm0kwZSD93nI2/UZxxmhQqKdmtVpq+wSmpbk2jeKZF8X3XhW7tJ724s8Szag6FYgzYIRc8nAOc1XtfDVrpfix/EGsST6jqxcyx3DSNHGikcKqjggDjnNdZaaM2jWbPPd3F3CpZ/wDSG3ybmbON3oM4HoKp+JL2/OhSy+HLGHUNRt1+SxnlEaSKT8xzjqO3TPtS9onLlp6J6b/1ZP7hJWV2cxeWuvaJfeIvEjyz+ILC6mSSzswX8y1yCNu1f4Rx065zWheWmuXOmwSRXMyy3EwluTuztx/yzT6c4qazfX/s9nc2NlBBbNbO19YSS73VyuU8thwQCCPauQvPFevWfhiw8R+JYIdPaO8Nq9kpLo8Jxh2weTnIz7VtGMp2aSv/AFZW+XQm9ju9B8Uw3106pZ3MCWzFD5qlC+Tg8EZrQ8RzQ2usaHIXEcctwsChjgFj0wPXHArhPFPiw33iQaBZlLDTorOPUVvUXlU/jyTwMc1Hb+INJ+Id9b6VoL3s0mjC3v7a9YBVkbJ+X/HP9Kz+rte/ZqNvuvsNyvp1PS9eiSK9jla7kto2U7xGMnORzxz0OK4DxxBpCaJNqnh/ZctGwS4KE7QM4LkAZY89sV3ss9hqsswiuEnaJfKlaI/6tuDgn0rlvC1ncyeHb2DXLGxt1kmkVIrTJVoj0DH+83Wooy5LTfS2hUk2rI5rTtVtfD0en7o5NRj1O3Ewit7IKI0Jxlic85HrWpe3ljbIywnJlTMax/KcHnBx7+lTamL9IVt7Oyk+z26hbeOGEOu3sucfj171Rg8Pob0NqBktJrhAzwxYIRecLnJCnjkjPXFKvZ8s1p+JrSvZpmLoTTXml3L6ppQjuEmI3cF1XI59v84qzNYq+tq3mkqp2Qsp6ce3vmleOI64E0+VpUHyzuDuDA8AEjqc1o2mky3bva6ajxXuGySQAp7Z/GuOOI9pNy3v+B1ypuEe1hglF8Jv7NTBDokxV8MoyDx74FYl1q2rjRp018PFNBM/2W2RcblP3T0JPAOK7L4e2Y0K+1Hw/wCbG+qxxo7zMSQzMpY49hx2qp4mh026e4j1aR4NQQjE6EqCvbafYgcVvXjCneMtU7a+X/BMKM+d6dLmP4TkOp6YzcrLanYrPHsZ8j354q5pd6uiedLqUL3UFxIwkjEe4MGYYyOexzntVLwrfyp9pje8j2sNo3QgM2c8npjp19639Nt766sZkudPhu0G3DRyBPMHTPPfHbPasVXUZNRj7rNZ0m1q9UYFrrFtqXiP/hG0upxewQM3niVSY4gcokgbBbIPGOQOtaVja3dxE5tmNsVHky70yMrxwe/4daqTNJDfQSal4f8A9PsziG4YJuVSDzvHbHbkV6F4DtpLfSZJ7qZZHkkaRghDKmTnaPpTnKElH2d1Za+pGsOZzs7kNg1v4S0GS6vmCyygS3FxOwTk8Asfy44FYD+JtYutVl0rTtEe4UwebLelgYtxPAAwd3HPHtWL8QPGY1HxLa+HLjw8dQ8NalCUuLsTbfL69QB247jrx0r0rwxp7WUSx/ZvKt4kCw7myR2/oK3UFSipTjvt/X6GDlz3Zd8PLcLpyC7lWWTplRjHtjtWH8Q9SEen/wBnxDfPNglc4yoPI9Mn0rqZ5orWJpZSETPJx3rxDxB4riGsXV3IJ/mYpFFNHgYB7k8Ae4NcdSV5csd2a0Icz5nshiWkwZx5KLDnaFQgYB7nPH4VINNsolmwlrHKybRLDIFYY525HBFUrrxDZam8TBFTc+/ynfaWOOVJGcjuOlMv/wCz7XSntZpbgRO+YzGPuZx0HufoK7HJJKPV+RVpSu/1ILSxzc+ZJCrWu5k3QuRknoCvY+v0qe+0y1mnNvcwJdWhwB8x3cDjjp37YqnE4to2mshJI7HcwT5WYLgfOenpXR6Uhv7Zbq7nWzt49yyrLEI8duuTz9KuSnzc8Ntl01EnFJKT1F8O6aG1ostpizjRSZXBGBggEHuR/WnXelW1xHqPgeSw1W003UYvPN/bLtWPB3YZjwc45/D1rttDt7RrW2XR4z9jXBMkg5lOev0rmfHV3NFLMBe3LHJEkTPlNnfC9AO3FCxLjLVa/k1szL2fO7RZIljqM+owxwNaPBHELVLsSB2SEDb+LY7+tL4Z+H7eGL1Lmx1i/urWK3aN47qYFWyxJc+grG8P6Nd6J4Sgt/DaCIIZJNvzMI8knPsO9dt4Lng1KEQ3UomaJDlST8xbhgVPUd+a1nWkk1F6ehl7NIfqUenanDpjyyOBdTf6OVbawJHJB9+OKwvANtdx314sF1Hd6bJczGdl+WSFiBtDZ/pxXL2V1deGpLiMTXczWl7LI7XoAdVz8rKOyMMgeuK7HwYbTRtIudTRZBaXbh03Zc4PPbk496uVN06bW6exMZXdyh4/ubKxSAX+Wt7adUaIEjcWHGe56VLZPDqkNrfxpp8VpEmyMNjlSB0YcdvwHatDW9O03xjYSSLci3hU8PPEUZX6hsnFcrpvhuLQTb2/2yHU/JB5TllbdnJA6nn36V5k6cYR1fvX2O6lU5ny9O51WmQLe62heK2P2eMxIVZvnXHIUkYO09cHvUHiHQBbXFi0KvetFKXhUFfvE8jn27npisjVtYvbvVUszamOwizuQAkyucbenQdeOKo6szyWUt601z/o7AgDI4Udh3znn6Vi4T0il/maxf2r6FLXdaudJ12xvpCguI5QTGrEqg6EE9+p6V6d4t1zTdH8PQ6pq9x9nt5HRgu0u7ll+6qjkmvOfDOl3vjHU7XVNQzHpls5HlyDCPz0HHJ967nxy2mT2g/tZI/skULTRPJBvSORThW/3skYFdlKjGHLCSd+pzYifNqmR/DxfEDXutXviNwlukxjsYIZlkTyuCGIHIbpweeTWre6o0RmGoNFHFxsdnwvPqaoeAnmsvD9ml9dCW5mfc7hPncH7u4fw8UeLfDcGrXEs32maTEPlLBGRw4PXH0qqvK6rvovJdjGKdtDn7G7TXtAcvbpBJ5hhV06rgkK31FQad4Kgs9QtY7G7eDA827m2bprthyAzk/Kv+yBzRRWGBr1OWcb6am2LguZF3xN5Wi2F2+m20EE0tu08kyJiSRh03MOSMDpXmd3qL6x4LMuvQW1897qcFsCE8raFPBYqcuPYkUUV7eDinBS63WvXY4artKxt+IX0i51zw/NdaOsxjvW0+BGmOyEbclwoHXiq+k6Xd+ENcm1Czvonh1G5Ja1+yqqqCc/eySzc9Sfwooppvk5Hqmn57NmM5Naov8Ahz+zPFvi/wAYWV/pMEXlMoaaNm3uA20DngDgHAHWqsmi6Y/izxZcNabo7WxaNYWc7SsShl568nrRRWkm4VZxi3a0ev8AhNuVWTt3ND4JXyeM9C1Se5sbPT7myfZDPYxBJEUr0DNkj6jFbtppEPhzQtSijmuby38ppZlupDI027khmPb8KKK5cb7mKnSj8N1oFPWCk97FzwJo40Xwlb3S3c1xDdt5qwyBR5IJ4VSoHA9xXk3xF8ba74c17UZ5717q1g1FYbeGIfZ2jBG7BZc71wCMEd85oorXLoqtWl7RX/4ciq2uVI98hmT7BcyeQmSoORwcmMNnP41wXgrW9Tt9RW21O9lvwZisRJ2eWBzjHORyPTpRRXDCKdKdzabalGx1XifXLqzildj5qqGfb04UdB9fWuF0DxJfa9rGj6nbyPp9kLiaCSwjIZZSFBDF8A9+nSiitqdKHsXO2uq/Bjcnex3Vvq32LxdDpEcJ8qW0ku1YPjZjnYBjke+ayL6z0jxH4hh0zUtJglkvbBZ/tD4Yx7DkKAR9e460UVjH3Upre1yeZ7eZv2GhyS6jqH2u9NxYCLyhZPEvl7ccqR3Fanha209IoXsdNtrJUi2RrAgUIo/hAAFFFc1actr9jZpI5+212S2+JTaIkEX2OfzA2Bg527yT6+lYnw+nub3xTfRS3UxtkmntGhZsq6oWAPsen5UUV2uKjCTS+yv1OeUndepF4wkutNvBYafdzW6/OvmKfnHIHB/H3rN0jWLqGB0una5SYM+CQuMZBHA6Hr9c0UV5+MSjheZLU9LDu89eweG5Z/tVxdQtFG0oEzL5WRl8njnjp1r0DwxC1rNL5kvnMymQMVAx3xx70UVyUElG/mdGJ3MDRt9j4y8SXeY5bhAGV3TkAhVxnPtn8axtRv7qTUHvfPfAUP5BO6LknOV79OtFFfQuKctV0X5I8aMmtu5n2MgXV5Lxo4nLOY1RkBCL0wM1Jc+L9S0S0eW0cBGyRHxgckdwfSiivBcIqUbI9p63TKOoxahf2cGp6jqk9x57fLFygQHtwcEfhXtuhafbr4dtLVVKxCPHykg57miirv77MMQrU1YS18L6NayLIlhC0qkne67jk9+a2VAUADoKKK0lOUviZxHl3xS1W7XUhZK/+hxwmRou0h561514baG4jt2gh+z+eSHAbcOpHQ8UUUqEIypzbXU74+7yWOkihs4bsxx2NurYJLhcEjpjisrxQsdpYqUTcVwgDnIwTzmiiowa5qkbmlX4SbwZZRX0DNKoKPhWjYZHGfpXba3bQ2us6Vo8EFt5flm+eSWISE4O3YoPCj35NFFelH+I/n+R589oiXfiDULI3IjeIqAwQbMbcKD6/wCcVF8NtDt9Q+267qjNeXDSbUjl5SPGDwPqaKKyrJUoylDR2QRfNG7K3i7xbqOjeI/tPmyz2My/ZlsCwWNG/wCemQu4n2JxWJ4Z0i71Px/etb6rNZrEY2VUXdgEZwOcZ9yDRRXZS9ylzRWtv8jKK5t+56HqugaT4n1Z49WtDKtv1HmECTGMbsYqhqXiVtM8J3V5p1lDD9llMEMWcquMgMfXp0oorza0pOla+it+L1NaSTml3OCg0e715INW8QarPeyMxIiC7EXkjgZIFdZ4mtfJtLd0kZNsqkhPl3AjGDj6/pRRWGIm3P2fRP8AU7YRSd0cFdW91pU1ykGoXDOEaUOxzjbjjBrR0fxVqdq8sbvFcBCP9dEpz+lFFdbipQcmtbkW99R6WO10bxHJ448BaxKIBps9qHVHibfhlBIYAgY+n61Xgv4LX4S6Zc6raf2nDK8KNDJIVBJk4JPJOD270UVqlypxX8yOCW5k+JtYb4ZafrWrWEP2uWe4+1zq7bN+eFQHB2qowBj0rt/htftr2irrkyLG18FkEI5EfGcZ79aKK0qQi8N7V/Fe1/ISk+Zx6H//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    E-cadherin strains prominent in the intercellular membranes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_1_40983=[""].join("\n");
var outline_f40_1_40983=null;
var title_f40_1_40984="Vaccines for the prevention of group B streptococcal disease";
var content_f40_1_40984=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vaccines for the prevention of group B streptococcal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/1/40984/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/1/40984/contributors\">",
"     Lawrence C Paoletti, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/1/40984/contributors\">",
"     Lawrence C Madoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/1/40984/contributors\">",
"     Carol J Baker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/1/40984/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/1/40984/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/1/40984/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/1/40984/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/1/40984/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/1/40984/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Group B streptococcus (GBS or Streptococcus agalactiae) is an encapsulated gram-positive bacterium that colonizes the human gastrointestinal and genital tracts. It causes invasive infections in three populations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonates, particularly in the first few days of life, and infants up to three months of age. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18698?source=see_link\">",
"       \"Group B streptococcal infection in neonates and young infants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnant women. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43062?source=see_link\">",
"       \"Group B streptococcal infection in pregnant women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adults over the age of 65 years or those immunocompromised by underlying medical conditions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36936?source=see_link\">",
"       \"Group B streptococcal infections in nonpregnant adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    GBS is the most frequent bacterial pathogen in neonates. Maternal antibody against type-specific capsular polysaccharide appears to be protective. However, many GBS-colonized pregnant women do not have sufficient antibody levels at delivery and infants born before 32 weeks of gestation do not benefit from optimal placental transport of available maternal IgG. Although intrapartum",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    four or more hours before delivery can prevent GBS infections in most neonates younger than seven days of age (early-onset disease), concern has been raised that administration of intrapartum antibiotics to large proportions of women could lead to the development of antibiotic resistance in this pathogen. Maternal intrapartum antibiotic prophylaxis also has attendant risk for allergic reactions, must be given with each pregnancy, and is invasive and expensive when compared with immunization. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19354?source=see_link\">",
"     \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vaccination strategies and the composition of potential GBS vaccines are reviewed here. The microbiology and epidemiology GBS infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9621?source=see_link\">",
"     \"Group B streptococcus: Virulence factors and pathogenic mechanisms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STRATEGIES FOR PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Centers for Disease Control and Prevention (CDC) with the American College of Obstetricians and Gynecologists (ACOG) and the American Academy of Pediatrics (AAP) issued consensus guidelines in 1996 for the prevention of early-onset GBS infections through maternal intrapartum chemoprophylaxis (IAP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/1\">",
"     1",
"    </a>",
"    ]. This risk-based strategy called for the routine administration of intravenous penicillin or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    to parturient women who are colonized with GBS or those who have risk factors associated with invasive GBS disease in neonates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43062?source=see_link\">",
"     \"Group B streptococcal infection in pregnant women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18698?source=see_link&amp;anchor=H9#H9\">",
"     \"Group B streptococcal infection in neonates and young infants\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Universal prenatal screening prevents significantly more neonatal disease than the risk-based approach. This culture-based screening strategy consists of testing for vaginal and rectal GBS colonization in all pregnant women at 35 to 37 weeks' gestation, followed by the administration of intrapartum antibiotic prophylaxis (IAP) at the time of labor to culture positive women.",
"   </p>",
"   <p>",
"    The culture-based strategy is now the recommended approach for prevention of GBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. However, both the culture-based and risk-based approaches to maternal IAP to prevent early-onset neonatal disease have inherent problems:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IAP administration to all women with positive cultures exposes large numbers of women to unneeded antibiotics, since only 0.5 to 1 percent of colonized women give birth to infants who develop early-onset GBS infection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18698?source=see_link&amp;anchor=H9#H9\">",
"       \"Group B streptococcal infection in neonates and young infants\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      IAP administered only to women with risk factors, such as premature rupture of membranes or intrapartum fever, will not protect term infants without identifiable risk factors who develop GBS disease. In a large, retrospective cohort study, infants born to mothers treated using the risk factor-based approach were 50 percent more likely to develop early-onset GBS disease than the offspring of mothers treated with the screening approach [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Maternal IAP does not reduce the incidence of late-onset (7 to 89 days) disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IAP requires intravenous administration (invasive), several hours for effectiveness to be achieved (at least 4 hours with penicillin), and repeated administration in subsequent pregnancies.",
"     </li>",
"     <li>",
"      The mothers are exposed to the adverse effects to the antibiotic, including anaphylaxis, and the possibility of promoting antibiotic-resistant flora in both the mother and infant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The problem of antibiotic resistance was illustrated in a study of early-onset sepsis in 5447 very low birth weight neonates born at &lt;1500 g between 1998 and 2000 compared with those born between 1991 and 1993 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/7\">",
"     7",
"    </a>",
"    ]. Although the incidence of neonatal sepsis had not changed significantly (15.4 versus 19.3 per 1000 very low birth weight infants), fewer GBS and more Escherichia coli infections occurred during the later time period. Sixty-five percent of the women in the more recent cohort had received antibiotics during hospitalization for the delivery, and 85 percent of E. coli strains isolated from neonates in the more recent cohort were resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    . Ampicillin-resistant isolates were much more common in neonates whose mothers had received IAP with ampicillin (93 versus 20 percent).",
"   </p>",
"   <p>",
"    In a cost-benefit analysis of strategies of neonatal GBS prevention (which considered only the direct costs of caring for invasive GBS infection and not attendant morbidity caused by chronic sequelae of infection), all strategies examined were found to be cost saving [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TARGETS OF PROTECTIVE IMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our current understanding of GBS antigens and their potential roles in inducing protective immunity stem from the studies of Rebecca Lancefield and colleagues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. GBS possesses two distinct surface saccharides, the group B carbohydrate (common to all strains) and the capsular polysaccharide (CPS). The group B carbohydrate is more closely associated with the cell wall of GBS than are CPS or protein antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/14\">",
"     14",
"    </a>",
"    ]. The GBS noncapsular polysaccharide antigen is not a vaccine candidate as antibodies to this protein are not protective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     GBS capsular polysaccharide antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CPS antigens confer serotype specificity for GBS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;With only two exceptions, all GBS CPS are composed of 150 or more oligosaccharide repeating units of galactose, glucose, N-acetylglucosamine, and N-acetylneuraminic acid. Type VI CPS lacks N-acetylglucosamine, and serotype VIII is the simplest structure, containing only four sugars including rhamnose, a saccharide previously only found in the group B carbohydrate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/17\">",
"     17",
"    </a>",
"    ]. Each CPS has a unique structure containing backbone saccharides and side chains comprised of mono-, di-, or trisaccharides. Despite containing similar sugars, each CPS is antigenically distinct, even types Ia and Ib in which the sole difference resides in a single linkage in the attachment of galactose to N-acetylglucosamine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Sialic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of N-acetylneuraminic (sialic) acid is preserved among all GBS CPS whose structures have been elucidated. This sugar is a virulence factor for GBS; GBS mutants with CPS that does not contain sialic acid lose their virulence in animal models of GBS infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     GBS protein antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most GBS also express surface proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]. The best characterized of them are the C proteins, present in most GBS strains that are not serotype III [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Lancefield and others initially showed that antibodies to these components protected against lethal infection in a mouse model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/27\">",
"     27",
"    </a>",
"    ]. At least two C proteins have been delineated and shown to be expressed independently in different strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/23,25,26,28\">",
"     23,25,26,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Beta C protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 130-kDa beta C protein binds specifically to human IgA via the Fc portion of the immunoglobulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. This antigen is present in nearly all strains of GBS type Ib, and some type Ia, II, and IV strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observations in animal models suggest that a beta C protein vaccine might protect against GBS infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibody to the cloned beta C protein protected mice from lethal infection with GBS that expressed the protein [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Purified beta C protein actively immunized adult female mice and protected their neonatal pups against challenge with GBS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recombinant beta C protein and a variant lacking the IgA binding domain were effective vaccines and carrier proteins for GBS CPS in mice [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Invasive disease, but not colonization, elicits IgM and IgG antibodies to beta C protein in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Alpha C protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alpha C protein is present in approximately 70 percent of non-type III GBS, primarily in Ia, Ib and type II strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/22,23,25\">",
"     22,23,25",
"    </a>",
"    ]. A monoclonal antibody directed at the alpha C protein identified a series of regularly spaced bands on Western blots of extracts from alpha-C-protein positive GBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/25,28\">",
"     25,28",
"    </a>",
"    ]. Moreover, the monoclonal antibody protected mice challenged with an alpha-positive strain of GBS. The cloned alpha C protein from the prototype",
"    <span class=\"nowrap\">",
"     Ia/C",
"    </span>",
"    strain A909 elicited antibody that protected mice from lethal challenge with alpha-positive GBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Deletions in the repeat region of the alpha C protein have been noted in both human isolates and an immune mouse model and appear to reflect a form of antigenic variation resulting in escape from host immunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/32\">",
"     32",
"    </a>",
"    ]. In contrast to antibodies raised to the wild-type, 9-repeat alpha C protein (antibodies raised to the 1- or 2-repeat species) bind with high affinity to both 1-repeat and 9-repeat alpha C protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition, alpha C protein with one or two repeats is more immunogenic and more protective than is the 9-repeat protein. A 2-repeat alpha C protein conjugated to type III CPS has been reported to confer significant protection against GBS strains expressing either antigen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/34\">",
"     34",
"    </a>",
"    ]. Thus, like the beta C protein, the alpha C protein is able to function both as a carrier protein for the CPS and as a protective immunogen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other GBS surface proteins share the properties of trypsin resistance and a ladder-like pattern on Western blot with the alpha C protein. The R proteins are present in many type II and III strains and may be involved in protective immunity in animals and in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/24,35\">",
"     24,35",
"    </a>",
"    ]. One group reported the presence of a novel protein termed \"Rib\" in most type III GBS strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/21\">",
"     21",
"    </a>",
"    ]. This protein seems to be analogous to the alpha C protein. It is a protective antigen that appears variable in molecular size in different strains and produces a ladder on western blot. Nucleotide sequencing of the gene for Rib protein reveals extensive homology to the alpha C protein, and it contains a series of identical tandem repeats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/36\">",
"     36",
"    </a>",
"    ]. Type V and type VIII clinical GBS isolates contain alpha-like proteins; nearly all GBS strains appear to express a surface protein that is a member of this family, regardless of serotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/37\">",
"     37",
"    </a>",
"    ]. Recombinant alpha C protein 3, found on most GBS types V and VIII isolates has been shown to be a viable vaccine candidate and an effective carrier protein for CPS antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/38\">",
"     38",
"    </a>",
"    ]. BibA, a surface-associated adhesin found predominantly on type III clinical isolates, confers active protection in mice against GBS challenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Genomic approaches to vaccine development",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of complete genome sequences for GBS has led to the discovery of novel vaccine candidates. Analysis of genomes from eight GBS strains representing five serotypes (Ia, Ib, II, III, and V) identified 589 potential surface-exposed and secreted proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/40\">",
"     40",
"    </a>",
"    ]. Of these, 312 could be expressed in recombinant form and used for production of antibodies. Many of the antibodies recognized a single predominant protein on Western blot of GBS extracts or could detect a surface exposed protein of GBS by fluorescence-activated cell sorting.",
"   </p>",
"   <p>",
"    A combination of four of these candidate proteins given to female mice provided protection to their offspring against GBS strains of the above five serotypes plus serotype VIII [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/40\">",
"     40",
"    </a>",
"    ]. These proteins, some of which are GBS pili antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/41\">",
"     41",
"    </a>",
"    ], may lead to the development of a combination vaccine capable of providing protection against several serotypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These candidate proteins can be screened for protective activity against GBS in animal models and may lead to the development of new vaccines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     VACCINE FORMULATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous different GBS antigens have been considered for inclusion in potential vaccines (",
"    <a class=\"graphic graphic_table graphicRef51470 \" href=\"mobipreview.htm?6/4/6221\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/43\">",
"     43",
"    </a>",
"    ]. CPS were the initial GBS vaccines tested in humans. Conjugation to protein antigens such as tetanus toxoid enhances the immunogenicity of these vaccines. Use of proteins from GBS in conjugate vaccines also is being studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Polysaccharide vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1975, Lancefield summarized years of work demonstrating that antibodies directed at CPS antigens of GBS protect mice against lethal challenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/15\">",
"     15",
"    </a>",
"    ]. These results in animals were followed by the observation that susceptibility of newborns to GBS infections correlated strongly with a lack of maternal antibody to the GBS CPS antigen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/44\">",
"     44",
"    </a>",
"    ]. Baker and Kasper first suggested that the CPS antigen might be a good vaccine candidate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first phase I GBS vaccine clinical trial used two native type III CPS vaccines that differed in the method of CPS extraction (EDTA compared to TCA extraction) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/45\">",
"     45",
"    </a>",
"    ]. Both vaccines passed safety tests in animals before administration to 40 healthy adults, 33 of whom had low levels of antibody to III CPS before vaccination. Although both vaccines elicited type III-specific antibodies, the EDTA-extracted preparation was superior in both magnitude of the antibody response and rate of response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/45\">",
"     45",
"    </a>",
"    ]. This trial suggested that GBS CPS were safe and immunogenic in humans and paved the way for evaluation of other clinically relevant GBS serotypes.",
"   </p>",
"   <p>",
"    Native type Ia CPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/46\">",
"     46",
"    </a>",
"    ] and II CPS vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/46,47\">",
"     46,47",
"    </a>",
"    ] also were shown to be safe in healthy adults and to elicit type-specific IgG over prevaccination levels. However, the magnitude of the response and the percent of the volunteers who achieved a &gt;1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    increase in type-specific antibody varied considerably from 40 to 88 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/46\">",
"     46",
"    </a>",
"    ]. Thus, the CPS vaccines were suboptimal for use in women of childbearing age with low levels of preexisting antibody to CPS of GBS, the target population for vaccination.",
"   </p>",
"   <p>",
"    However, a pivotal study with the \"first generation\" GBS vaccines in pregnant women demonstrated that GBS type III unconjugated CPS vaccine was safe and immunogenic when administered early in the third trimester to 40 pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/48\">",
"     48",
"    </a>",
"    ]. The direct correlation (r = 0.913) between maternal delivery and infant cord sera type III CPS-specific IgG levels provided evidence that a strategy of maternal vaccination to prevent infant GBS disease would be feasible if the immunogenicity of the vaccine was improved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Polysaccharide-protein conjugate vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that humoral responses to poorly immunogenic carbohydrate antigens could be augmented by covalent attachment to proteins was first reported in 1931 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/49\">",
"     49",
"    </a>",
"    ]. GBS type III oligosaccharide and CPS conjugate vaccines were developed and shown to be more immunogenic in rabbits and mice compared to uncoupled CPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]. These GBS CPS conjugate vaccines were generated by first creating aldehydes on a selected number of sialic acid sugars on the CPS, then using these aldehydes as coupling sites to proteins by a reaction known as reductive amination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Animal models",
"    </span>",
"    &nbsp;&mdash;&nbsp;An animal model was developed in which pregnant female mice were actively immunized with GBS conjugate vaccines to induce IgG responses. Their newborn pups were subsequently challenged with a lethal concentration of the homologous GBS strain. As hypothesized, conjugated but not uncoupled GBS CPS was highly immunogenic in adult mice, and the type-specific antibody provided protection against GBS challenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first phase I clinical study with the \"second generation\" of GBS vaccines was performed in healthy women ages 18 to 40 years. Type III CPS coupled to tetanus toxoid (III-TT) was safe and substantially more immunogenic than was uncoupled type III CPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/57\">",
"     57",
"    </a>",
"    ]. Antibodies elicited to the III-TT conjugate vaccine were predominately IgG class, were functionally active in vitro, and recognized III CPS, indicating that the reductive deamination coupling method did not alter critical conformational epitopes on the type III CPS. Tetanus toxoid was chosen as the carrier protein because of its safety and efficacy as a vaccine when administered to pregnant women worldwide to prevent neonatal tetanus infections.",
"   </p>",
"   <p>",
"    Additional GBS CPS-TT conjugates have been evaluated. Type Ia-TT and Ib-TT conjugate vaccines were well tolerated by healthy, childbearing age women, and the serotype-specific IgG response was significantly greater in recipients of the conjugate compared to the uncoupled CPS vaccine (",
"    <a class=\"graphic graphic_figure graphicRef79484 \" href=\"mobipreview.htm?10/4/10319\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/58\">",
"     58",
"    </a>",
"    ]. In addition, Ia and Ib CPS-specific antibodies elicited by the conjugate vaccines were functionally active in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/58\">",
"     58",
"    </a>",
"    ] and in vivo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/59\">",
"     59",
"    </a>",
"    ]. Similar findings were reported for the type II-TT conjugate and unconjugated type II CPS vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/60\">",
"     60",
"    </a>",
"    ] and for the type V conjugate and unconjugated type V CPS vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One-third of the cases of invasive GBS disease occur in adults older than 65 years of age. The safety and immunogenicity of a type V conjugate vaccine was assessed in 32 healthy elderly individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/63\">",
"     63",
"    </a>",
"    ]. The vaccine elicited specific antibodies that were opsonically-active, suggesting that a type V conjugate vaccine may benefit this age group.",
"   </p>",
"   <p>",
"    A successful formulation for an effective GBS vaccine will include several antigens to provide protection against multiple serotypes. Toward that goal, a trial was conducted in healthy adults to study the safety and immunogenicity of a GBS conjugate vaccine containing both types II and III CPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/64\">",
"     64",
"    </a>",
"    ]. The bivalent vaccine was well tolerated and postvaccination sera contained functionally active antibodies against both serotypes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Potential GBS protein vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inclusion of proteins in future GBS vaccines offers several potential advantages over vaccines containing irrelevant proteins such as tetanus toxoid. Since any GBS vaccine will need to be multivalent, the inclusion of surface proteins in the vaccine could simplify a vaccine by covering strains not among the CPS serotypes included. As an example, the inclusion of the beta C protein could eliminate the need for the Ib CPS in a multivalent vaccine. Likewise, the alpha C protein could provide protection against many Ia serotype strains. The inclusion of protein antigens might also enhance the protective efficacy of the vaccine against some strains.",
"   </p>",
"   <p>",
"    The use of a GBS protein as a carrier in a CPS conjugate vaccine could reduce the need for \"irrelevant\" carrier proteins such as tetanus toxoid. A growing number of conjugate vaccines are employing a limited number of carrier proteins, which could lead to increased reactogenicity of a vaccine and the potential for suppression of immune response to the CPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/65\">",
"     65",
"    </a>",
"    ]. Thus, future clinical trials may well involve vaccines containing one or more GBS surface proteins.",
"   </p>",
"   <p>",
"    In an effort to develop a GBS vaccine against more than one serotype of GBS, a conjugate vaccine composed of type III CPS and beta C protein was synthesized and shown to elicit protective antibodies against both components [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/66\">",
"     66",
"    </a>",
"    ]. This vaccine was able to protect neonatal mice from challenge with strains that bore either the beta C protein or the type III CPS. The antibodies elicited were broadly and strongly opsonic against a variety of strains that expressed either antigen.",
"   </p>",
"   <p>",
"    Other GBS surface proteins have the potential to be effective vaccine candidates. Streptococcal C5a peptidase is located on the surface of the organism and conserved among GBS serotypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/67\">",
"     67",
"    </a>",
"    ]. Rabbit antisera to this enzyme promoted killing of GBS by macrophages in vitro. C5a peptidase has also been shown to function as an effective carrier protein for GBS polysaccharide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/67\">",
"     67",
"    </a>",
"    ]. Surface immunogenic protein (Sip) is a 53 kDa protein that is also highly conserved among GBS isolates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Active vaccination of mice with purified Sip resulted in protection against lethal challenge with GBS serotypes Ia, Ib, II, III, V, and VI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recombinant form of another GBS surface protein, called LrrG, protected mice against lethal GBS challenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/70\">",
"     70",
"    </a>",
"    ]. This observation suggests that this highly conserved protein may be a viable vaccine candidate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Vaccination for adults at risk of GBS disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although maternal deficiency of IgG specific for GBS CPS is clearly a risk factor for infant GBS disease, the immune defects leading to adult GBS infection are poorly characterized.",
"   </p>",
"   <p>",
"    In a surveillance study of adults with GBS bacteremia, acute serum samples from seven of twelve patients contained levels of type-specific antibody thought to be protective in neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/71\">",
"     71",
"    </a>",
"    ]. Since these patients became bacteremic despite protective levels of antibody, other factors must account for the increased susceptibility to GBS infection in adults with malignancy, diabetes, liver disease, or age 65 years or older without underlying illness.",
"   </p>",
"   <p>",
"    An alternative explanation is that higher levels of antibodies to CPS might be needed for protection in adults. In a cross-sectional study of adults &ge;65 years of age, the serum level and functional activity of type V GBS CPS-specific IgG was measured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/72\">",
"     72",
"    </a>",
"    ]. Thirty-six of 40 adults studied (90 percent) lacked GBS antibody in amounts sufficient to be effective against GBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40984/abstract/72\">",
"     72",
"    </a>",
"    ]. There was no apparent impairment of neutrophil function, which is another possible risk factor for susceptibility to GBS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21182546\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Group B streptococcus (GBS) is the most frequent bacterial pathogen in neonates. Most pregnant women who are colonized with GBS do not have sufficient antibody levels at delivery to provide passive protection from infection for the neonate. The current prevention approach of antenatal culture-based screening and maternal intrapartum antibiotic prophylaxis for those women who are positive is effective but has several downsides, including the risk of adverse effects, the selection for resistant organisms, and the lack of efficacy at reducing late-onset disease. Thus, development of an effective vaccine is an attractive strategy for the prevention of neonatal GBS disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Strategies for prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Targets for potential vaccines include both carbohydrate (from the capsular polysaccharide) and protein (cell surface and secreted) antigens (",
"      <a class=\"graphic graphic_table graphicRef51470 \" href=\"mobipreview.htm?6/4/6221\">",
"       table 1",
"      </a>",
"      ). The GBS group antigen is not a vaccine candidate as antibodies to this protein are not protective. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Targets of protective immunity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no commercially available GBS vaccine; however, a trivalent Ia, Ib, III glycoconjugate vaccine is being developed and phase 1 and early phase 2 trials have been completed. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Vaccine formulations'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/1\">",
"      Prevention of perinatal group B streptococcal disease: A public health perspective. Centers for Disease Control and Prevention (published erratum appears in MMWR Morb Mortal Wkly Rep 1996; 45:679). MMWR Morb Mortal Wkly Rep 1996; 45(RR-7):1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/2\">",
"      Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000; 342:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/3\">",
"      Schrag SJ, Zell ER, Lynfield R, et al. A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med 2002; 347:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/4\">",
"      Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/5\">",
"      Edwards RK, Clark P, Sistrom CL, Duff P. Intrapartum antibiotic prophylaxis 1: relative effects of recommended antibiotics on gram-negative pathogens. Obstet Gynecol 2002; 100:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/6\">",
"      McDuffie RS Jr, McGregor JA, Gibbs RS. Adverse perinatal outcome and resistant Enterobacteriaceae after antibiotic usage for premature rupture of the membranes and group B streptococcus carriage. Obstet Gynecol 1993; 82:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/7\">",
"      Stoll BJ, Hansen N, Fanaroff AA, et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med 2002; 347:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/8\">",
"      Mohle-Boetani JC, Schuchat A, Plikaytis BD, et al. Comparison of prevention strategies for neonatal group B streptococcal infection. A population-based economic analysis. JAMA 1993; 270:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/9\">",
"      Lancefield RC. A SEROLOGICAL DIFFERENTIATION OF HUMAN AND OTHER GROUPS OF HEMOLYTIC STREPTOCOCCI. J Exp Med 1933; 57:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/10\">",
"      Lancefield RC. A SEROLOGICAL DIFFERENTIATION OF SPECIFIC TYPES OF BOVINE HEMOLYTIC STREPTOCOCCI (GROUP B). J Exp Med 1934; 59:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/11\">",
"      Lancefield RC, Hare R. THE SEROLOGICAL DIFFERENTIATION OF PATHOGENIC AND NON-PATHOGENIC STRAINS OF HEMOLYTIC STREPTOCOCCI FROM PARTURIENT WOMEN. J Exp Med 1935; 61:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/12\">",
"      Lancefield RC. A microprecipitin-technic for classifying hemolytic streptococci, and improved methods for producing antisera. Proc Soc Exp Biol Med 1938; 38:473.",
"     </a>",
"    </li>",
"    <li>",
"     Lancefield RC. Cellular antigens of group B streptococci. In: Streptococci and Streptococcal Diseases: Recognition, Understanding and Management, Wannamaker LW, Matsen JM (Eds), Academic Press, Inc, New York 1972. p.57.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/14\">",
"      Kasper DL, Baker CJ, Jennings HJ. Cell structure and antigenic composition of GBS. Antibiot Chemother 1985; 35:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/15\">",
"      Lancefield RC, McCarty M, Everly WN. Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens. J Exp Med 1975; 142:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/16\">",
"      Marques MB, Kasper DL, Shroff A, et al. Functional activity of antibodies to the group B polysaccharide of group B streptococci elicited by a polysaccharide-protein conjugate vaccine. Infect Immun 1994; 62:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/17\">",
"      Kogan G, Uhr&iacute;n D, Brisson JR, et al. Structural and immunochemical characterization of the type VIII group B Streptococcus capsular polysaccharide. J Biol Chem 1996; 271:8786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/18\">",
"      Lancefield RC. TWO SEROLOGICAL TYPES OF GROUP B HEMOLYTIC STREPTOCOCCI WITH RELATED, BUT NOT IDENTICAL, TYPE-SPECIFIC SUBSTANCES. J Exp Med 1938; 67:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/19\">",
"      Wessels MR, Paoletti LC, Rodewald AK, et al. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun 1993; 61:4760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/20\">",
"      Wessels MR, Rubens CE, Bened&iacute; VJ, Kasper DL. Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule. Proc Natl Acad Sci U S A 1989; 86:8983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/21\">",
"      St&aring;lhammar-Carlemalm M, Stenberg L, Lindahl G. Protein rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections. J Exp Med 1993; 177:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/22\">",
"      Ferrieri P, Flores AE. Surface protein expression in group B streptococcal invasive isolates. Adv Exp Med Biol 1997; 418:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/23\">",
"      Johnson DR, Ferrieri P. Group B streptococcal Ibc protein antigen: distribution of two determinants in wild-type strains of common serotypes. J Clin Microbiol 1984; 19:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/24\">",
"      Flores AE, Ferrieri P. Molecular species of R-protein antigens produced by clinical isolates of group B streptococci. J Clin Microbiol 1989; 27:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/25\">",
"      Madoff LC, Hori S, Michel JL, et al. Phenotypic diversity in the alpha C protein of group B streptococci. Infect Immun 1991; 59:2638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/26\">",
"      Michel JL, Madoff LC, Kling DE, et al. Cloned alpha and beta C-protein antigens of group B streptococci elicit protective immunity. Infect Immun 1991; 59:2023.",
"     </a>",
"    </li>",
"    <li>",
"     Lancefield RC. Antigens of group B streptococci relating mouse-protective antibodies and immunity. In: New Approaches for Inducing Natural Immunity to Pyogenic Organisms, Robbins JE (Ed), National Institutes of Health, Bethesda 1975. p.145.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/28\">",
"      Madoff LC, Michel JL, Kasper DL. A monoclonal antibody identifies a protective C-protein alpha-antigen epitope in group B streptococci. Infect Immun 1991; 59:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/29\">",
"      Madoff LC, Michel JL, Gong EW, et al. Protection of neonatal mice from group B streptococcal infection by maternal immunization with beta C protein. Infect Immun 1992; 60:4989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/30\">",
"      Yang HH, Madoff LC, Guttormsen HK, et al. Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines. Infect Immun 2007; 75:3455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/31\">",
"      Pannaraj PS, Kelly JK, Madoff LC, et al. Group B Streptococcus bacteremia elicits beta C protein-specific IgMand IgG in humans. J Infect Dis 2007; 195:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/32\">",
"      Madoff LC, Michel JL, Gong EW, et al. Group B streptococci escape host immunity by deletion of tandem repeat elements of the alpha C protein. Proc Natl Acad Sci U S A 1996; 93:4131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/33\">",
"      Gravekamp C, Kasper DL, Michel JL, et al. Immunogenicity and protective efficacy of the alpha C protein of group B streptococci are inversely related to the number of repeats. Infect Immun 1997; 65:5216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/34\">",
"      Gravekamp C, Kasper DL, Paoletti LC, Madoff LC. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines. Infect Immun 1999; 67:2491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/35\">",
"      Lind&eacute;n V, Christensen KK, Christensen P. Correlation between low levels of maternal IgG antibodies to R protein and neonatal septicemia with group B streptococci carrying R protein. Int Arch Allergy Appl Immunol 1983; 71:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/36\">",
"      W&auml;stfelt M, St&acirc;lhammar-Carlemalm M, Delisse AM, et al. Identification of a family of streptococcal surface proteins with extremely repetitive structure. J Biol Chem 1996; 271:18892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/37\">",
"      Lachenauer CS, Madoff LC. A protective surface protein from type V group B streptococci shares N-terminal sequence homology with the alpha C protein. Infect Immun 1996; 64:4255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/38\">",
"      Yang HH, Mascuch SJ, Madoff LC, Paoletti LC. Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier protein. Clin Vaccine Immunol 2008; 15:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/39\">",
"      Santi I, Maione D, Galeotti CL, et al. BibA induces opsonizing antibodies conferring in vivo protection against group B Streptococcus. J Infect Dis 2009; 200:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/40\">",
"      Maione D, Margarit I, Rinaudo CD, et al. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 2005; 309:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/41\">",
"      Lauer P, Rinaudo CD, Soriani M, et al. Genome analysis reveals pili in Group B Streptococcus. Science 2005; 309:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/42\">",
"      Margarit I, Rinaudo CD, Galeotti CL, et al. Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis 2009; 199:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/43\">",
"      Johri AK, Paoletti LC, Glaser P, et al. Group B Streptococcus: global incidence and vaccine development. Nat Rev Microbiol 2006; 4:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/44\">",
"      Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 1976; 294:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/45\">",
"      Baker CJ, Edwards MS, Kasper DL. Immunogenicity of polysaccharides from type III, group B Streptococcus. J Clin Invest 1978; 61:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/46\">",
"      Baker CJ, Kasper DL. Group B streptococcal vaccines. Rev Infect Dis 1985; 7:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/47\">",
"      Eisenstein TK, De Cueninck BJ, Resavy D, et al. Quantitative determination in human sera of vaccine-induced antibody to type-specific polysaccharides of group B streptococci using an enzyme-linked immunosorbent assay. J Infect Dis 1983; 147:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/48\">",
"      Baker CJ, Rench MA, Edwards MS, et al. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. N Engl J Med 1988; 319:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/49\">",
"      Avery OT, Goebel WF. CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : V. THE IMMUNOLOGICAL SPECIFITY OF AN ANTIGEN PREPARED BY COMBINING THE CAPSULAR POLYSACCHARIDE OF TYPE III PNEUMOCOCCUS WITH FOREIGN PROTEIN. J Exp Med 1931; 54:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/50\">",
"      Wessels MR, Paoletti LC, Kasper DL, et al. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J Clin Invest 1990; 86:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/51\">",
"      Lagergard T, Shiloach J, Robbins JB, Schneerson R. Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid. Infect Immun 1990; 58:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/52\">",
"      Paoletti LC, Kasper DL, Michon F, et al. An oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus. J Biol Chem 1990; 265:18278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/53\">",
"      Paoletti LC, Wessels MR, Michon F, et al. Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun 1992; 60:4009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/54\">",
"      Jennings HJ, Lugowski C. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J Immunol 1981; 127:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/55\">",
"      Rodewald AK, Onderdonk AB, Warren HB, Kasper DL. Neonatal mouse model of group B streptococcal infection. J Infect Dis 1992; 166:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/56\">",
"      Paoletti LC, Wessels MR, Rodewald AK, et al. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun 1994; 62:3236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/57\">",
"      Kasper DL, Paoletti LC, Wessels MR, et al. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest 1996; 98:2308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/58\">",
"      Baker CJ, Paoletti LC, Wessels MR, et al. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis 1999; 179:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/59\">",
"      Paoletti LC, Pinel J, Rodewald AK, Kasper DL. Therapeutic potential of human antisera to group B streptococcal glycoconjugate vaccines in neonatal mice. J Infect Dis 1997; 175:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/60\">",
"      Baker CJ, Paoletti LC, Rench MA, et al. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. J Infect Dis 2000; 182:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/61\">",
"      Baker CJ, Paoletti LC, Rench MA, et al. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. J Infect Dis 2004; 189:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/62\">",
"      Baker CJ, Rench MA, Paoletti LC, Edwards MS. Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 2007; 25:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/63\">",
"      Palazzi DL, Rench MA, Edwards MS, Baker CJ. Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old. J Infect Dis 2004; 190:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/64\">",
"      Baker CJ, Rench MA, Fernandez M, et al. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J Infect Dis 2003; 188:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/65\">",
"      Schutze MP, Leclerc C, Jolivet M, et al. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol 1985; 135:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/66\">",
"      Madoff LC, Paoletti LC, Tai JY, Kasper DL. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes. J Clin Invest 1994; 94:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/67\">",
"      Cheng Q, Carlson B, Pillai S, et al. Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci. Infect Immun 2001; 69:2302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/68\">",
"      Brodeur BR, Boyer M, Charlebois I, et al. Identification of group B streptococcal Sip protein, which elicits cross-protective immunity. Infect Immun 2000; 68:5610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/69\">",
"      Rioux S, Martin D, Ackermann HW, et al. Localization of surface immunogenic protein on group B streptococcus. Infect Immun 2001; 69:5162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/70\">",
"      Seepersaud R, Hanniffy SB, Mayne P, et al. Characterization of a novel leucine-rich repeat protein antigen from group B streptococci that elicits protective immunity. Infect Immun 2005; 73:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/71\">",
"      Wessels MR, Kasper DL, Johnson KD, Harrison LH. Antibody responses in invasive group B streptococcal infection in adults. J Infect Dis 1998; 178:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40984/abstract/72\">",
"      Amaya RA, Baker CJ, Keitel WA, Edwards MS. Healthy elderly people lack neutrophil-mediated functional activity to type V group B Streptococcus. J Am Geriatr Soc 2004; 52:46.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3881 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-C0B5FDA9AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_1_40984=[""].join("\n");
var outline_f40_1_40984=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21182546\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STRATEGIES FOR PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TARGETS OF PROTECTIVE IMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GBS capsular polysaccharide antigens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Composition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Sialic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GBS protein antigens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Beta C protein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Alpha C protein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other proteins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Genomic approaches to vaccine development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      VACCINE FORMULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Polysaccharide vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Polysaccharide-protein conjugate vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Animal models",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Potential GBS protein vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Vaccination for adults at risk of GBS disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21182546\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3881\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3881|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/4/10319\" title=\"figure 1\">",
"      Antibodies to GBS conjugates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3881|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/4/6221\" title=\"table 1\">",
"      GBS antigens for vaccine use",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19354?source=related_link\">",
"      Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18698?source=related_link\">",
"      Group B streptococcal infection in neonates and young infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43062?source=related_link\">",
"      Group B streptococcal infection in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36936?source=related_link\">",
"      Group B streptococcal infections in nonpregnant adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9621?source=related_link\">",
"      Group B streptococcus: Virulence factors and pathogenic mechanisms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_1_40985="Localized scleroderma in childhood";
var content_f40_1_40985=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Localized scleroderma in childhood",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/1/40985/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/1/40985/contributors\">",
"     Francesco Zulian, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/1/40985/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/1/40985/contributors\">",
"     Thomas JA Lehman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/1/40985/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/1/40985/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/1/40985/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/1/40985/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although scleroderma is a spectrum of disorders that can occur at any stage of life, the clinical patterns of childhood sclerosis differ from that of adulthood.",
"   </p>",
"   <p>",
"    The predominant form of childhood sclerosis is localized scleroderma (LSc), also sometimes called morphea, which principally involves the skin, subcutaneous fascia, muscle, and bone (",
"    <a class=\"graphic graphic_picture graphicRef62616 \" href=\"mobipreview.htm?20/56/21381\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It includes circumscribed morphea, generalized morphea, bullous morphea, deep morphea, and linear morphea with the en coup de sabre subtype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Juvenile systemic sclerosis (JSSc) is a chronic multisystem connective tissue disorder characterized by sclerodermic skin changes and abnormalities of the visceral organs. LSc infrequently progresses into a systemic form [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/4-6\">",
"     4-6",
"    </a>",
"    ] and can sometimes merge or overlap with eosinophilic fasciitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/10/8360?source=see_link\">",
"     \"Eosinophilic fasciitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the incidence, etiology, diagnosis, and management of localized scleroderma (LSc) in children. Juvenile systemic sclerosis and the pathogenesis of systemic sclerosis are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39433?source=see_link\">",
"     \"Juvenile systemic sclerosis (scleroderma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/63/19450?source=see_link\">",
"     \"Pathogenesis of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized scleroderma (LSc), has been differentiated from systemic sclerosis based upon the clinical findings of almost exclusive cutaneous involvement (typically with some involvement of the underlying musculature) with absence of internal organ involvement. This distinction may not be as clear as previously thought, as a significant minority of patients who present initially as LSc develop extracutaneous findings during the course of their disease. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Extracutaneous manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The outcome for most children with LSc depends upon the type and extent of the lesion. The major problem in untreated patients is not survival, but morbidity as a result of skin, muscle, and bone atrophy; growth defects; and deformities of varying severity, mostly seen in patients with linear morphea and deep morphea. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Linear scleroderma'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11\">",
"     'Pansclerotic morphea'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The forms of localized scleroderma (LSc) are distinguished by the distribution of skin lesions and other associated findings. The most widely used classification divides LSc into five types (",
"    <a class=\"graphic graphic_table graphicRef79254 \" href=\"mobipreview.htm?33/48/34572\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Circumscribed (plaque) morphea &mdash; This is the most benign form of LSc and the most common of the morphea types. It is confined to the dermis with occasional involvement of the superficial panniculus or subcutaneous tissue (",
"      <a class=\"graphic graphic_picture graphicRef73912 \" href=\"mobipreview.htm?27/25/28063\">",
"       picture 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef79820 \" href=\"mobipreview.htm?38/58/39855\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef73941 \" href=\"mobipreview.htm?13/21/13656\">",
"       picture 4",
"      </a>",
"      ). Plaques are discrete, few in number, and confined to two or less anatomic areas. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Circumscribed (plaque) morphea'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Generalized morphea &mdash; This form of LSc occurs when there are &ge;4 plaques that affect two or more anatomic sites and become confluent (",
"      <a class=\"graphic graphic_picture graphicRef68904 graphicRef56113 \" href=\"mobipreview.htm?36/42/37539\">",
"       picture 5A-B",
"      </a>",
"      ). Generalized morphea can be superficial or deep. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Generalized morphea'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Linear scleroderma &mdash; This is the most common type of LSc in children. The fibrotic lesion is elongated, and the direction is usually transverse when on the trunk and longitudinal on the limbs. When the lesion involves the face or scalp, it is referred to as \"en coup de sabre\" (",
"      <a class=\"graphic graphic_picture graphicRef78212 \" href=\"mobipreview.htm?18/22/18797\">",
"       picture 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef75258 \" href=\"mobipreview.htm?25/21/25938\">",
"       picture 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef62452 \" href=\"mobipreview.htm?2/52/2883\">",
"       picture 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef73173 \" href=\"mobipreview.htm?12/26/12704\">",
"       picture 9",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef80877 \" href=\"mobipreview.htm?41/52/42816\">",
"       picture 10",
"      </a>",
"      ). Patients may develop contractures and defects of the limb with associated poor growth and disabilities. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Linear scleroderma'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Pansclerotic morphea &mdash; This is the least common but the most disabling form of LSc. The primary site of involvement is the panniculus or subcutaneous tissue. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pansclerotic morphea'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Mixed scleroderma &mdash; A combination of two or more of the other subtypes. (See",
"      <a class=\"local\" href=\"#H13148703\">",
"       'Mixed scleroderma'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bullous involvement, although very rare, may occur in LSc including plaque morphea and linear scleroderma. The bullous lesions may be the result of localized trauma or lymphatic obstruction secondary to the sclerodermatous process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although localized scleroderma (LSc) is uncommon, it is 10 times more common than systemic sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. Few studies have addressed the incidence or prevalence of this order in children, which is believed to occur only in 1 per 1 million [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/3\">",
"     3",
"    </a>",
"    ]. Linear morphea is the predominant form in childhood as compared to circumscribed morphea, which is predominant in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/3\">",
"     3",
"    </a>",
"    ]. LSc has been reported at birth in six neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/9\">",
"     9",
"    </a>",
"    ]. All these patients with so called \"congenital LSc\" had linear morphea, of which four involved the face with an en coup de sabre appearance.",
"   </p>",
"   <p>",
"    Further evidence that LSc is relatively uncommon in children is illustrated by a report from a pediatric rheumatology center that found only 2 percent of all referred patients had LSc [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/10\">",
"     10",
"    </a>",
"    ]. Others have reported a referral rate for LSc that is 5 percent that of juvenile idiopathic arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/11\">",
"     11",
"    </a>",
"    ]. However, LSc may be underreported because of bias of referral patterns and misdiagnosis, as other cutaneous diseases have sclerodermatous changes resembling LSc. As an example, the en coup de sabre subtype of linear morphea may be misdiagnosed as alopecia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology and pathogenesis of localized scleroderma (LSc), remain uncertain. Two possible contributing pathogenic processes include abnormal fibroblast function and autoimmune dysfunction.",
"   </p>",
"   <p>",
"    The skin lesion of LSc demonstrates an initial marked inflammatory reaction, followed by matrix deposition (including collagen), fibrosis, and ultimately atrophy (",
"    <a class=\"graphic graphic_picture graphicRef62616 \" href=\"mobipreview.htm?20/56/21381\">",
"     picture 1",
"    </a>",
"    ). Because of these histological changes, investigations have focused on abnormal regulation of collagen production by fibroblasts. As an example, one study demonstrated increased collagen production by fibroblasts in skin biopsy specimens from patients with morphea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, raised levels of cytokines, that increase collagen synthesis by fibroblasts, have been reported in LSc lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/14\">",
"     14",
"    </a>",
"    ]. Further studies are needed to elucidate whether there is an underlying dysregulation of fibroblasts.",
"   </p>",
"   <p>",
"    Autoimmune dysfunction as a contributing cause of LSc is supported by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with LSc, there is an increased incidence of autoimmune disorders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/3,15,16\">",
"       3,15,16",
"      </a>",
"      ]. The most commonly associated diseases include Hashimoto's thyroiditis, vitiligo, and type 1 diabetes mellitus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/15,17-19\">",
"       15,17-19",
"      </a>",
"      ]. Relatives of affected patients also have an increased incidence of autoimmune disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/8,15\">",
"       8,15",
"      </a>",
"      ]. In one study, 12 percent of patients reported a positive family history for rheumatic or autoimmune diseases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Biopsies of linear morphea have similar histologic findings to those seen in skin lesions of patients with GVHD and morphea-like lesions are seen in chronic graft-versus-host disease (GVHD) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/20\">",
"       20",
"      </a>",
"      ]. For this reason, it has been proposed that nonself cells or chimerism may be involved in the pathogenesis of LSc. In one study, tissue biopsies of morphea were found to contain chimeric infiltrating cells, which were primarily epithelial cells surrounded by CD4, CD8 T cells and B cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/21\">",
"       21",
"      </a>",
"      ]. These findings resembled lymphoid aggregates, which have been reported in other autoimmune processes.",
"      <br/>",
"      <br/>",
"      The presence of immature chimeric cells in LSc lesions suggests a possible role for chimerism in the pathogenesis of this disease, similar to other autoimmune diseases such as juvenile dermatomyositis, neonatal lupus, Sj&ouml;gren's syndrome, and systemic scleroderma.",
"     </li>",
"     <li>",
"      Autoantibodies are a frequent finding in patients with LSc [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/8,15\">",
"       8,15",
"      </a>",
"      ]. Relatives of affected patients also have an increase in organ-specific autoantibodies compared with control patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/15\">",
"       15",
"      </a>",
"      ].Unlike many autoimmune diseases, there appears to be no significant increased risk for LSc in family members.",
"      <br/>",
"      <br/>",
"      Similar to adult sclerosis, numerous etiologic agents have been suggested as possible causes of LSc, including drugs and environmental toxins, local trauma, and infection. However, no definitive link has been established in any of these.",
"     </li>",
"     <li>",
"      Drugs and environmental toxins that have been associated with scleroderma-like skin reactions include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      , ergot,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/48/29446?source=see_link\">",
"       pentazocine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/9/3221?source=see_link\">",
"       carbidopa",
"      </a>",
"      , and vitamin K [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/22\">",
"       22",
"      </a>",
"      ]. In a large multicenter retrospective review of 750 patients, 13.3 percent of the patients reported specific environmental events as a potential trigger for their disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/23\">",
"       23",
"      </a>",
"      ]. These included infections, drugs, mechanical events (eg, accidental trauma, insect bite, and vaccination), and psychological stress.",
"     </li>",
"     <li>",
"      Trauma has been implicated in the initiation of morphea lesions and also with the onset of eosinophilic fasciitis. A history of trauma has been reported in 3 to 13 percent of patients with LSc [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/8,23,24\">",
"       8,23,24",
"      </a>",
"      ]. The underlying pathogenesis of how trauma would contribute to development of LSc is unclear. Although cytokines and neuropeptides (eg, endothelin-1), which are normally involved in wound healing, have been suggested to play a causative role [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/8\">",
"       8",
"      </a>",
"      ], there is no confirmatory evidence.",
"     </li>",
"     <li>",
"      Since the first report of a patient with linear morphea and Borrelia burgdorferi [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/25\">",
"       25",
"      </a>",
"      ], investigations have focused on whether this spirochete, which causes Lyme disease, may play an etiologic role in LSc [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/26-28\">",
"       26-28",
"      </a>",
"      ]. However, patients with morphea who live in non-endemic areas have no evidence of Borrelia infection, as documented by negative serologic testing and polymerase chain reaction tests in skin biopsy specimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although circumscribed morphea and linear morphea are often described as separate forms of localized scleroderma (LSc), it is common for patients to have overlapping lesions. This possible evolution should be monitored carefully, because linear morphea is associated with greater morbidity and increased complication rates than circumscribed morphea.",
"   </p>",
"   <p>",
"    In a large retrospective multicenter review of 750 children with LSc, the most common subtype was linear morphea (65 percent), followed by circumscribed morphea (26 percent), generalized morphea (7 percent), and deep morphea (2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/23\">",
"     23",
"    </a>",
"    ]. However, 15 percent of patients had clinical features that overlapped and were defined as a mixed subtype. In 12 percent of patients there was a family history of rheumatic or autoimmune diseases. Overall, the mean age of presentation was 7.3 years (range 0 to 16 years, median age 6.1 years).",
"   </p>",
"   <p>",
"    The most widely used classification divides juvenile localized scleroderma into five general types: circumscribed morphea (CM), linear scleroderma, generalized morphea (GM), pansclerotic morphea, and a mixed subtype where a combination of two or more of the previous subtypes is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Circumscribed (plaque) morphea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circumscribed morphea is the most benign form of LSc. These lesions are confined to the dermis with only occasional involvement of the superficial panniculus (subcutaneous tissue). Plaques are discrete, few in number, and confined to one anatomic area. Depending on the shape and size of the lesions, various subtypes of circumscribed morphea have been described (",
"    <a class=\"graphic graphic_picture graphicRef79820 \" href=\"mobipreview.htm?38/58/39855\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef73941 \" href=\"mobipreview.htm?13/21/13656\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It is characterized by oval or round circumscribed areas of induration with a central waxy, ivory color surrounded by a violaceous halo (the \"lilac ring\") (",
"    <a class=\"graphic graphic_picture graphicRef73912 \" href=\"mobipreview.htm?27/25/28063\">",
"     picture 2",
"    </a>",
"    ). The plaques are typically several centimeters in diameter and occur most frequently on the trunk, less often on the limbs, and infrequently on the face. Plaques evolve through several stages:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Initial erythematous inflammatory stage",
"     </li>",
"     <li>",
"      Sclerotic indurated phase with surrounding inflammation",
"     </li>",
"     <li>",
"      Softening and dermal atrophy phase with associated hypo or hyper pigmentation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These lesions usually self-resolve within three to five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/30\">",
"     30",
"    </a>",
"    ], although a patch may sometimes persist. New patches occasionally appear many years after initial presentation.",
"   </p>",
"   <p>",
"    Other subtypes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Guttate morphea &mdash; Guttate morphea is less common and frequently involves the shoulders and chest. Lesions are multiple, small (2 to 10 mm in diameter) hypopigmented and pigmented papules with minimal sclerosis (",
"      <a class=\"graphic graphic_picture graphicRef55918 \" href=\"mobipreview.htm?40/4/41038\">",
"       picture 11",
"      </a>",
"      ). The epidermis is thin and atrophic, resembling lichen sclerosus et atrophicus.",
"     </li>",
"     <li>",
"      Keloid morphea &mdash; Keloid morphea, also known as \"nodular morphea\", is a rare condition characterized by indurated plaques that resemble post-traumatic scars. Keloid morphea can be several centimeters in diameter, and is found either as a single lesion or as multiple lesions (",
"      <a class=\"graphic graphic_picture graphicRef54463 \" href=\"mobipreview.htm?26/38/27247\">",
"       picture 12",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Atrophoderma of Pasini and Pierini &mdash; This subtype usually involves the trunk and is characterized by hyperpigmented atrophic patches with well-demarcated borders. It may exist with other types of sclerotic lesions or represent the involutionary phase of morphea en plaque.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Generalized morphea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized morphea, which can be superficial or deep, is defined by the presence of &ge;4 plaques involving at least two different anatomic sites (",
"    <a class=\"graphic graphic_picture graphicRef68904 graphicRef56113 \" href=\"mobipreview.htm?36/42/37539\">",
"     picture 5A-B",
"    </a>",
"    ). Usually, the trunk and legs are involved and the acral (fingers, toes, or ears) parts may be spared. Onset of sclerosis is rapid over a period of several months, and the degree of inflammation is greater than in other subtypes. Generalized morphea can extend, resulting in disfigurement and contractures, disability, and ulcerations that, on rare occasions, become malignant.",
"   </p>",
"   <p>",
"    Sometimes circumscribed deep induration of the skin involves subcutaneous tissue extending to fascia and underlying muscle. The skin can appear bound down with a solitary, indurated plaque [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/31\">",
"     31",
"    </a>",
"    ]. Lesions can be single or multiple.",
"   </p>",
"   <p>",
"    Other times the primary site of involvement is the subcutaneous tissue without involvement of the skin. These plaques are hyperpigmented, symmetric, and somewhat ill defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Linear scleroderma",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is the most frequent form of LSc. The fibrotic lesion is elongated into an appearance of linear bands. Plaque direction is usually transverse in the trunk and longitudinal in the extremities.",
"   </p>",
"   <p>",
"    There is considerable debate on whether these lesions follow specific dermatomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/33\">",
"     33",
"    </a>",
"    ]. One theory speculates the involved distribution reflects an abnormal migration of neuroepidermal cells during embryogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/34\">",
"     34",
"    </a>",
"    ]. This theory is supported by the frequent development of seizures, hemiparesis, and headaches during the evolution of a facial lesion called en coup de sabre [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/35\">",
"     35",
"    </a>",
"    ]. Imaging studies of the brain also have shown vascular and cerebral changes even in patients without neurologic symptoms. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Linear scleroderma of the face'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Linear scleroderma of the limbs and trunk may result in the following findings and complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrophy of soft tissue muscle, periosteum, bone, and occasionally synovium (",
"      <a class=\"graphic graphic_picture graphicRef50834 \" href=\"mobipreview.htm?37/27/38334\">",
"       picture 13",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Extensive and disfiguring growth defects in either all or part of an affected limb. These defects may require major surgery, and may continue even after the cutaneous inflammation abates.",
"     </li>",
"     <li>",
"      Fixed valgus or varus deformities, which occur because of leg length inequalities.",
"     </li>",
"     <li>",
"      Lesions that cross joint-lines, causing disabling flexion contractures.",
"     </li>",
"     <li>",
"      Hammer toes or claw hands may develop if the toes or fingers are involved.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Linear scleroderma of the face",
"    </span>",
"    &nbsp;&mdash;&nbsp;This subtype includes the so called \"en coup de sabre\", a term that denotes the resemblance of the lesion to the consequence of a sabre blow, and the Perry Romberg syndrome. Linear lesions occur on the face or scalp, and after an acute inflammatory phase, assume a depressed, ivory appearance. They usually are restricted to one half of the face, often with a loss of scalp hair and eyelids as well as asymmetric facial development (",
"    <a class=\"graphic graphic_picture graphicRef75258 \" href=\"mobipreview.htm?25/21/25938\">",
"     picture 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62452 \" href=\"mobipreview.htm?2/52/2883\">",
"     picture 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef73173 \" href=\"mobipreview.htm?12/26/12704\">",
"     picture 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef80877 \" href=\"mobipreview.htm?41/52/42816\">",
"     picture 10",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Perioral skin involvement may extend into the oral cavity and cause major dental problems, such as early loss of the primary teeth, delayed or abnormal eruption of the permanent teeth, and lack of bone growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vascular abnormalities of the brain also may occur, and several eye lesions have been described, reflecting extension of the same pathologic processes into the brain and orbit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, the patient with en coup de sabre can have morphea lesions elsewhere. In patients with en coup de sabre, associated neurologic manifestations include seizures (particularly complex partial seizures), headaches, and facial paralysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/37\">",
"     37",
"    </a>",
"    ]. The neurological findings may occur before, concurrent with, or after the skin manifestations.",
"   </p>",
"   <p>",
"    An area of controversy is the relationship between en coup de sabre and the Parry-Romberg syndrome. The latter syndrome is characterized by hemifacial atrophy of the skin and tissue below the forehead. In patients with Parry-Romberg compared with those with en coup de sabre, there is usually greater involvement of the lower face, and the superficial skin is involved in a relatively minor fashion. Seizures, uveitis, and dental and ocular abnormalities have been described in both conditions. Evidence that these two conditions are included in the same spectrum of disease has been provided by a study showing that 15 of 54 patients (28 percent) with either en coup de sabre or Parry-Romberg syndrome had similar clinical features, such as frequency of neurologic abnormalities (one-fourth of the patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/38\">",
"     38",
"    </a>",
"    ]. Both electroencephalography (EEG) and central nervous system (CNS) imaging abnormalities were often ipsilateral to the affected side of face also supporting a pathogenetic link between the two clinical manifestations of the disease.",
"   </p>",
"   <p>",
"    Parry-Romberg may represent the severe end of the spectrum of en coup de sabre as supported by cases of patients who have definite linear lesions on the face and other parts of the body. However, in other reports, there is no evidence of inflammation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sclerosis preceding the severe atrophy seen in patients with Parry-Romberg syndrome, suggesting the two are separate entities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pansclerotic morphea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pansclerotic morphea is the least common but most disabling variant of LSc. A deep biopsy will show inflammation of the entire panniculus with fibrosis confined largely to the deep dermis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/31\">",
"     31",
"    </a>",
"    ]. It is characterized by generalized full-thickness skin involvement of the trunk, extremities, face, and scalp with sparing of the fingertips and toes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/41\">",
"     41",
"    </a>",
"    ]. The progression of the disorder is unrelenting, and there have been reports of squamous cell carcinoma developing in affected children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a number of cases, histologic changes include a significant eosinophilic inflammatory process, suggesting deep morphea may be a chronic form of eosinophilic fasciitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13148703\">",
"    <span class=\"h2\">",
"     Mixed scleroderma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed scleroderma is a condition in which a combination of two or more of the previous subtypes coexist. This subtype represents around one-fifth of the whole pediatric cohort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Extracutaneous manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distinction between localized scleroderma (LSc) and systemic sclerosis may not be as clear as previously thought. Rather than representing two distinct entities, LSc and systemic sclerosis may represent two ends of a continuous spectrum of disease. Support for this continuum theory includes the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One-fourth of children diagnosed with LSc develop one or more extracutaneous manifestations during the course of their disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/44,45\">",
"       44,45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a few patients with LSc, their disease progressed to systemic sclerosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/4-6\">",
"       4-6",
"      </a>",
"      ]. The diagnosis of systemic disease is made when the skin induration becomes diffuse, internal organ involvement is severe, and specific autoantibodies for diffuse systemic sclerosis are present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39433?source=see_link\">",
"       \"Juvenile systemic sclerosis (scleroderma)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An increased risk of an autoimmune systemic disease was demonstrated primarily in adult patients in a large retrospective case series of patients with morphea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/46\">",
"       46",
"      </a>",
"      ]. In this study, 30 percent of adult patients (37 of 123) and 5 percent of pediatric patients (6 of 122) reported concomitant findings of other rheumatic or autoimmune disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Extracutaneous manifestations in patients with LSc include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arthritis &mdash; Articular involvement is the most frequent finding and accounts for one-half of the extracutaneous manifestations in patients with LSc [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. It is especially prevalent in patients with linear morphea. The joint involved sometimes is completely unrelated to the site of the skin lesion. Children with LSc who develop arthritis often have a positive rheumatoid factor (RF), and sometimes an elevated erythrocyte sedimentation rate (ESR) and circulating autoantibodies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/45\">",
"       45",
"      </a>",
"      ]. These children tend to have an accelerated course with predominant musculoskeletal disease, including rapid development of contractures (",
"      <a class=\"graphic graphic_picture graphicRef61487 \" href=\"mobipreview.htm?41/33/42526\">",
"       picture 14",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Neurologic findings &mdash; The most frequent neurologic conditions are epilepsy and headaches, although behavioral changes and learning disabilities also have been described [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/45,47-49\">",
"       45,47-49",
"      </a>",
"      ]. Abnormalities on magnetic resonance imaging (MRI), such as calcifications, white matter changes, vascular malformations, and changes consistent with central nervous system (CNS) vasculitis, also have been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/50,51\">",
"       50,51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ocular findings &mdash; Ocular changes are reported in about 3 percent of pediatric patients affected by LSc. In a report from a multi-center study, 24 of 750 patients (3 percent) with LSc had ocular involvement, of which 16 had en coup de sabre of the face [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/52\">",
"       52",
"      </a>",
"      ]. Ten patients had adnexa (eyelids and eyelashes) abnormalities, seven had anterior segment inflammation (including five with anterior uveitis and two with episcleritis), three had central nervous system abnormalities, two had refractive errors, and one patient each had paralytic strabismus and pseudopapilledema. Based upon these findings, a careful ophthalmic monitoring for every patient with LSc is recommended, particularly in the presence of skin lesions on the face",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      concomitant CNS involvement.",
"     </li>",
"     <li>",
"      Gastrointestinal findings &mdash;Esophageal motor function abnormalities with gastro-esophageal reflux (GER) have been reported both in children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/44,53\">",
"       44,53",
"      </a>",
"      ] and in adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/43\">",
"       43",
"      </a>",
"      ] with LSc. In one study of 14 children with LSc, esophageal abnormalities were detected in eight patients including seven with abnormal 24-hour pH monitoring results, five with non-specific esophageal motor abnormalities, and five with endoscopy-proven esophagitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/53\">",
"       53",
"      </a>",
"      ]. These findings suggest that an extensive gastrointestinal evaluation be performed in patients with LSc and gastrointestinal symptoms.",
"     </li>",
"     <li>",
"      Pulmonary findings &mdash; There have been reports of respiratory involvement, primarily restrictive changes with a mild decrease in respiratory volume and impaired diffusing capacity of the lungs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. These patients do not have systemic sclerosis, as they have circumscribed (not diffuse) skin lesions, no other organ involvement, and lack systemic sclerosis associated autoantibodies, and their nailfold capillaroscopy is normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a multi-center European study of 750 children with LSc, the prevalence and the clinical features of extracutaneous findings in patients with LSc were determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/45\">",
"     45",
"    </a>",
"    ]. There was at least one extracutaneous manifestation present in 22 percent of children, and 4 percent had multiple manifestations. In 92 percent of cases, a skin lesion was the presenting sign of disease. Systemic sclerosis developed in only one patient. The overall distribution of extracutaneous manifestations was as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Arthritis: 19 percent",
"     </li>",
"     <li>",
"      Neurologic findings: 4 percent",
"     </li>",
"     <li>",
"      Other autoimmune conditions (eg, Raynaud's phenomenon): 3 percent",
"     </li>",
"     <li>",
"      Vascular findings (vasculitic rash and deep vein thrombosis): 2 percent",
"     </li>",
"     <li>",
"      Ocular findings: 3 percent",
"     </li>",
"     <li>",
"      Gastrointestinal symptoms (exclusively GER): 2 percent",
"     </li>",
"     <li>",
"      Respiratory findings (restrictive lung disease): 1 percent",
"     </li>",
"     <li>",
"      Two patients had cardiac findings (pericarditis and arrhythmia) and one patient had nephritis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of localized scleroderma (LSc) is established on clinical grounds, usually by the physical appearance of the lesions. A biopsy of the skin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subcutaneous tissue may be useful for confirmation if there is doubt about the diagnosis. There is no laboratory test that is diagnostic for LSc.",
"   </p>",
"   <p>",
"    Evaluating the progression or response to therapy of LSc may be difficult. Charting the evolution of involved areas often is cumbersome and imprecise. Nevertheless, the evaluation of a patient with LSc includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recording the size of the lesion",
"     </li>",
"     <li>",
"      Monitoring the leg length, limb circumference, and posture",
"     </li>",
"     <li>",
"      Assessing muscle function and neurologic status",
"     </li>",
"     <li>",
"      Serial photographic evaluation for any new lesions",
"     </li>",
"     <li>",
"      MRI (most useful to determine whether there is CNS or ocular involvement when it is suspected [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/54\">",
"       54",
"      </a>",
"      ], but may also be useful in identifying musculoskeletal involvement even when not clinically evident [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/55\">",
"       55",
"      </a>",
"      ])",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of LSc is not dependent on laboratory testing. Routine studies such as complete blood count, blood chemistries, and urinalysis are normal.",
"   </p>",
"   <p>",
"    Antibodies to single-stranded DNA (ss-DNA) have been reported in 20 to 55 percent of patients with LSc and correlate with the extent of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/8,56,57\">",
"     8,56,57",
"    </a>",
"    ]. In contrast, antibodies to double-stranded DNA (ds-DNA) are rarely found. In a large retrospective study, 42 percent of tested patients had a positive antinuclear antibody (ANA) test, but a positive test for ds-ANA was found only in 4.2 percent of tested patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/23\">",
"     23",
"    </a>",
"    ]. Tests for anti-centromere and anti-topoisomerase are rarely positive (1.7 and 3.2 percent, respectively).",
"   </p>",
"   <p>",
"    Elevated markers of inflammation (eg, ESR and C reactive protein) as well as positive ANA and rheumatoid factor (RF), are more frequently seen in patients with LSc who have extracutaneous manifestations than those with only skin involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/23,45\">",
"     23,45",
"    </a>",
"    ]. RF in particular is seen more commonly in patients with arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present, there are no specific laboratory tests for measuring disease activity. One report found elevated soluble interleukin-2 receptor levels with active disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/58\">",
"     58",
"    </a>",
"    ]; however, another study failed to confirm this [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/8\">",
"     8",
"    </a>",
"    ]. The latter report also evaluated the utility of circulating levels of von Willebrand factor, angiotensin converting enzyme, E-selectin, and procollagen peptides, none of which were significantly elevated. In another study, antihistone antibodies appeared to be associated with more extensive localized disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive technology, including thermography, ultrasonography, and magnetic resonance imaging (MRI), may be helpful in following the extent of disease in selected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thermography, which measures the radiation of infrared heat from the body, shows promise in discriminating active from inactive disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/60,61\">",
"       60,61",
"      </a>",
"      ]. This procedure is noninvasive and usually well tolerated. It allows for easy interpretation and rapid results that are helpful in decision-making. There are false-positive results in cases of atrophic or old lesions, particularly in the scalp region [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/60,61\">",
"       60,61",
"      </a>",
"      ]. In these cases, a careful clinical examination is needed to confirm doubtful active lesions.",
"     </li>",
"     <li>",
"      Ultrasonography is a noninvasive useful tool that also may be useful in the evaluation of LSc patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/62,63\">",
"       62,63",
"      </a>",
"      ] and monitoring of disease activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/64,65\">",
"       64,65",
"      </a>",
"      ]. With the 13 MHz probe, the penetration depth reaches 60 mm, allowing for quantitative assessment of LSc lesions. Thypodermis echogenicity and deep tissue layer vascularity are the most sensitive indicators of disease activity.",
"     </li>",
"     <li>",
"      A computerized skin score (CSS) method allows the measurement of single target skin lesions and their comparison over the time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/66\">",
"       66",
"      </a>",
"      ]. The indurate borders of the lesions are demarcated upon an adhesive transparent film, which is transferred to a computer as a scanned image. The dimensions of the scanned image to are converted to a computerized skin score. This new technique is applicable in day-to-day practice, is not time consuming, and does not need specialized equipment.",
"     </li>",
"     <li>",
"      Laser Doppler flowmetry (LDF) is a noninvasive tool that measures cutaneous microcirculation and has been used in dermatology and microvascular surgery. In one study of 41 children with LSc, LDF appeared to be more accurate in detecting active lesions than thermography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) is indicated when CNS or orbital involvement are suspected [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/68\">",
"       68",
"      </a>",
"      ]. It is also indicated in the assessment of musculoskeletal involvement, particularly in linear scleroderma and pansclerotic morphea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the lesions of localized scleroderma (LSc) are fairly distinctive, the cutaneous manifestations of the following disorders may have a similar appearance:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lichen sclerosus et atrophicus (",
"      <a class=\"graphic graphic_picture graphicRef76573 \" href=\"mobipreview.htm?7/37/7762\">",
"       picture 15",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef67078 \" href=\"mobipreview.htm?20/6/20582\">",
"       picture 16",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lupus panniculitis",
"     </li>",
"     <li>",
"      Lipodystrophy",
"     </li>",
"     <li>",
"      Morphea-like lesions of phenylketonuria",
"     </li>",
"     <li>",
"      Graft-versus-host disease (",
"      <a class=\"graphic graphic_picture graphicRef77052 \" href=\"mobipreview.htm?17/30/17903\">",
"       picture 17",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Borrelia infection",
"     </li>",
"     <li>",
"      Eosinophilic fasciitis (",
"      <a class=\"graphic graphic_picture graphicRef65829 \" href=\"mobipreview.htm?26/37/27230\">",
"       picture 18",
"      </a>",
"      ) may merge into generalized morphea",
"     </li>",
"     <li>",
"      Acquired port-wine stain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/69\">",
"       69",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Education of the patient and family is critical in the management of localized scleroderma. Undue anxiety often is created by the family's confusion of localized scleroderma (LSc) and systemic sclerosis. Explanation of the difference between these conditions and their expected outcome should be emphasized to the family.",
"   </p>",
"   <p>",
"    Treatment may include general non-pharmacologic measures",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pharmacologic therapy. Care should include advice on skin care, an exercise schedule to maintain functional ability, psychologic and social support, and pharmacologic therapy. Surgical procedures are rarely necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Nonpharmacologic measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;A carefully designed treatment program, including physiotherapy and massage, is beneficial in many children with LSc. Physiotherapy maintains functional ability, muscle strength, and joint movement while preventing flexion contractures. It should be performed consistently.",
"   </p>",
"   <p>",
"    Deep connective tissue massage taught to parents may be helpful in improving dermal elasticity. Massage can be aided by the use of oils, while wax therapy can facilitate hand exercises. The use of corrective splints and gait analysis also may be helpful. Attention to positive joint alignment and muscle development is particularly important in linear scleroderma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pharmacologic measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy for LSc has been challenging, as only one controlled trial in children has been published so far. Decisions for management must be based upon the realization that these disorders are sometimes benign and may spontaneously enter remission after three to five years (",
"    <a class=\"graphic graphic_table graphicRef77267 \" href=\"mobipreview.htm?22/14/22764\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No therapy is usually needed for the single circumscribed lesion, as in circumscribed morphea, but emollients (any lanolin-based cream) and low concentration topical corticosteroids or calcipotriene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/70\">",
"     70",
"    </a>",
"    ] may help relieve dryness and itching.",
"   </p>",
"   <p>",
"    Systemic treatment is recommended when there is a significant risk for disability, such as in deep pansclerotic morphea, progressive linear morphea crossing joint lines or involving the face (en coup de sabre), or generalized morphea. Although there are no controlled trials, there is extensive experience using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      &mdash; Methotrexate has been used successfully in children and adults with LSc [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/30,71-74\">",
"       30,71-74",
"      </a>",
"      ]. We recommend a weekly regimen of methotrexate of 15",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      given as a single oral or subcutaneous dose per week (maximum dose 25 mg per week) for at least one year. During the first two to three months of therapy, a course of glucocorticoids may be used as adjunctive bridge therapy for those with rapidly progressive disease. We use either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      day (maximum dose to 50 mg per day) administered orally or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      20 to 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (maximum dose to 1000",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) administered intravenously for three consecutive days monthly for two to three months.",
"      <br/>",
"      <br/>",
"      A randomized trial comparing a 12 month course of oral methotrexate (15",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      for 12 months with a three month course of oral prednisone (1",
"      <span class=\"nowrap\">",
"       mg/kg/day,",
"      </span>",
"      maximum dose 50 mg) showed that methotrexate was effective and well tolerated in more than two-thirds of the patients with LSc [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/74\">",
"       74",
"      </a>",
"      ].New lesions appeared in only 6.5 percent of methotrexate-treated patients compared with 16.7 percent of the prednisone group. In addition, the skin score rate, which evaluates lesions&rsquo; extension changes and the mean target lesion temperature as evaluated by infrared thermography, significantly decreased in the methotrexate group.",
"      <br/>",
"      <br/>",
"      A long-term follow-up study of the same patient cohort showed that prolonged remission off medication was achieved in patients treated for more than 24 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/75\">",
"       75",
"      </a>",
"      ]. A relapse rate of 12.5 percent was reported in a group of forty patients treated for less than 24 months, whereas no relapses were noted in those treated longer. Similar results were reported in a single center study in which methotrexate was given subcutaneously for 24 months and then switched to oral administration for 12 additional months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/76\">",
"       76",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Patients who do not respond to this treatment approach may be treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil at a dose of 500 to 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interferon &mdash; Intralesional cytokine interferon has proved no better than placebo for established lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ultraviolet light &mdash; The use of ultraviolet (UV) light therapy, with or without chemical agents such as psoralen, has been reported to be beneficial for localized or superficial lesions in a number of studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/79-82\">",
"       79-82",
"      </a>",
"      ]. UVA1 phototherapy up-regulates specific matrix mRNA metalloproteinases, depletes skin-infiltrating T cells, and inhibits the production of proinflammatory cytokines, namely IL-1, IL-6 and IL-8 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/83\">",
"       83",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Extracorporeal photochemotherapy (with UVA and psoralen) has been used in LSc, but the evidence to support this modality is weak [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/80,84,85\">",
"       80,84,85",
"      </a>",
"      ]. Because of the risk of mutagenicity, the use of ultraviolet light is contraindicated in children.",
"     </li>",
"     <li>",
"      Vitamin D &mdash; Use of vitamin D or its analogues (topically and systemically) has been reported in several case series with encouraging results [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/70,86\">",
"       70,86",
"      </a>",
"      ]. However, in the only controlled trial, results indicated it was no more effective than placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical reconstruction may be required if the disease has not been adequately controlled. Surgery should only be performed after the active phase of the disease has abated and when the child's growth is complete [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. Orthopedic problems can occur and may require complex corrective surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/90\">",
"     90",
"    </a>",
"    ]. Facial recontouring is a surgical treatment option that may improve quality of life in adolescents with facial asymmetry due to en coupe de sabre morphea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40985/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The predominant form of scleroderma in childhood is localized scleroderma (LSc). It is classified into five types based upon the extent of disease: circumscribed (plaque) morphea, generalized morphea (superficial or deep), linear scleroderma, pansclerotic morphea, and mixed scleroderma. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Localized disease principally involves the skin, subcutaneous fascia, muscle, and bone, although a quarter of patients will have extracutaneous findings. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Extracutaneous manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment needs to be individualized and be matched to both the type of localized scleroderma and stage of disease. Care should include advice on skin softening agents, exercise to maintain functional ability, pharmacologic therapy and, if indicated, surgery.",
"     </li>",
"     <li>",
"      We suggest",
"      <strong>",
"       not",
"      </strong>",
"      treating a single localized lesion with systemic therapy unless it crosses a joint line and produces contracture (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Emollients (any lanolin-based cream) and low concentration weak topical corticosteroids (1 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      cream) may relieve dryness and itching.",
"     </li>",
"     <li>",
"      For pansclerotic morphea, progressive linear scleroderma crossing joint lines or involving the face (en coup de sabre), or generalized morphea, we recommend treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      for at least 24 months, in combination with oral glucocorticoids for the first two to three months (",
"      <a class=\"graphic graphic_table graphicRef77267 \" href=\"mobipreview.htm?22/14/22764\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/1\">",
"      Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 2011; 64:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/2\">",
"      Fett N, Werth VP. Update on morphea: part II. Outcome measures and treatment. J Am Acad Dermatol 2011; 64:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/3\">",
"      Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc 1995; 70:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/4\">",
"      Rossi P, Fossaluzza V, Gonano L. Localized scleroderma evolving into systemic sclerosis. J Rheumatol 1985; 12:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/5\">",
"      Mayorquin FJ, McCurley TL, Levernier JE, et al. Progression of childhood linear scleroderma to fatal systemic sclerosis. J Rheumatol 1994; 21:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/6\">",
"      Birdi N, Laxer RM, Thorner P, et al. Localized scleroderma progressing to systemic disease. Case report and review of the literature. Arthritis Rheum 1993; 36:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/7\">",
"      Daoud MS, Su WP, Leiferman KM, Perniciaro C. Bullous morphea: clinical, pathologic, and immunopathologic evaluation of thirteen cases. J Am Acad Dermatol 1994; 30:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/8\">",
"      Vancheeswaran R, Black CM, David J, et al. Childhood-onset scleroderma: is it different from adult-onset disease. Arthritis Rheum 1996; 39:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/9\">",
"      Zulian F, Vallongo C, de Oliveira SK, et al. Congenital localized scleroderma. J Pediatr 2006; 149:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/10\">",
"      Woo P, David J, Vancheeswaran R, et al. Is scleroderma the same disease in childhood. Athritis Rheum 1992; 35:S137.",
"     </a>",
"    </li>",
"    <li>",
"     Levinson JE, Bove KE. Scleroderma. In: Musculoskeletal disease of children, Gershwin, ME, Robbins, DE (Eds), Orlando 1983. p.195.",
"    </li>",
"    <li>",
"     Dabich L. Scleroderma. In: Textbook of paediatric rheumatology, Cassidy JT (Ed), Wiley, New York 1982. p.433.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/13\">",
"      K&auml;h&auml;ri VM, Sandberg M, Kalimo H, et al. Identification of fibroblasts responsible for increased collagen production in localized scleroderma by in situ hybridization. J Invest Dermatol 1988; 90:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/14\">",
"      Liu B, Connolly MK. The pathogenesis of cutaneous fibrosis. Semin Cutan Med Surg 1998; 17:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/15\">",
"      Harrington CI, Dunsmore IR. An investigation into the incidence of auto-immune disorders in patients with localized morphoea. Br J Dermatol 1989; 120:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/16\">",
"      Seow WK, Young W. Localized scleroderma in childhood: review of the literature and case report. Pediatr Dent 1987; 9:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/17\">",
"      Lee HJ, Kim MY, Ha SJ, Kim JW. Two cases of morphea associated with Hashimoto's thyroiditis. Acta Derm Venereol 2002; 82:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/18\">",
"      Dervis E, Acbay O, Barut G, et al. Association of vitiligo, morphea, and Hashimoto's thyroiditis. Int J Dermatol 2004; 43:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/19\">",
"      Lerner AB, Sansung J. Vitiligo and linear scleroderma Arch Dermatol 1973; 108:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/20\">",
"      Van Vloten WA, Scheffer E, Dooren LJ. Localized scleroderma-like lesions after bone marrow transplantation in man. A chronic graft versus host reaction. Br J Dermatol 1977; 96:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/21\">",
"      McNallan KT, Aponte C, el-Azhary R, et al. Immunophenotyping of chimeric cells in localized scleroderma. Rheumatology (Oxford) 2007; 46:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/22\">",
"      Haustein UF, Haupt B. Drug-induced scleroderma and sclerodermiform conditions. Clin Dermatol 1998; 16:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/23\">",
"      Zulian F, Athreya BH, Laxer R, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) 2006; 45:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/24\">",
"      Falanga V, Medsger TA Jr, Reichlin M, Rodnan GP. Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med 1986; 104:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/25\">",
"      Aberer E, Neumann R, Stanek G. Is localised scleroderma a Borrelia infection? Lancet 1985; 2:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/26\">",
"      Stanek G, Konrad K, Jung M, Ehringer H. Shulman syndrome, a scleroderma subtype caused by Borrelia burgdorferi? Lancet 1987; 1:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/27\">",
"      Weide B, Schittek B, Klyscz T, et al. Morphoea is neither associated with features of Borrelia burgdorferi infection, nor is this agent detectable in lesional skin by polymerase chain reaction. Br J Dermatol 2000; 143:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/28\">",
"      Fan W, Leonardi CL, Penneys NS. Absence of Borrelia burgdorferi in patients with localized scleroderma (morphea). J Am Acad Dermatol 1995; 33:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/29\">",
"      Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol 2006; 18:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/30\">",
"      CHRISTIANSON HB, DORSEY CS, KIERLAND RR, O'LEARY PA. Localized scleroderma; a clinical study of two hundred thirty-five cases. AMA Arch Derm 1956; 74:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/31\">",
"      Su WP, Person JR. Morphea profunda. A new concept and a histopathologic study of 23 cases. Am J Dermatopathol 1981; 3:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/32\">",
"      Person JR, Su WP. Subcutaneous morphoea: a clinical study of sixteen cases. Br J Dermatol 1979; 100:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/33\">",
"      Serup J. Clinical appearance of skin lesions and disturbances of pigmentation in localized scleroderma. Acta Derm Venereol 1984; 64:485.",
"     </a>",
"    </li>",
"    <li>",
"     Johnston MC. The neural crest in abnormalities of the face and brain. In: Morphogenesis and malformations of the face and brain, Bersma D, Paul NW (Eds), Liss, New York 1975.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/35\">",
"      Krafchik BR. Localized cutaneous scleroderma. Semin Dermatol 1992; 11:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/36\">",
"      SEGAL P, JABLONSKA S, MRZYGLOD S. Ocular changes in linear scleroderma. Am J Ophthalmol 1961; 51:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/37\">",
"      Holland KE, Steffes B, Nocton JJ, et al. Linear scleroderma en coup de sabre with associated neurologic abnormalities. Pediatrics 2006; 117:e132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/38\">",
"      Tollefson MM, Witman PM. En coup de sabre morphea and Parry-Romberg syndrome: a retrospective review of 54 patients. J Am Acad Dermatol 2007; 56:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/39\">",
"      Blaszczyk M, Jablonska S. Linear scleroderma en Coup de Sabre. Relationship with progressive facial hemiatrophy (PFH). Adv Exp Med Biol 1999; 455:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/40\">",
"      Lehman TJ. The Parry Romberg syndrome of progressive facial hemiatrophy and linear scleroderma en coup de sabre. Mistaken diagnosis or overlapping conditions? J Rheumatol 1992; 19:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/41\">",
"      Diaz-Perez JL, Connolly SM, Winkelmann RK. Disabling pansclerotic morphea of children. Arch Dermatol 1980; 116:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/42\">",
"      Wollina U, Buslau M, Weyers W. Squamous cell carcinoma in pansclerotic morphea of childhood. Pediatr Dermatol 2002; 19:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/43\">",
"      Parodi PC, Riberti C, Draganic Stinco D, et al. Squamous cell carcinoma arising in a patient with long-standing pansclerotic morphea. Br J Dermatol 2001; 144:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/44\">",
"      Dehen L, Roujeau JC, Cosnes A, Revuz J. Internal involvement in localized scleroderma. Medicine (Baltimore) 1994; 73:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/45\">",
"      Zulian F, Vallongo C, Woo P, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 2005; 52:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/46\">",
"      Leitenberger JJ, Cayce RL, Haley RW, et al. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol 2009; 145:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/47\">",
"      Blaszczyk M, Kr&oacute;licki L, Krasu M, et al. Progressive facial hemiatrophy: central nervous system involvement and relationship with scleroderma en coup de sabre. J Rheumatol 2003; 30:1997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/48\">",
"      DeFelipe J, Segura T, Arellano JI, et al. Neuropathological findings in a patient with epilepsy and the Parry-Romberg syndrome. Epilepsia 2001; 42:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/49\">",
"      David J, Wilson J, Woo P. Scleroderma 'en coup de sabre'. Ann Rheum Dis 1991; 50:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/50\">",
"      Flores-Alvarado DE, Esquivel-Valerio JA, Garza-Elizondo M, Espinoza LR. Linear scleroderma en coup de sabre and brain calcification: is there a pathogenic relationship? J Rheumatol 2003; 30:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/51\">",
"      Higashi Y, Kanekura T, Fukumaru K, Kanzaki T. Scleroderma en coup de sabre with central nervous system involvement. J Dermatol 2000; 27:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/52\">",
"      Zannin ME, Martini G, Athreya BH, et al. Ocular involvement in children with localised scleroderma: a multi-centre study. Br J Ophthalmol 2007; 91:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/53\">",
"      Guariso G, Conte S, Galeazzi F, et al. Esophageal involvement in juvenile localized scleroderma: a pilot study. Clin Exp Rheumatol 2007; 25:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/54\">",
"      Liu P, Uziel Y, Chuang S, et al. Localized scleroderma: imaging features. Pediatr Radiol 1994; 24:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/55\">",
"      Schanz S, Fierlbeck G, Ulmer A, et al. Localized scleroderma: MR findings and clinical features. Radiology 2011; 260:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/56\">",
"      Su&aacute;rez-Almazor ME, Catoggio LJ, Maldonado-Cocco JA, et al. Juvenile progressive systemic sclerosis: clinical and serologic findings. Arthritis Rheum 1985; 28:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/57\">",
"      Falanga V, Medsger TA Jr, Reichlin M. Antinuclear and anti-single-stranded DNA antibodies in morphea and generalized morphea. Arch Dermatol 1987; 123:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/58\">",
"      Uziel Y, Krafchik BR, Feldman B, et al. Serum levels of soluble interleukin-2 receptor. A marker of disease activity in localized scleroderma. Arthritis Rheum 1994; 37:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/59\">",
"      Sato S, Fujimoto M, Ihn H, et al. Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma. J Am Acad Dermatol 1994; 31:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/60\">",
"      Birdi N, Shore A, Rush P, et al. Childhood linear scleroderma: a possible role of thermography for evaluation. J Rheumatol 1992; 19:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/61\">",
"      Martini G, Murray KJ, Howell KJ, et al. Juvenile-onset localized scleroderma activity detection by infrared thermography. Rheumatology (Oxford) 2002; 41:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/62\">",
"      Seidenari S, Conti A, Pepe P, Giannetti A. Quantitative description of echographic images of morphea plaques as assessed by computerized image analysis on 20 MHz B-scan recordings. Acta Derm Venereol 1995; 75:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/63\">",
"      Cosnes A, Anglade MC, Revuz J, Radier C. Thirteen-megahertz ultrasound probe: its role in diagnosing localized scleroderma. Br J Dermatol 2003; 148:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/64\">",
"      Li SC, Liebling MS, Haines KA, et al. Initial evaluation of an ultrasound measure for assessing the activity of skin lesions in juvenile localized scleroderma. Arthritis Care Res (Hoboken) 2011; 63:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/65\">",
"      Wortsman X, Wortsman J, Sazunic I, Carre&ntilde;o L. Activity assessment in morphea using color Doppler ultrasound. J Am Acad Dermatol 2011; 65:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/66\">",
"      Zulian F, Meneghesso D, Grisan E, et al. A new computerized method for the assessment of skin lesions in localized scleroderma. Rheumatology (Oxford) 2007; 46:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/67\">",
"      Weibel L, Howell KJ, Visentin MT, et al. Laser Doppler flowmetry for assessing localized scleroderma in children. Arthritis Rheum 2007; 56:3489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/68\">",
"      Ramboer K, Demaerel P, Baert AL, et al. Linear scleroderma with orbital involvement: follow up and magnetic resonance imaging. Br J Ophthalmol 1997; 81:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/69\">",
"      Nijhawan RI, Bard S, Blyumin M, et al. Early localized morphea mimicking an acquired port-wine stain. J Am Acad Dermatol 2011; 64:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/70\">",
"      Cunningham BB, Landells ID, Langman C, et al. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol 1998; 39:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/71\">",
"      Kreuter A, Gambichler T, Breuckmann F, et al. Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Arch Dermatol 2005; 141:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/72\">",
"      Fitch PG, Rettig P, Burnham JM, et al. Treatment of pediatric localized scleroderma with methotrexate. J Rheumatol 2006; 33:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/73\">",
"      Uziel Y, Feldman BM, Krafchik BR, et al. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 2000; 136:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/74\">",
"      Zulian F, Martini G, Vallongo C, et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2011; 63:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/75\">",
"      Zulian F, Vallongo C, Patrizi A, et al. A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea). J Am Acad Dermatol 2012; 67:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/76\">",
"      Torok KS, Arkachaisri T. Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study. J Rheumatol 2012; 39:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/77\">",
"      Martini G, Ramanan AV, Falcini F, et al. Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology (Oxford) 2009; 48:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/78\">",
"      Hunzelmann N, Anders S, Fierlbeck G, et al. Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma. J Am Acad Dermatol 1997; 36:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/79\">",
"      Kerscher M, Volkenandt M, Gruss C, et al. Low-dose UVA phototherapy for treatment of localized scleroderma. J Am Acad Dermatol 1998; 38:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/80\">",
"      Camacho NR, S&aacute;nchez JE, Martin RF, et al. Medium-dose UVA1 phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells. J Am Acad Dermatol 2001; 45:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/81\">",
"      Kreuter A, Hyun J, St&uuml;cker M, et al. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 2006; 54:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/82\">",
"      De Rie MA, Bos JD. Photochemotherapy for systemic and localized scleroderma. J Am Acad Dermatol 2000; 43:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/83\">",
"      Kreuter A, Hyun J, Skrygan M, et al. Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma. Br J Dermatol 2006; 155:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/84\">",
"      Cribier B, Faradji T, Le Coz C, et al. Extracorporeal photochemotherapy in systemic sclerosis and severe morphea. Dermatology 1995; 191:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/85\">",
"      Grundmann-Kollmann M, Ochsendorf F, Zollner TM, et al. PUVA-cream photochemotherapy for the treatment of localized scleroderma. J Am Acad Dermatol 2000; 43:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/86\">",
"      Caca-Biljanovska NG, Vlckova-Laskoska MT, Dervendi DV, et al. Treatment of generalized morphea with oral 1,25-dihydroxyvitamin D3. Adv Exp Med Biol 1999; 455:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/87\">",
"      Hulshof MM, Bouwes Bavinck JN, Bergman W, et al. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol 2000; 43:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/88\">",
"      Sengezer M, Deveci M, Selmanpakoglu N. Repair of \"coup de sabre,\" a linear form of scleroderma. Ann Plast Surg 1996; 37:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/89\">",
"      Lapiere JC, Aasi S, Cook B, Montalvo A. Successful correction of depressed scars of the forehead secondary to trauma and morphea en coup de sabre by en bloc autologous dermal fat graft. Dermatol Surg 2000; 26:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/90\">",
"      Krafchik BR, Silverman ED, et al. Orthopedic manifestations of localized scleroderma in children. J Orthop Rheumatol 1994; 7:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40985/abstract/91\">",
"      Palmero ML, Uziel Y, Laxer RM, et al. En coup de sabre scleroderma and Parry-Romberg syndrome in adolescents: surgical options and patient-related outcomes. J Rheumatol 2010; 37:2174.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6399 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-C1AFB1FE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_1_40985=[""].join("\n");
var outline_f40_1_40985=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Circumscribed (plaque) morphea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Generalized morphea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Linear scleroderma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Linear scleroderma of the face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pansclerotic morphea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13148703\">",
"      Mixed scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Extracutaneous manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS AND EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Nonpharmacologic measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pharmacologic measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6399\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6399|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/56/21381\" title=\"picture 1\">",
"      Skin biopsy scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/25/28063\" title=\"picture 2\">",
"      Circumscribed morphea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/58/39855\" title=\"picture 3\">",
"      Stages of morphea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/21/13656\" title=\"picture 4\">",
"      Skin biopsy morphea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/40/26255\" title=\"picture 5A\">",
"      Generalized morphea - legs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/38/1632\" title=\"picture 5B\">",
"      Generalized morphea - trunk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/22/18797\" title=\"picture 6\">",
"      Linear scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/21/25938\" title=\"picture 7\">",
"      En coup de sabre - central forehead",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/52/2883\" title=\"picture 8\">",
"      En coup de sabre - alopecia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/26/12704\" title=\"picture 9\">",
"      En coup de sabre - two examples",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/52/42816\" title=\"picture 10\">",
"      En coup de sabre - face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/4/41038\" title=\"picture 11\">",
"      Guttate morphea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/38/27247\" title=\"picture 12\">",
"      Keloid morphea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/27/38334\" title=\"picture 13\">",
"      Extensor nodules in scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/33/42526\" title=\"picture 14\">",
"      Juvenile contractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/37/7762\" title=\"picture 15\">",
"      Lichen sclerosis et atrophicus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/6/20582\" title=\"picture 16\">",
"      Skin biopsy lichen sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/30/17903\" title=\"picture 17\">",
"      Skin changes post transplant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/37/27230\" title=\"picture 18\">",
"      Skin in eosinophilic fasciitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6399|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/48/34572\" title=\"table 1\">",
"      Classification of juvenile localized scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/14/22764\" title=\"table 2\">",
"      Management of localized scleroderma in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/10/8360?source=related_link\">",
"      Eosinophilic fasciitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39433?source=related_link\">",
"      Juvenile systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/63/19450?source=related_link\">",
"      Pathogenesis of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_1_40986="Treatment of community-acquired pneumonia in adults who require hospitalization";
var content_f40_1_40986=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of community-acquired pneumonia in adults who require hospitalization",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/1/40986/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/1/40986/contributors\">",
"     Thomas M File, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/1/40986/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/1/40986/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/1/40986/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/1/40986/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/1/40986/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community-acquired pneumonia (CAP) is defined as an acute infection of the pulmonary parenchyma in a patient who has acquired the infection in the community, as distinguished from hospital-acquired (nosocomial) pneumonia (HAP). A third category of pneumonia, designated healthcare-associated pneumonia (HCAP), is acquired in other healthcare facilities, such as nursing homes, dialysis centers, and outpatient clinics.",
"   </p>",
"   <p>",
"    CAP is a common and potentially serious illness. It is associated with considerable morbidity and mortality, particularly in elderly patients and those with significant comorbidities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1801?source=see_link\">",
"     \"Prognosis of community-acquired pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of CAP in adults who require hospitalization will be reviewed here. A variety of other important issues related to CAP are discussed separately. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnostic approach to patients with CAP. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=see_link\">",
"       \"Diagnostic approach to community-acquired pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      How one makes the decision to admit patients with CAP to the hospital. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38473?source=see_link\">",
"       \"Community-acquired pneumonia in adults: Risk stratification and the decision to admit\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment recommendations for CAP in patients treated in the outpatient setting. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24969?source=see_link\">",
"       \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The evidence for efficacy of different antibiotic medications in the empiric treatment of CAP and issues related to drug resistance. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29210?source=see_link\">",
"       \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The epidemiology and microbiology of CAP. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31514?source=see_link\">",
"       \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pneumonia in special populations, such as aspiration pneumonia, immunocompromised patients, and HAP, ventilator-associated pneumonia (VAP), and HCAP. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=see_link\">",
"       \"Aspiration pneumonia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21273?source=see_link\">",
"       \"Pulmonary infections in immunocompromised patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36858?source=see_link\">",
"       \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR HOSPITALIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determination of whether a patient with community-acquired pneumonia (CAP) can be treated safely as an outpatient or requires hospitalization is essential before selecting an antibiotic regimen. Severity of illness is the most critical factor in making this determination, but other factors should also be taken into account. These include ability to maintain oral intake, likelihood of compliance, history of substance abuse, cognitive impairment, living situation, and patient functional status. These issues with appropriate references are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38473?source=see_link\">",
"     \"Community-acquired pneumonia in adults: Risk stratification and the decision to admit\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, prediction rules have been developed to assist in the decision of site of care for CAP. The two most commonly used prediction rules are the Pneumonia Severity Index (PSI) and CURB-65. The PSI is better studied and validated, but requires a more complicated assessment (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?43/42/44705?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    CURB-65 uses five prognostic variables:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       C",
"      </strong>",
"      onfusion (based upon a specific mental test or disorientation to person, place, or time)",
"     </li>",
"     <li>",
"      <strong>",
"       U",
"      </strong>",
"      rea (blood urea nitrogen in the United States) &gt;7",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"     <li>",
"      <strong>",
"       R",
"      </strong>",
"      espiratory rate &ge;30",
"      <span class=\"nowrap\">",
"       breaths/minute",
"      </span>",
"     </li>",
"     <li>",
"      <strong>",
"       B",
"      </strong>",
"      lood pressure (BP) (systolic &lt;90 mmHg or diastolic &le;60 mmHg)",
"     </li>",
"     <li>",
"      Age &ge;",
"      <strong>",
"       65",
"      </strong>",
"      years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors of the original CURB-65 report suggested that patients with a CURB-65 score of 0 to 1, who comprised 45 percent of the original cohort and 61 percent of the later cohort, were at low risk and could probably be treated as outpatients. Those with a score of 2 should be admitted to the hospital, and those with a score of 3 or more should be assessed for care in the intensive care unit (ICU), particularly if the score was 4 or 5 (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?40/62/41952?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A simplified version (CRB-65), which does not require testing for blood urea nitrogen, may be appropriate for decision-making in primary care practitioners' offices. With either version, admission to the hospital is recommended if one or more points are present.",
"   </p>",
"   <p>",
"    Other severity scoring systems have been developed that focus on severe CAP, such as SMART-COP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/3\">",
"     3",
"    </a>",
"    ] and the Severe CAP (SCAP) score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/4\">",
"     4",
"    </a>",
"    ]; there is less experience with these scoring systems compared to the other systems described above (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38473?source=see_link&amp;anchor=H15#H15\">",
"     \"Community-acquired pneumonia in adults: Risk stratification and the decision to admit\", section on 'Admission to intensive care'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38473?source=see_link&amp;anchor=H12#H12\">",
"     \"Community-acquired pneumonia in adults: Risk stratification and the decision to admit\", section on 'Severe community-acquired pneumonia score'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical judgment should be used for all patients, incorporating the prediction rule scores as a component of the decision for hospitalization or ICU admission, but not as an absolute determinant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/5\">",
"     5",
"    </a>",
"    ]. Limitations in the PSI scoring are the complexity of the system, and the failure to account for comorbidities and social factors, such as homelessness, for making site of care decisions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF ANTIMICROBIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community-acquired pneumonia (CAP) can be caused by a variety of pathogens, with bacteria being the most common identifiable cause (",
"    <a class=\"graphic graphic_table graphicRef63248 \" href=\"mobipreview.htm?39/50/40751\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef72014 \" href=\"mobipreview.htm?8/18/8495\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef54365 \" href=\"mobipreview.htm?38/29/39390\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2,9,10\">",
"     2,9,10",
"    </a>",
"    ]. The predominant pathogen is Streptococcus pneumoniae. Other common pathogens include Haemophilus influenzae, the atypical bacteria (Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella spp), oropharyngeal aerobes and anaerobes (in the setting of aspiration), and respiratory viruses. A randomized trial and a retrospective study have suggested that Staphylococcus aureus is increasing as a cause of CAP requiring admission to the hospital (some are due to community-associated methicillin-resistant S. aureus strains) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Gram-negative bacilli (Enterobacteriaceae and Pseudomonas aeruginosa) are the cause of CAP in some patients. The frequency of other causes, such as Mycobacterium tuberculosis, Chlamydophila psittaci (cause of psittacosis), C. burnetii (cause of Q fever), and endemic fungi vary in different epidemiologic settings.",
"   </p>",
"   <p>",
"    Studies utilizing molecular diagnostic methods have reported the rate of detection of a viral etiology in patients with CAP at approximately 30 percent; influenza has been identified in many of these patients (",
"    <a class=\"graphic graphic_table graphicRef63248 \" href=\"mobipreview.htm?39/50/40751\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef54365 \" href=\"mobipreview.htm?38/29/39390\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The rate of mixed viral-bacterial infection is approximately 20 percent; such mixed infections have been found to be associated with more severe CAP and longer hospitalization than CAP caused by bacteria alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31514?source=see_link&amp;anchor=H24#H24\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\", section on 'Viruses'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p>",
"    The choice of initial therapy is complicated by the emergence of antibiotic resistance among S. pneumoniae, the most common bacterium responsible for CAP as well as concern for MRSA in severe CAP. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31514?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\", section on 'Microbiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29210?source=see_link&amp;anchor=H16#H16\">",
"     \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\", section on 'Drug resistance and choice of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy is typically begun on an empiric basis, since the causative organism is not identified in an appreciable proportion of patients (",
"    <a class=\"graphic graphic_table graphicRef63248 \" href=\"mobipreview.htm?39/50/40751\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef72014 \" href=\"mobipreview.htm?8/18/8495\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. In addition, the clinical features and chest radiographic findings are not sufficiently specific to determine etiology and influence treatment decisions. The Gram stain of respiratory secretions can be useful for directing the choice of initial therapy if performed on a good quality sputum sample and interpreted by skilled examiners using appropriate criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\", section on 'Sputum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Benefit from a pathogen-directed approach to treatment, particularly for moderate to severe CAP, may emerge as rapid diagnostic tests become more widely available. However, there has been some concern that narrowing the coverage spectrum of antibiotics when a specific pathogen is identified may undertreat patients who have concurrent infection with atypical organisms.",
"   </p>",
"   <p>",
"    This concern was not borne out in a prospective randomized trial comparing pathogen-directed treatment (PDT) and empiric broad-spectrum antibiotic treatment (EAT) in 262 hospitalized patients with CAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/17\">",
"     17",
"    </a>",
"    ]. PDT was based upon microbiologic studies (rapid diagnostic tests) or clinical presentation; EAT patients received a",
"    <span class=\"nowrap\">",
"     beta-lactam/beta-lactamase",
"    </span>",
"    inhibitor plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    or, if admitted to the intensive care unit (ICU),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    and erythromycin. Overall, clinical outcomes (length of stay, 30 day mortality, fever resolution, and clinical failure) were the same for both groups. Adverse events were more frequent in the EAT group, but were primarily related to the specific antimicrobial choice (ie, erythromycin).",
"   </p>",
"   <p>",
"    Despite the general use of empiric therapy, testing for a microbial diagnosis is important in clinical or epidemiologic settings suggesting possible infection with an organism that requires treatment different from standard empiric regimens. These include Legionella species, influenza A and B or avian influenza, community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA), or agents of bioterrorism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=see_link\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17591?source=see_link&amp;anchor=H6#H6\">",
"     \"Sputum cultures for the evaluation of bacterial pneumonia\", section on 'Community-acquired pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The selection of antimicrobial regimens for empiric therapy is based upon a number of factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most likely pathogen(s). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Common pathogens'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Clinical trials proving efficacy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29210?source=see_link\">",
"       \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Risk factors for antimicrobial resistance. The choice of empiric therapy must take into account the emergence of antibiotic resistance among S. pneumoniae, the most common cause of CAP in adults who require hospitalization. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors for drug resistance'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Medical comorbidities, which may influence the likelihood of a specific pathogen and may be a risk factor for treatment failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional factors that may affect the choice of antimicrobial regimen include the potential for inducing antimicrobial resistance, pharmacokinetic and pharmacodynamic properties, safety profile, and cost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness of empiric antimicrobial regimens may be decreased by the emergence of newly recognized pathogens, such as CA-MRSA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\", section on 'Community-associated methicillin-resistant Staphylococcus aureus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Common pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a variety of bacterial pathogens can cause CAP, a limited number are responsible for the majority of cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31514?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With respect to patients who require hospitalization but not admission to an ICU, the most frequently isolated pathogens are S. pneumoniae, respiratory viruses (eg, influenza, parainfluenza, respiratory syncytial virus), and, less often, M. pneumoniae, H. influenzae, C. pneumoniae, and Legionella (",
"    <a class=\"graphic graphic_table graphicRef72014 \" href=\"mobipreview.htm?8/18/8495\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The distribution is different in patients with CAP who require admission to an ICU. S. pneumoniae is most common but Legionella, gram-negative bacilli, Staphylococcus aureus, and influenza are also important (",
"    <a class=\"graphic graphic_table graphicRef72014 \" href=\"mobipreview.htm?8/18/8495\">",
"     table 2",
"    </a>",
"    ). Community-associated MRSA typically produces a necrotizing pneumonia with high morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31514?source=see_link&amp;anchor=H18#H18\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\", section on 'S. aureus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for CAP due to gram-negative bacilli include previous antibiotic therapy, immunosuppression, pulmonary comorbidity (eg, cystic fibrosis, bronchiectasis, or repeated exacerbations of chronic obstructive pulmonary disease that require frequent glucocorticoid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antibiotic use), probable aspiration, and multiple medical comorbidities (eg, diabetes mellitus, alcoholism) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2,18,19\">",
"     2,18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31514?source=see_link&amp;anchor=H17#H17\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\", section on 'Gram-negative bacilli'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2007 Infectious Diseases Society of",
"    <span class=\"nowrap\">",
"     America/American",
"    </span>",
"    Thoracic Society",
"    <span class=\"nowrap\">",
"     (IDSA/ATS)",
"    </span>",
"    guidelines on the management of CAP recommend empiric antibiotic therapy directed against P. aeruginosa in patients with gram-negative bacilli on Gram stain, since such a regimen will also cover other gram-negative bacilli, such as Klebsiella pneumoniae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31494?source=see_link\">",
"     \"Pseudomonas aeruginosa pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38426?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection\", section on 'Community-acquired pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Risk factors for drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for and other issues related to drug resistance in patients with CAP are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29210?source=see_link&amp;anchor=H16#H16\">",
"     \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\", section on 'Drug resistance and choice of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, risk factors for drug-resistant S. pneumoniae in adults include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;65 years",
"     </li>",
"     <li>",
"      Beta-lactam, macrolide, or fluoroquinolone therapy within the past three to six months",
"     </li>",
"     <li>",
"      Alcoholism",
"     </li>",
"     <li>",
"      Medical comorbidities",
"     </li>",
"     <li>",
"      Immunosuppressive illness or therapy",
"     </li>",
"     <li>",
"      Exposure to a child in a day care center",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recent therapy or a repeated course of therapy with beta-lactams, macrolides, or fluoroquinolones are risk factors for pneumococcal resistance to the same class of antibiotic.",
"   </p>",
"   <p>",
"    The impact of discordant drug therapy, which refers to treatment of an infection with an antimicrobial agent to which the causative organism has demonstrated in vitro resistance, appears to vary with antibiotic class and possibly with specific agents within a class. Most studies have been performed in patients with S. pneumoniae infection and suggest that current levels of beta-lactam resistance generally do not cause treatment failure when appropriate agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ) and doses are used.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"     Cefuroxime",
"    </a>",
"    is a possible exception with beta-lactams and there appears to be an increased risk of macrolide failure in patients with macrolide-resistant S. pneumoniae. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29210?source=see_link&amp;anchor=H18#H18\">",
"     \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\", section on 'Outcomes with discordant drug therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of medical societies have issued guidelines for the treatment of community-acquired pneumonia (CAP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2,20,21\">",
"     2,20,21",
"    </a>",
"    ]. The antibiotic regimens advocated by a collaboration between the Infectious Diseases Society of",
"    <span class=\"nowrap\">",
"     America/American",
"    </span>",
"    Thoracic Society",
"    <span class=\"nowrap\">",
"     (IDSA/ATS)",
"    </span>",
"    in 2007 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2\">",
"     2",
"    </a>",
"    ] and the British Thoracic Society (BTS) in 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/20\">",
"     20",
"    </a>",
"    ] are summarized in Tables 3 and 4, respectively (",
"    <a class=\"graphic graphic_table graphicRef71665 \" href=\"mobipreview.htm?42/46/43757\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74382 \" href=\"mobipreview.htm?13/43/14013\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The following discussion will review antibiotic therapy in patients with CAP who require hospitalization. Guideline recommendations for therapy in patients with CAP treated in the outpatient setting are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24969?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For hospitalized patients on the general wards, the",
"      <span class=\"nowrap\">",
"       IDSA/ATS",
"      </span>",
"      guidelines recommend an antipneumococcal fluoroquinolone (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      ) or the combination of a beta-lactam plus a macrolide (",
"      <a class=\"graphic graphic_table graphicRef71665 \" href=\"mobipreview.htm?42/46/43757\">",
"       table 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For patients with severe CAP requiring intensive care unit (ICU) admission, the",
"      <span class=\"nowrap\">",
"       IDSA/ATS",
"      </span>",
"      guidelines recommend a beta-lactam (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"       ampicillin-sulbactam",
"      </a>",
"      ) plus either intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      or an antipneumococcal fluoroquinolone unless there is concern for Pseudomonas or methicillin-resistant Staphylococcus aureus (MRSA) infection. If Pseudomonas is a concern, an antipseudomonal agent (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"       piperacillin-tazobactam",
"      </a>",
"      , imipenem,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      ) PLUS an antipseudomonal fluoroquinolone (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      or high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      ) should be used. If MRSA is a concern, either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      should be added (",
"      <a class=\"graphic graphic_table graphicRef71665 \" href=\"mobipreview.htm?42/46/43757\">",
"       table 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Admitted to an ICU'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The BTS guidelines tend to select older antibiotics than those recommended in North America (",
"      <a class=\"graphic graphic_table graphicRef74382 \" href=\"mobipreview.htm?13/43/14013\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In studies from different regions of the world, atypical pathogens account for 20 to 30 percent of cases of CAP in hospitalized patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/22\">",
"     22",
"    </a>",
"    ]. However, the value of providing empiric coverage for atypical pathogens (eg, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila) is unclear. One reason for this is that testing for M. pneumoniae and C. pneumoniae is not usually done, and until 2012, there were no United States Food and Drug Administration (FDA)-cleared tests to detect them. Thus, their role in an individual case or in population-based studies is not well elucidated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=see_link&amp;anchor=H19#H19\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\", section on 'Chlamydophila (Chlamydia) pneumoniae'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=see_link&amp;anchor=H20#H20\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\", section on 'Mycoplasma pneumoniae'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The issue of coverage of atypical bacteria was addressed in a meta-analysis of 24 randomized trials of over 5000 patients with CAP requiring hospitalization; most trials compared fluoroquinolone monotherapy to non-atypical monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/23\">",
"     23",
"    </a>",
"    ]. There was no significant difference in mortality (RR 1.13, 95% CI 0.82-1.54) or adverse effects between the atypical arm and non-atypical arm. There was a nonsignificant trend toward clinical success when treatment covered atypical bacteria, a difference that disappeared when only methodologically high quality trials were evaluated. Clinical success was significantly higher in the atypical arm for Legionella pneumophila. The trials were not designed to compare the time to response with different regimens.",
"   </p>",
"   <p>",
"    An international observational study of over 4300 hospitalized patients with CAP published after the meta-analysis found that antimicrobial regimens with atypical coverage, compared to regimens that did not have atypical coverage, were associated with significant reductions in time to clinical stability (3.2 versus 3.7 days), length of stay in hospital (6.1 versus 7.1 days), and CAP-related mortality (3.8 versus 6.4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A well-designed prospective trial is required to more definitively determine the need to cover atypical pathogens in empiric regimens for CAP requiring hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic recommendations for hospitalized patients with community-acquired pneumonia (CAP) are divided by the site of care (intensive care unit [ICU] or non-ICU). Most hospitalized patients are initially treated with an intravenous regimen. However, many patients without risk factors for severe pneumonia can be treated with oral therapy, especially with highly bioavailable agents such as the fluoroquinolones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hospitalized patients with CAP are initially treated with empiric antibiotic therapy. When the etiology of CAP has been identified based upon reliable microbiologic methods, and there is no laboratory or epidemiologic evidence of coinfection, treatment regimens may be simplified and directed to that pathogen. The results of diagnostic studies that provide identification of a specific etiology within 24 to 72 hours can be useful for guiding continued therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=see_link\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pathogen-specific therapy is discussed separately (",
"    <a class=\"graphic graphic_table graphicRef64816 \" href=\"mobipreview.htm?19/63/20478\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/4/13386?source=see_link\">",
"     \"Pneumococcal pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/5/3162?source=see_link\">",
"     \"Mycoplasma pneumoniae infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/6/7270?source=see_link\">",
"     \"Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33015?source=see_link\">",
"     \"Treatment and prevention of Legionella infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31494?source=see_link\">",
"     \"Pseudomonas aeruginosa pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38426?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pneumonia in patients admitted to the hospital from long-term care facilities is not considered community-acquired. It is categorized as healthcare-associated pneumonia (HCAP), and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/57/12183?source=see_link\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/34/26152?source=see_link\">",
"     \"Important sites and pathogens causing infections in long-term care facilities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Not in the ICU",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients admitted to a general ward, we suggest one of the following regimens (",
"    <a class=\"graphic graphic_table graphicRef71665 \" href=\"mobipreview.htm?42/46/43757\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combination therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (1 to 2 g IV daily),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      (1 to 2 g IV every eight hours),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/33/4628?source=see_link\">",
"       ceftaroline",
"      </a>",
"      (600 mg IV every 12 hours),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/36/41542?source=see_link\">",
"       ertapenem",
"      </a>",
"      (1 g IV daily), or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"       ampicillin-sulbactam",
"      </a>",
"      (1.5 to 3 g IV every six hours)",
"      <strong>",
"       plus",
"      </strong>",
"      a macrolide (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      [500 mg IV or orally daily] or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      XL [two 500 mg tablets once daily]).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      (100 mg orally or IV twice daily) may be used as an alternative to a macrolide. Oral therapy with a macrolide or doxycycline is appropriate only for selected patients without evidence of or risk factors for severe pneumonia.",
"     </li>",
"     <li>",
"      Monotherapy with a respiratory fluoroquinolone given either IV or orally except as noted (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      750 mg daily or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      400 mg daily).",
"     </li>",
"     <li>",
"      Monotherapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/7/40053?source=see_link\">",
"       tigecycline",
"      </a>",
"      should be limited to patients intolerant of beta-lactams and fluoroquinolones since it has been associated with increased mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H89730288\">",
"       'Other agents'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the patient has risk factors for drug-resistant pathogens, such as Pseudomonas or MRSA, coverage for these organisms should be included, as discussed in the following section. Patients with necrotizing or cavitary infiltrates or empyema should also be treated empirically for MRSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both the macrolides and the fluoroquinolones can cause a prolonged QT interval, which can result in torsades de pointes.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    have been associated with a small absolute increase in cardiovascular mortality (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/30/1514?source=see_link&amp;anchor=H22#H22\">",
"     \"Azithromycin, clarithromycin, and telithromycin\", section on 'Long QT syndrome'",
"    </a>",
"    ). For patients with known QT interval prolongation or risk factors for QT interval prolongation, we favor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    since it has not been associated with QT interval prolongation. However, doxycycline should be avoided during pregnancy. It should also be noted that doxycycline has been less well studied for the treatment of CAP than the macrolides and fluoroquinolones. Risk factors for QT interval prolongation include advanced age, hypokalemia, hypomagnesemia, clinically significant bradycardia, and the use of other agents that prolong the QT interval, including class IA (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ) and class III (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ) antiarrhythmic agents and certain azoles (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28618?source=see_link&amp;anchor=H30#H30\">",
"     \"Fluoroquinolones\", section on 'QT interval prolongation and arrhythmia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/30/1514?source=see_link&amp;anchor=H22#H22\">",
"     \"Azithromycin, clarithromycin, and telithromycin\", section on 'Long QT syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=see_link&amp;anchor=H34#H34\">",
"     \"Pharmacology of azoles\", section on 'Selected clinical effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When aspiration pneumonia is suspected, it is important to cover oral anaerobes. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=see_link&amp;anchor=H14#H14\">",
"     \"Aspiration pneumonia in adults\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Admitted to an ICU",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients requiring admission to an ICU are more likely to have risk factors for resistant pathogens, including community-associated MRSA and Legionella spp.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients without risk factors for or microbiologic evidence of Pseudomonas aeruginosa or MRSA, we recommend intravenous combination therapy with a potent anti-pneumococcal beta-lactam (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      1 to 2 g daily,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      1 to 2 g every eight hours, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"       ampicillin-sulbactam",
"      </a>",
"      1.5 to 3 g every six hours)",
"      <strong>",
"       plus",
"      </strong>",
"      either an advanced macrolide (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      500 mg daily) or a respiratory fluoroquinolone (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      750 mg daily or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      400 mg daily) (",
"      <a class=\"graphic graphic_table graphicRef71665 \" href=\"mobipreview.htm?42/46/43757\">",
"       table 3",
"      </a>",
"      ). Although the optimal doses of the beta-lactams (ceftriaxone, cefotaxime, ampicillin-sulbactam) have not been studied adequately, we favor the higher doses, at least initially, until the minimum inhibitory concentrations against possible isolates (eg, Streptococcus pneumoniae) are known.",
"     </li>",
"     <li>",
"      In patients (particularly those with bronchiectasis or COPD and frequent antimicrobial or glucocorticoid use) who may be infected with Pseudomonas aeruginosa or other resistant pathogens, therapy should include agents effective against the pneumococcus, P. aeruginosa, and Legionella spp. Acceptable regimens include combination therapy with a beta-lactam antibiotic and a fluoroquinolone, such as the following regimens:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"       Piperacillin-tazobactam",
"      </a>",
"      (4.5 g every six hours) OR",
"     </li>",
"     <li>",
"      Imipenem (500 mg IV every six hours) OR",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       Meropenem",
"      </a>",
"      (1 g every eight hours) OR",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"       Cefepime",
"      </a>",
"      (2 g every eight hours) OR",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       Ceftazidime",
"      </a>",
"      (2 g every eight hours)",
"      <br/>",
"      <br/>",
"      <strong>",
"       PLUS",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      (400 mg every eight hours) OR",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       Levofloxacin",
"      </a>",
"      (750 mg daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For penicillin-allergic patients, the type and severity of reaction should be assessed. The great majority of patients who are allergic to penicillin by skin testing can still receive cephalosporins (especially third-generation cephalosporins) or carbapenems. If there is a history of a mild reaction to penicillin (",
"      <strong>",
"       not",
"      </strong>",
"      an IgE-mediated reaction, Stevens Johnson syndrome or toxic epidermal necrolysis), it is reasonable to administer a cephalosporin or carbapenem using a simple graded challenge (eg, give",
"      <span class=\"nowrap\">",
"       1/10",
"      </span>",
"      of dose, observe closely for one hour, then give remaining",
"      <span class=\"nowrap\">",
"       9/10",
"      </span>",
"      of dose, observe closely for one hour). Skin testing is indicated in some situations. For penicillin-allergic patients, if a skin test is positive or if there is significant concern to warrant avoidance of a cephalosporin or carbapenem, options include:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      (2 g IV every six to eight hours) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      (750 mg daily); or aztreonam plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      plus an aminoglycoside. Indications and strategies for skin testing are reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15672?source=see_link\">",
"       \"Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with past allergic reactions to cephalosporins may be treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      (2 g IV every six to eight hours), with the possible exception of those allergic to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      . Ceftazidime and aztreonam have similar side chain groups, and cross reactivity between the two drugs is variable. The prevalence of cross-sensitivity has been estimated at &lt;5 percent of patients, based upon limited data. Patients with past reactions to ceftazidime that were life-threatening or suggestive of anaphylaxis (involving urticaria, bronchospasm,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypotension) should not be given aztreonam unless evaluated by an allergy specialist. In contrast, a reasonable approach in those with mild past reactions to ceftazidime (eg, uncomplicated maculopapular rash) would involve informing the patient of the low risk of cross-reactivity and administering aztreonam with a graded challenge",
"      <span class=\"nowrap\">",
"       (1/100,",
"      </span>",
"      <span class=\"nowrap\">",
"       1/10,",
"      </span>",
"      full dose, each separated by one hour of observation). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5400?source=see_link&amp;anchor=H209441#H209441\">",
"       \"Cephalosporin-allergic patients: Subsequent use of cephalosporins and related antibiotics\", section on 'Use of carbapenems and monobactams'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The fluoroquinolones may be administered orally when the patient is able to take oral medications. The dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    is the same when given intravenously and orally, while the dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    is 750 mg orally twice daily.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Empiric therapy for CA-MRSA should be given to hospitalized patients with severe CAP, as defined by any of the following: admission to the ICU, necrotizing or cavitary infiltrates, or empyema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/27\">",
"       27",
"      </a>",
"      ]. We also suggest empiric therapy of MRSA in patients with severe CAP who have risk factors for community-acquired (CA)-MRSA (recent antimicrobial therapy or recent influenza-like illness). In such patients, we recommend treatment for MRSA with the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours, adjusted to a trough level of 15 to 20",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      and for renal function) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      (600 mg IV every 12 hours) until the results of culture and susceptibility testing are known.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      (600 mg IV or orally three times daily) may be used as an alternative to vancomycin or linezolid if the isolate is known to be susceptible.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/33/4628?source=see_link\">",
"       Ceftaroline",
"      </a>",
"      is active against most strains of MRSA, but is not FDA-approved for pneumonia caused by S. aureus. Linezolid may be given orally when the patient is able to receive oral medications. If MRSA is not isolated, coverage for this organism should be discontinued.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     CA-MRSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, strong consideration should be given for empiric treatment for CA-MRSA with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    in hospitalized patients with severe CAP. Although data regarding the therapy of pneumonia caused by CA-MRSA are limited, a randomized trial showed superiority in clinical outcomes, but not mortality, of linezolid compared with vancomycin in nosocomial pneumonia caused by MRSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/28\">",
"     28",
"    </a>",
"    ]. The treatment of MRSA pneumonia is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36858?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Methicillin-resistant Staphylococcus aureus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although community-acquired MRSA (CA-MRSA) is typically susceptible to more antibiotics than hospital-acquired MRSA, it appears to be more virulent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/29\">",
"     29",
"    </a>",
"    ]. CA-MRSA often causes a necrotizing pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The strain causing CA-MRSA is known as &ldquo;USA 300&rdquo; and the gene for Panton Valentine Leukocidin (PVL) characterizes this strain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. However, an animal study suggests that the virulence of CA-MRSA strains is probably not due to PVL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/37\">",
"     37",
"    </a>",
"    ]. In addition, one study of patients with hospital-acquired pneumonia due to MRSA observed that the severity of infection and clinical outcome was not influenced by the presence of the PVL gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/38\">",
"     38",
"    </a>",
"    ]. It is possible that other cytolytic toxins play a role in the pathogenesis of CA-MRSA infections.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    does not decrease toxin production, whereas",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    has been shown to reduce toxin production in experimental models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40758?source=see_link\">",
"     \"Virulence determinants of community acquired methicillin-resistant Staphylococcus aureus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One concern with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    is the increasing MICs of MRSA that have emerged in recent years, which may reduce the efficacy of vancomycin in pulmonary infection. In patients with a MRSA isolate with an increased vancomycin MIC (&ge;1",
"    <span class=\"nowrap\">",
"     mcg/mL),",
"    </span>",
"    we prefer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    . Vancomycin-intermediate and vancomycin-resistant S. aureus infection is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/2/16425?source=see_link\">",
"     \"Vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    is used, trough concentrations should be monitored in order to ensure that a target trough concentration between 15 and 20",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    is achieved. There may be important differences in potency and toxicity based on the supply source of generic formulations of vancomycin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/47/15096?source=see_link\">",
"     \"Vancomycin dosing and serum concentration monitoring in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CA-MRSA as the cause of CAP should be suspected when pneumonia develops in a person known to be colonized with CA-MRSA or in those with risk factors for CA-MRSA colonization (eg, contact sport participants, injection drug users, those living in crowded conditions, men who have sex with men, prisoners). CA-MRSA pneumonia should also be suspected in young, previously healthy adults with a recent influenza-like illness or if the course is fulminant, imaging shows pulmonary necrosis or empyema",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the sputum Gram stain shows gram-positive cocci in clusters.",
"   </p>",
"   <p>",
"    Factors associated with rapid mortality include infection with influenza, the need for ventilator or inotropic support, onset of respiratory distress syndrome, hemoptysis, and leukopenia. In a report of 51 cases of CAP caused by Staphylococcus aureus (79 percent of which were MRSA), 39 percent had a WBC count",
"    <span class=\"nowrap\">",
"     &lt;4000/microL,",
"    </span>",
"    and this finding was associated with a poor prognosis. In contrast, a WBC",
"    <span class=\"nowrap\">",
"     &gt;10,000/microL",
"    </span>",
"    appeared to be protective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a sputum culture reveals methicillin-susceptible Staphylococcus aureus (MSSA), therapy should be changed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    (2 g IV every four hours) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    (2 g IV every four hours) (",
"    <a class=\"graphic graphic_table graphicRef64816 \" href=\"mobipreview.htm?19/63/20478\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Fluoroquinolone monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of monotherapy with a respiratory fluoroquinolone has not been established for severe CAP. In an observational study of 270 patients with CAP and shock, the 58 percent treated with combination antibiotic therapy (with a third-generation cephalosporin and a macrolide) had a significantly higher 28-day in-ICU survival than the 42 percent who received fluoroquinolone monotherapy (HR 1.69, 95% CI 1.09-2.60) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/43\">",
"     43",
"    </a>",
"    ]. Survival was not different comparing combination and monotherapy in ICU patients without shock. If the patient has pneumococcal meningitis, monotherapy with a fluoroquinolone is not recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15306?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of bacterial meningitis caused by specific pathogens in adults\", section on 'Streptococcus pneumoniae'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Macrolide-containing regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have suggested that combination regimens containing a macrolide plus a beta-lactam may result in better clinical outcomes in patients with severe CAP, especially bacteremic pneumococcal pneumonia; this is likely due to the immunomodulatory effects of macrolides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. Randomized controlled trials should ideally be performed to clarify this issue, but this will be logistically difficult to do.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1600933\">",
"    <span class=\"h3\">",
"     Influenza therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral treatment is recommended as soon as possible for all persons with suspected or confirmed influenza requiring hospitalization or who have progressive, severe, or complicated illness, regardless of previous health or vaccination status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89730288\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other antibiotics that have been studied and approved by the FDA for the treatment of CAP include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/33/4628?source=see_link\">",
"     ceftaroline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Studies of these and other agents are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29210?source=see_link\">",
"     \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/7/40053?source=see_link\">",
"     Tigecycline",
"    </a>",
"    is associated with increased mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Thus, we generally do not recommend tigecycline for the treatment of CAP, except in patients who cannot take either a fluoroquinolone or a beta-lactam. We only use tigecycline in patients who do not have severe CAP (non-ICU patients) and whose pneumonia is not caused by MRSA. The association between tigecycline and mortality is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29210?source=see_link&amp;anchor=H14#H14\">",
"     \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\", section on 'Tigecycline versus other drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Timing of antimicrobial initiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that antimicrobials be administered as soon as possible after diagnosing CAP and before leaving the emergency department or clinic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2\">",
"     2",
"    </a>",
"    ]. The benefit of prompt initiation of antimicrobial therapy has been evaluated, with more recent findings questioning if this is an independent risk factor for outcome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of 13,771 Medicare patients, antibiotic administration within four hours of hospital arrival was associated with reductions in mortality (6.8 compared to 7.4 percent with delay in antibiotics) and length of stay (0.4 days shorter) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective study of 603 patients with CAP at a single academic center found no difference in the time to clinical stability between those who received antibiotics within four hours and those whose treatment was later [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The time to first antibiotic dose was not independently associated with mortality in an observational study of 451 CAP patients from another tertiary center [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/53\">",
"       53",
"      </a>",
"      ]. Delay in antibiotics was more common in patients with an altered mental status or signs of sepsis. Time to first antibiotic dose was possibly a marker of comorbidities driving both an atypical presentation and mortality rather than directly contributing to the outcome. Diagnostic uncertainty led to delay of initial antimicrobial therapy in another study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective study of 548 patients found that when the required time to first antibiotic dose changed from eight hours to four hours, a reduction in the accuracy of the initial diagnosis of CAP occurred, although the mean time to first antibiotic dose was similar in both groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The United States National Pneumonia Medicare Quality Improvement Project and the National Quality Forum formerly recommended the target for initial administration of antimicrobial therapy to be four hours after arrival at the hospital; this was later changed to six hours, and in 2012 it was retired as a quality measure altogether [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Performance measures'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;With appropriate antibiotic therapy, some improvement in the patient's clinical course is usually seen within 48 to 72 hours (",
"    <a class=\"graphic graphic_table graphicRef74599 \" href=\"mobipreview.htm?3/31/3579\">",
"     table 6",
"    </a>",
"    ). Patients who do not demonstrate some clinical improvement within 72 hours are considered nonresponders. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'The nonresponding patient'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The time course of the clinical response to therapy is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective, multicenter cohort study of 686 adults hospitalized with CAP, the median time to becoming afebrile was two days when fever was defined as 38.3&ordm;C (101&ordm;F), and three days when defined as either 37.8&ordm;C (100&ordm;F) or 37.2&ordm;C (99&ordm;F) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/58\">",
"       58",
"      </a>",
"      ]. However, fever in patients with lobar pneumonia may take three days or longer to improve.",
"     </li>",
"     <li>",
"      In a second prospective, multicenter trial of 1424 patients hospitalized with CAP, the median time to stability (defined as resolution of fever, heart rate &lt;100",
"      <span class=\"nowrap\">",
"       beats/min,",
"      </span>",
"      respiratory rate &lt;24",
"      <span class=\"nowrap\">",
"       breaths/min,",
"      </span>",
"      systolic blood pressure of &ge;90 mmHg, and oxygen saturation &ge;90 percent for patients not receiving prior home oxygen) was four days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although a clinical response to appropriate antibiotic therapy is seen relatively quickly, the time to resolution of all symptoms and radiographic findings is more prolonged. With pneumococcal pneumonia, for example, the cough usually resolves within eight days and auscultatory crackles clear within three weeks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/4/13386?source=see_link\">",
"     \"Pneumococcal pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, as many as 87 percent of inpatients with CAP have persistence of at least one pneumonia-related symptom (eg, fatigue, cough with or without sputum production, dyspnea, chest pain) at 30 days compared to 65 percent by history in the month prior to the onset of CAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/60\">",
"     60",
"    </a>",
"    ]. Patients should be told that some symptoms can last this long so that they are able to set reasonable expectations for their clinical course. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1801?source=see_link&amp;anchor=H2#H2\">",
"     \"Prognosis of community-acquired pneumonia in adults\", section on 'Mortality and symptom resolution'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Radiographic response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic improvement typically lags behind the clinical response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. This issue was addressed in a prospective multicenter trial of 288 patients hospitalized for severe CAP; the patients were followed for 28 days in order to assess the timing of resolution of chest x-ray abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/61\">",
"     61",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At day 7, 56 percent had clinical improvement but only 25 had resolution of chest x-ray abnormalities.",
"     </li>",
"     <li>",
"      At day 28, 78 percent had attained clinical cure but only 53 percent had resolution of chest x-ray abnormalities. The clinical outcomes were not significantly different between patients with and without deterioration of chest x-ray findings during the follow-up period.",
"     </li>",
"     <li>",
"      Delayed radiographic resolution was independently associated with multilobar disease. In other studies, the timing of radiologic resolution of the pneumonia varied with patient age and the presence of underlying lung disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/62,63\">",
"       62,63",
"      </a>",
"      ]. The chest x-ray usually cleared within four weeks in patients younger than 50 years of age without underlying pulmonary disease. In contrast, resolution could be delayed for 12 weeks or more in older individuals and in those with underlying lung disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Switch to oral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients requiring hospitalization for CAP are generally begun on intravenous therapy. They can be switched to oral therapy when they are improving clinically, hemodynamically stable, able to take oral medications, and have a normally functioning gastrointestinal tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the pathogen has been identified, the choice of oral antibiotic therapy is based upon the susceptibility profile (",
"    <a class=\"graphic graphic_table graphicRef64816 \" href=\"mobipreview.htm?19/63/20478\">",
"     table 5",
"    </a>",
"    ). If a pathogen is not identified, the choice of antibiotic for oral therapy is usually either the same as the intravenous antibiotic, or in the same drug class. If neither S. aureus nor a resistant gram-negative bacillus has been isolated from a good quality sputum specimen, then empiric therapy for these organisms is not necessary. The choice of oral regimen depends on the risk of drug-resistant S. pneumoniae and on the initial IV regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who are treated with the combination of an intravenous beta-lactam and a macrolide who have risk factors for drug-resistant S. pneumoniae (DRSP), we use high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (1 g orally three times daily) to complete the course of therapy. When DRSP is not a concern, amoxicillin can be given at a dose of 500 mg orally three times daily or 875 mg orally twice daily. An alternative for patients without risk factors for DRSP is to give a macrolide alone to complete the course of therapy.(See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors for drug resistance'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24969?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment of community-acquired pneumonia in adults in the outpatient setting\", section on 'Treatment regimens'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who are treated initially with an IV respiratory fluoroquinolone can switch to the oral formulation of the same agent to complete the course of therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The duration of therapy is discussed below. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Duration of therapy'",
"    </a>",
"    below.)",
"    <br/>",
"    <br/>",
"    Two prospective observational studies in 253 patients evaluated the clinical outcome of an early switch from intravenous to oral therapy in the treatment of CAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Patients met the following criteria prior to switching: resolution of fever, improvement in respiratory function, decrease in white blood cell (WBC) count, and normal gastrointestinal tract absorption. Only two patients failed treatment and the protocol was associated with high patient satisfaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar outcomes were noted in a multicenter randomized trial in the Netherlands of 265 patients with CAP (mean age 70) admitted to non-intensive care wards [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/67\">",
"     67",
"    </a>",
"    ]. Patients were initially treated with three days of intravenous antibiotics and, when clinically stable, were assigned either to oral antibiotics to complete a total course of ten days, or to a standard regimen of seven days of intravenous antibiotics. There was no difference in 28 day mortality (4 versus 2 percent) or clinical cure rate (83 versus 85 percent), while the length of hospital stay was reduced in the oral switch group by a mean of 1.9 days (9.6 versus 11.5 days).",
"   </p>",
"   <p>",
"    In another randomized trial, a three-step pathway that involved early mobilization of patients in combination with the use of objective criteria for switching to an oral antibiotic regimen and for deciding on hospital discharge was compared to usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/68\">",
"     68",
"    </a>",
"    ]. The median length of stay was significantly shorter in the patients who were assigned to the three-step pathway (3.9 versus 6.0 days). In addition, the median duration of intravenous antibiotics was significantly shorter in the patients who were assigned to the three-step pathway (2.0 versus 4.0 days). More patients assigned to usual care experienced adverse drug reactions (4.5 versus 16 percent). No significant differences were observed in the rate of readmission, the case-fatality rate, or patients&rsquo; satisfaction with care.",
"   </p>",
"   <p>",
"    Documentation of pneumococcal bacteremia does not appear to alter the effect of switching to oral therapy early (no clinical failures in 18 such patients switched based upon the above criteria in one report) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Duration of hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have shown that it is not necessary to observe stable patients overnight after switching from intravenous to oral therapy, although this has been common practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2,70,71\">",
"     2,70,71",
"    </a>",
"    ]. As an example, a retrospective review of the United States Medicare National Pneumonia Project database compared outcomes between patients hospitalized for CAP who were not (n = 2536) and were (n = 2712) observed overnight after switching to oral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/71\">",
"     71",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No significant difference in 14-day hospital readmission rate (7.8 versus 7.2 percent)",
"     </li>",
"     <li>",
"      No significant difference in the 30-day mortality rate (5.1 versus 4.4 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of clinical stability at discharge was illustrated in a prospective observational study of 373 Israeli patients discharged with a diagnosis of CAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/72\">",
"     72",
"    </a>",
"    ]. On the last day of hospitalization, seven parameters of instability were evaluated (temperature &gt;37.8 &ordm;C [100 &ordm;F], respiratory rate &gt;24",
"    <span class=\"nowrap\">",
"     breaths/min,",
"    </span>",
"    heart rate (HR) &gt;100",
"    <span class=\"nowrap\">",
"     beats/min,",
"    </span>",
"    systolic BP &le;90 mmHg, oxygen saturation &lt;90 percent on room air, inability to receive oral nutrition, and change of mental status from baseline). At 60 days post discharge, patients with at least one parameter of instability at discharge were significantly more likely to have died or required readmission than patients with no parameters of instability (death rates, 14.6 versus 2.1 percent; readmission rates, 14.6 versus 6.5 percent).",
"   </p>",
"   <p>",
"    As noted above, in one trial, a three-step pathway that involved early mobilization of patients in combination with the use of objective criteria for switching to an oral antibiotic regimen and for deciding on hospital discharge was compared to usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/68\">",
"     68",
"    </a>",
"    ]. The median length of stay was significantly shorter in the patients who were assigned to the three-step pathway (3.9 versus 6.0 days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the available data, we agree with the recommendation of the",
"    <span class=\"nowrap\">",
"     IDSA/ATS",
"    </span>",
"    guidelines that patients with CAP should be treated for a minimum of five days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, the recommended duration for patients with good clinical response within the first two to three days of therapy is five to seven days total. Support for this recommendation comes from a meta-analysis of 15 randomized controlled trials of almost 2800 patients with mild to moderate CAP, which found comparable clinical outcomes with less than seven days compared to more than seven days of antimicrobial therapy; however, only two of these trials were specifically about hospitalized patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29210?source=see_link&amp;anchor=H25#H25\">",
"     \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\", section on 'Duration of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Before stopping therapy, the patient should be afebrile for 48 to 72 hours, breathing without supplemental oxygen (unless required for preexisting disease), and have no more than one clinical instability factor (defined as heart rate [HR] &gt;100",
"    <span class=\"nowrap\">",
"     beats/min,",
"    </span>",
"    respiratory rate [RR] &gt;24",
"    <span class=\"nowrap\">",
"     breaths/min,",
"    </span>",
"    and systolic blood pressure [SBP] &le;90 mmHg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A longer duration of therapy is needed in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the initial therapy was not active against the subsequently identified pathogen (see",
"      <a class=\"local\" href=\"#H22\">",
"       'The nonresponding patient'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      If extrapulmonary infection is identified (eg, meningitis or endocarditis).",
"     </li>",
"     <li>",
"      If the patient has pneumonia caused by P. aeruginosa, S. aureus, or Legionella spp, or pneumonia caused by some unusual and less common pathogens (eg, Burkholderia pseudomallei, fungus).",
"     </li>",
"     <li>",
"      If the patient has necrotizing pneumonia, empyema, or lung abscess [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The duration of therapy in these patients should be individualized based upon the clinical response to treatment and patient comorbidities. For the treatment of MRSA pneumonia, duration will vary, with a recommendation of 7 to 21 days depending upon the extent of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/27\">",
"     27",
"    </a>",
"    ]. In a study of VAP due to MRSA (although not likely due to the USA 300 strain that causes community-acquired MRSA pneumonia), eight days of therapy was as effective as 15 days of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/75\">",
"     75",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Patients are often treated with antibiotics for longer than necessary. Antimicrobial stewardship programs can help to shorten the duration of antibiotics and narrow the spectrum of antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H610314277\">",
"    <span class=\"h2\">",
"     Follow-up chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest x-ray findings usually clear more slowly than clinical manifestations (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Radiographic response'",
"    </a>",
"    above). Routine chest x-rays for follow-up of CAP patients who are responding clinically are unnecessary. In a large population-based cohort study of patients with CAP, new lung cancer was diagnosed within 90 days of CAP in 1.1 percent and within five years of the index CAP episode in 2.3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/77\">",
"     77",
"    </a>",
"    ]. On multivariate analysis, the characteristic most strongly associated with lung cancer was an age &gt;50 years (adjusted hazard ratio [HR] 19.0, 95% CI 5.7-63.6); other risk factors were male sex (adjusted HR 1.8, 95% CI 1.1-2.9) and smoking (adjusted HR 1.7, 95% CI 1.0-3.0). Since nearly 99 percent of patients will not have lung cancer after CAP, the authors suggested that routine follow-up chest x-ray is not warranted in patients &lt;50 years of age, except in patients who do not experience a resolution of pneumonia symptoms. This study also indicated that the greatest yield for the diagnosis of cancer would occur if routine follow-up chest x-rays were restricted to patients &gt;50 years of age.",
"    <br/>",
"    <br/>",
"    Among patients who have clinical resolution following treatment for CAP, we recommend restricting follow-up chest x-rays to patients &gt;50 years of age; follow-up chest x-ray is particularly important for males and smokers in this age group. When indicated, we suggest that follow-up chest x-rays be performed 7 to 12 weeks following treatment to document resolution of the pneumonia and exclude underlying diseases, such as malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     The nonresponding patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues relating to nonresolving pneumonia are discussed in detail separately. This section will be limited to a general overview of nonresponding pneumonia in patients with CAP who require hospitalization. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23945?source=see_link\">",
"     \"Nonresolving pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with CAP show clinical improvement within 72 hours of initial antibiotic treatment. It has been estimated that 6 to 15 percent of hospitalized patients with CAP do not respond within this time frame, and the failure rate may be as high as 40 percent in patients initially admitted to an ICU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2,79-81\">",
"     2,79-81",
"    </a>",
"    ]. These patients have significantly increased mortality compared to responders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2,80,81\">",
"     2,80,81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1801?source=see_link&amp;anchor=H10#H10\">",
"     \"Prognosis of community-acquired pneumonia in adults\", section on 'The nonresponding patient'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two general patterns of nonresponse have been described in patients with CAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2,79\">",
"     2,79",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progressive pneumonia or clinical deterioration, with requirement for ventilator support",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      septic shock usually occurring in the first 72 hours. Deterioration after 72 hours is often due to an intercurrent complication, progression of the underlying infection, or a superimposed nosocomial infection. Many patients who ultimately require ICU admission for CAP are initially admitted to a non-ICU ward and then transferred because of clinical deterioration (59 of 113 in one report, 50 in the first 24 hours) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Persistent or nonresponding pneumonia, defined as the absence of or delay in achieving clinical stability after 72 hours of antibiotic therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common causes of treatment failure are lack of or delayed response by the host despite appropriate antibiotics and infection with an organism that is not covered by the initial antibiotic regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2,79,83\">",
"     2,79,83",
"    </a>",
"    ]. Patient-related factors include severity of illness, neoplasia, aspiration pneumonia, and neurologic disease (",
"    <a class=\"graphic graphic_table graphicRef62007 \" href=\"mobipreview.htm?21/14/21739\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/83\">",
"     83",
"    </a>",
"    ], while lack of responsiveness to initial therapy may be due to drug-resistant organisms, unusual pathogens (eg, Legionella spp, viruses, fungi including Pneumocystis jirovecii [formerly P. carinii], or Mycobacterium tuberculosis), or an infectious complication, such as postobstructive pneumonia, empyema, abscess, or superimposed nosocomial pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2,79,84\">",
"     2,79,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a review of treatment failure in 49 hospitalized patients with CAP, a definite diagnosis was established in 32 and a probable diagnosis was made in 9 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/79\">",
"     79",
"    </a>",
"    ]. The major causes were infection with a pathogen not detected in the initial evaluation (atypical or unusual pathogens or pathogens associated with the development of empyema), persistent infection with the same pathogen, usually reflecting resistance to initial empiric therapy, and nosocomial infection with a new pathogen, most often associated with ventilator-associated pneumonia.",
"   </p>",
"   <p>",
"    In addition, treatment failure may be wrongly presumed when the infiltrates are responding slowly but the patient has developed a superimposed problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2,64,79,85\">",
"     2,64,79,85",
"    </a>",
"    ]. These include noninfectious entities, such as drug fever, malignancy, interstitial lung disease (eg, bronchiolitis obliterans organizing pneumonia), inflammatory conditions, or heart failure, or a hospital-acquired infection of another body system (eg, intravascular catheter infection, urinary tract infection due to an indwelling urinary catheter, or Clostridium difficile infection) (",
"    <a class=\"graphic graphic_table graphicRef62007 \" href=\"mobipreview.htm?21/14/21739\">",
"     table 7",
"    </a>",
"    ). Noninfectious causes were considered responsible for nine of the treatment failures in the above series of 49 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment failure may also be incorrectly diagnosed in patients who have repeat sputum cultures that grow a new pathogen. The upper airway of hospitalized patients receiving antibiotics may become colonized, particularly with gram-negative bacilli and S. aureus, and may be misinterpreted as contributing to the pneumonia. Thus, repeat sputum cultures should be interpreted with caution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have evaluated risk factors for nonresponse in hospitalized patients with CAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/80,81,86\">",
"     80,81,86",
"    </a>",
"    ]. The rate of treatment failure in different large series was 13 and 15 percent overall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/80,86\">",
"     80,86",
"    </a>",
"    ], with early treatment failure (lack of response or worsening at 48 to 72 hours) occurring in 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective multicenter study identified risk factors for treatment failure in CAP, which occurred in 15 percent of 1424 hospitalized patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/80\">",
"     80",
"    </a>",
"    ]. Independent risk factors were multilobar pneumonia, cavitation on chest x-ray, pleural effusion, liver disease, leukopenia, and a high Pneumonia Severity Index (PSI). Three factors were protective: influenza vaccination, chronic obstructive pulmonary disease, and treatment with a fluoroquinolone.",
"   </p>",
"   <p>",
"    A second observational analysis of 1383 hospitalized adults with CAP identified the following risk factors for early treatment failure (lack of response or worsening at 48 to 72 hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/81\">",
"     81",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Multilobar pneumonia",
"     </li>",
"     <li>",
"      Pneumonia caused by MRSA, Legionella, or gram-negative bacilli (Enterobacteriaceae or Pseudomonas aeruginosa)",
"     </li>",
"     <li>",
"      PSI &gt;90",
"     </li>",
"     <li>",
"      Treatment with an antimicrobial agent to which the causative organism was not susceptible",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Further evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When evaluating a patient who is not responding to therapy, the initial approach may include repeating the history (including travel and pet exposures to look for unusual pathogens), chest x-ray, and sputum and blood cultures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2,79\">",
"     2,79",
"    </a>",
"    ]. If this is unrevealing, then further diagnostic procedures, such as chest CT, bronchoscopy, and, lung biopsy can be performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23945?source=see_link&amp;anchor=H26#H26\">",
"     \"Nonresolving pneumonia\", section on 'Further evaluation of nonresolving pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chest CT can detect pleural effusion, lung abscess, or central airway obstruction, all of which can cause treatment failure. It may also detect noninfectious causes such as bronchiolitis obliterans organizing pneumonia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2\">",
"       2",
"      </a>",
"      ]. Since empyema and parapneumonic effusion can contribute to nonresponse, thoracentesis should be performed in all nonresponding patients with significant pleural fluid accumulation.",
"     </li>",
"     <li>",
"      Bronchoscopy can evaluate the airway for obstruction due to a foreign body or malignancy, which can cause a postobstructive pneumonia. Protected brushings and bronchoalveolar lavage (BAL) may be obtained for microbiologic and cytologic studies; in some cases, transbronchial biopsy may be helpful. The microbiologic evaluation of the nonresponding patient can be complicated by the effect of the initial antimicrobial therapy that may reduce the yield of pathogen isolation, or select for colonization with resistant organisms. In addition, BAL may reveal evidence of noninfectious disorders or, if there is a lymphocytic rather than neutrophilic alveolitis, viral or Chlamydophila infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thoracoscopic or open lung biopsy may be performed if all of these procedures are nondiagnostic and the patient continues to be ill. The advent of thoracoscopic procedures has significantly reduced the need for open lung biopsy, and its associated morbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure to respond to antibiotics usually results in one or more of the following: patient transfer to a higher level of care, further diagnostic testing,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    escalation of or change in treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2\">",
"     2",
"    </a>",
"    ]. There is no convincing evidence of benefit from combination antibiotic therapy in patients with progressive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2\">",
"     2",
"    </a>",
"    ] with the exception of those with severe bacteremic pneumococcal pneumonia requiring admission to an ICU; in such patients, the most commonly used combination regimens were a beta-lactam plus a macrolide or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    plus a macrolide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/88\">",
"     88",
"    </a>",
"    ]. This is a presumed reflection of the primary importance of severe illness at presentation or delayed treatment response due to host factors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23945?source=see_link\">",
"     \"Nonresolving pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/4/13386?source=see_link&amp;anchor=H28#H28\">",
"     \"Pneumococcal pneumonia in adults\", section on 'Bacteremic pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Risk factors for rehospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for rehospitalization were assessed in a multicenter randomized trial of hospitalized patients with CAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/89\">",
"     89",
"    </a>",
"    ]. Among 577 patients, 70 (12 percent) were rehospitalized within 30 days; 52 were related to comorbidities (most commonly cardiovascular, pulmonary, or neurologic); and 14 were related to pneumonia. Factors that were independently associated with rehospitalization included less than a high school education, unemployment, coronary artery disease, and chronic obstructive pulmonary disease.",
"   </p>",
"   <p>",
"    In a similar study of 1117 patients from a single center, 81 (7 percent) were rehospitalized within 30 days; 29 due to pneumonia-related causes and the remainder due to pneumonia-unrelated causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/90\">",
"     90",
"    </a>",
"    ]. Risk factors for pneumonia-related rehospitalization were initial treatment failure and one or more instability factors (eg, vital signs or oxygenation) on discharge; risk factors for non-pneumonia related readmissions were age &ge;65 and decompensated comorbidities (most commonly cardiac or pulmonary).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Adjunctive therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37793382\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been interest in using glucocorticoids as adjunctive therapy to antibiotics in hospitalized patients with CAP. However, there are conflicting data on the potential benefit of this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small randomized trial of 46 patients and a retrospective study of 308 patients, 70 of whom received glucocorticoids suggested improvement in survival among patients with severe CAP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/91,92\">",
"       91,92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a much larger randomized trial of 213 immunocompetent patients did not demonstrate improved outcomes (clinical cure or mortality) in hospitalized patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/93\">",
"       93",
"      </a>",
"      ]. Most of these patients did not have severe CAP, but there was also no benefit in the subset of patients with severe disease. In addition, the patients who received glucocorticoids had a higher rate of late failure, which was defined as a recurrence of signs and symptoms of pneumonia &gt;72 hours after admission; this may have been due at least in part to abrupt discontinuation of glucocorticoids, leading to a rebound inflammatory response.",
"     </li>",
"     <li>",
"      A third randomized trial included 304 immunocompetent patients with CAP who were admitted to the hospital but did not require immediate ICU admission; almost one-half had more severe disease as defined by a PSI class of IV or V (",
"      <a class=\"graphic graphic_table graphicRef59537 \" href=\"mobipreview.htm?13/7/13435\">",
"       table 8",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/94\">",
"       94",
"      </a>",
"      ]. The patients who received glucocorticoids had a significantly shorter median length of hospital stay of one day (6.5 versus 7.5 days). In-hospital mortality was infrequent and not different between the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above data do not provide convincing evidence of benefit from glucocorticoid therapy. Whether or not there is a benefit of glucocorticoids in severe CAP is being evaluated in a large Veteran Administration cooperative study, which is investigating prolonged low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    treatment in patients admitted to the ICU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/95\">",
"     95",
"    </a>",
"    ]. Pending these results and based upon the available data, glucocorticoids are",
"    <strong>",
"     not",
"    </strong>",
"    recommended as adjunctive therapy for CAP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37793367\">",
"    <span class=\"h3\">",
"     Tissue factor pathway inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;A recombinant tissue factor pathway inhibitor, tifacogin, which is a systemic inhibitor of coagulation, has been evaluated in an international multicenter randomized trial of patients with severe CAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/96\">",
"     96",
"    </a>",
"    ]. Despite evidence of biologic activity, tifacogin was not associated with a mortality benefit compared with placebo. Therefore, tifacogin is",
"    <strong>",
"     not",
"    </strong>",
"    recommended in patients with severe CAP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     VACCINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with community-acquired pneumonia (CAP) should be appropriately vaccinated for influenza and pneumococcal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2\">",
"     2",
"    </a>",
"    ]. Screening for influenza vaccination status is warranted during influenza season (eg, from October through March in the northern hemisphere) in all patients. Screening for pneumococcal vaccination status is warranted in patients age 65 or older or with other indications for vaccination (",
"    <a class=\"graphic graphic_table graphicRef86782 \" href=\"mobipreview.htm?11/48/12046\">",
"     table 9",
"    </a>",
"    ). Vaccination can be administered at any time during hospitalization after the patient has become stable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SMOKING CESSATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking cessation should be a goal for hospitalized patients with community-acquired pneumonia (CAP) who smoke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PERFORMANCE MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Centers for Medicare and Medicaid Services (CMS), as part of the National Pneumonia Medicare Quality Improvement Project and the Joint Commission on Accreditation of Healthcare Organizations (JCAHO), have established performance indicators to assess the quality of hospital care for pneumonia patients.",
"   </p>",
"   <p>",
"    As of January 2012, the specific CMS performance measures for CAP include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/57\">",
"     57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood cultures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who were transferred or admitted to the intensive care unit within 24 hours of hospital arrival, blood cultures should be performed within 24 hours prior to or 24 hours after hospital arrival.",
"     </li>",
"     <li>",
"      For other patients with an indication for blood cultures, they should be obtained in the emergency department prior to initiating antibiotics. The indications for blood cultures are reviewed in the Table (",
"      <a class=\"graphic graphic_table graphicRef77432 \" href=\"mobipreview.htm?4/63/5117\">",
"       table 10",
"      </a>",
"      ) and are discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=see_link&amp;anchor=H8#H8\">",
"       \"Diagnostic approach to community-acquired pneumonia in adults\", section on 'Blood cultures'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use of a guideline-compliant initial antibiotic regimen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several of the CMS performance measures changed in 2012 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/97\">",
"     97",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial antibiotic timing measure was retired. Previously, the target for initial administration of antimicrobial therapy was four hours after arrival at the hospital; this was later changed to six hours, and in 2012, the timing target was retired altogether [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. The previously recommended four-hour window resulted in the unintended consequence of overuse of antimicrobials before the diagnosis of pneumonia could be definitively established, and there was no significant difference in outcome when the delay was six hours rather than four hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/98-100\">",
"       98-100",
"      </a>",
"      ]. The need to give antibiotics within six hours also led to antibiotic overuse due to confusion in distinguishing CAP from pulmonary embolism, congestive heart failure, and other pulmonary processes.",
"     </li>",
"     <li>",
"      Pneumococcal and influenza vaccination were retired as specific pneumonia measures and become global measures.",
"     </li>",
"     <li>",
"      The smoking cessation measure became a global measure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary intent of these indicators is to implement evidence-based processes of care to maximize survival rates for patients with pneumonia. Meta-analysis of each of the previously used performance measures (pneumococcal vaccination, blood cultures, antibiotic administration within six hours of presentation, use of a guideline-compliant antibiotic regimen, influenza vaccination, inpatient smoking cessation counseling) has shown that the estimated effects favor the interventions recommended for the first five of these measures, although only influenza vaccination is supported by high quality evidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compliance with these performance measures has been linked to reimbursement (ie, Pay for Performance). Concern has been raised that this may drive pressure for hospitals and physicians to act based on these measures rather than on what may be best for an individual patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/102\">",
"     102",
"    </a>",
"    ], or for triaging other patients in an emergency department [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/56\">",
"     56",
"    </a>",
"    ]. Specific performance measures cannot cover all host and epidemiologic settings, especially when the presentation of pneumonia is atypical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/103\">",
"     103",
"    </a>",
"    ], and deviation from the performance measurement criteria may be reasonable in particular circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/1/40986/abstract/98\">",
"     98",
"    </a>",
"    ]; the reason for deviation should be documented in the chart.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/29/12754?source=see_link\">",
"       \"Patient information: Community-acquired pneumonia in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/38/30308?source=see_link\">",
"       \"Patient information: Pneumonia in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most initial treatment regimens for hospitalized patients with community-acquired pneumonia (CAP) are empiric. A limited number of pathogens are responsible for the majority of cases (",
"      <a class=\"graphic graphic_table graphicRef63248 \" href=\"mobipreview.htm?39/50/40751\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef72014 \" href=\"mobipreview.htm?8/18/8495\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef54365 \" href=\"mobipreview.htm?38/29/39390\">",
"       figure 1",
"      </a>",
"      ). The predominant pathogen is Streptococcus pneumoniae. Other common pathogens include Haemophilus influenzae, the atypical bacteria (Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella spp), oropharyngeal aerobes and anaerobes (in the setting of aspiration), and respiratory viruses. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Principles of antimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Emerging drug-resistant S. pneumoniae (DRSP) complicates the use of empiric treatment. Treatment failures have been demonstrated with use of macrolides for macrolide-resistant organisms. Most pneumococci respond to higher dose beta-lactams, other than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"       cefuroxime",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors for drug resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For hospitalized patients not requiring intensive care unit (ICU) admission, we suggest initial combination therapy with an anti-pneumococcal beta-lactam (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/33/4628?source=see_link\">",
"       ceftaroline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/36/41542?source=see_link\">",
"       ertapenem",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"       ampicillin-sulbactam",
"      </a>",
"      ) plus a macrolide (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      XL), or monotherapy with a respiratory fluoroquinolone (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest that monotherapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/7/40053?source=see_link\">",
"       tigecycline",
"      </a>",
"      be limited to patients intolerant of beta-lactams and fluoroquinolones (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Coverage for drug-resistant pathogens, such as Pseudomonas or methicillin-resistant Staphylococcus aureus (MRSA), should be included in patients with risk factors.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      may be used as an alternative to a macrolide, especially in patients at risk for QT interval prolongation. Oral therapy with a macrolide or doxycycline is appropriate only for selected patients without evidence of or risk factors for severe pneumonia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Not in the ICU'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For hospitalized patients requiring ICU care, we suggest initial combination therapy with an anti-pneumococcal beta-lactam (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"       ampicillin-sulbactam",
"      </a>",
"      )",
"      <strong>",
"       plus",
"      </strong>",
"      either intravenous therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      or a respiratory fluoroquinolone (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      )",
"      <strong>",
"       plus",
"      </strong>",
"      , if MRSA is suspected,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours, adjusted to a trough level of 15 to 20",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      and for renal function) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      (600 mg IV every 12 hours) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Coverage for other drug-resistant pathogens, such as Pseudomonas, should be included in patients with risk factors. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Admitted to an ICU'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that empiric treatment regimens be modified when results of diagnostic studies indicate a specific pathogen, and if coinfection is unlikely based upon clinical or epidemiologic data (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients should demonstrate some improvement in clinical parameters by 72 hours, although fever may persist with lobar pneumonia. Cough from pneumococcal pneumonia may not clear for a week; abnormal chest x-ray findings usually clear within four weeks but may persist for 12 weeks in older individuals, and those with underlying pulmonary disease. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Clinical response to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest switching from intravenous to oral therapy when patients are hemodynamically stable, demonstrate some clinical improvement (in fever, respiratory status, white blood count) and are able to take oral medications (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Switch to oral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest hospital discharge when the patient can take oral medication; we suggest not keeping the patient overnight for observation following the switch (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Duration of hospitalization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with CAP who have a good clinical response within the first two to three days of therapy should generally be treated for five to seven days, but longer treatment is indicated if the initial therapy was not active against the subsequently identified pathogen, if extrapulmonary infection is identified (eg, meningitis or endocarditis), or if the patient has documented P. aeruginosa, S. aureus, or Legionella pneumonia, or pneumonia caused by some less common pathogens. The duration of therapy in these patients should be individualized based upon the clinical response to treatment and patient comorbidities. For the treatment of MRSA pneumonia, we recommend a treatment duration of 7 to 21 days, depending upon the extent of infection and response to therapy; the shorter duration is recommended if the patient has a clear and early clinical response and no evidence of metastatic infection. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine follow-up chest x-rays for patients who are responding clinically within the first week are unnecessary. We suggest a follow-up chest x-ray at 7 to 12 weeks after treatment for patients who are over age 50 years, to document resolution of the pneumonia and exclude underlying diseases, such as malignancy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Follow-up chest x-ray is particularly important for males and smokers in this age group. (See",
"      <a class=\"local\" href=\"#H610314277\">",
"       'Follow-up chest radiograph'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common cause of treatment failure is the lack of response by the host, despite appropriate antibiotics. Risk factors for treatment failure include neoplasia, aspiration pneumonia, neurologic disease, multilobar pneumonia, infection with MRSA, Legionella, or gram-negative bacilli, high Pneumonia Severity Index (PSI) (&gt;90), antibiotic-resistant pathogen, cavitation, pleural effusion, liver disease, and leukopenia. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'The nonresponding patient'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/1\">",
"      File TM. Community-acquired pneumonia. Lancet 2003; 362:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/2\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/3\">",
"      Charles PG, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008; 47:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/4\">",
"      Espa&ntilde;a PP, Capelastegui A, Gorordo I, et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med 2006; 174:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/5\">",
"      Marrie TJ, Shariatzadeh MR. Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study. Medicine (Baltimore) 2007; 86:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/6\">",
"      Arnold FW, Ramirez JA, McDonald LC, Xia EL. Hospitalization for community-acquired pneumonia: the pneumonia severity index vs clinical judgment. Chest 2003; 124:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/7\">",
"      Niederman MS. Making sense of scoring systems in community acquired pneumonia. Respirology 2009; 14:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/8\">",
"      Chalmers JD, Singanayagam A, Akram AR, et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax 2010; 65:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/9\">",
"      Marrie TJ, Poulin-Costello M, Beecroft MD, Herman-Gnjidic Z. Etiology of community-acquired pneumonia treated in an ambulatory setting. Respir Med 2005; 99:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/10\">",
"      Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001; 56:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/11\">",
"      File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/12\">",
"      Restrepo MI, Mortensen EM, Velez JA, et al. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 2008; 133:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/13\">",
"      Lieberman D, Shimoni A, Shemer-Avni Y, et al. Respiratory viruses in adults with community-acquired pneumonia. Chest 2010; 138:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/14\">",
"      Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010; 50:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/15\">",
"      Johansson N, Kalin M, Hedlund J. Clinical impact of combined viral and bacterial infection in patients with community-acquired pneumonia. Scand J Infect Dis 2011; 43:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/16\">",
"      Read RC. Evidence-based medicine: empiric antibiotic therapy in community-acquired pneumonia. J Infect 1999; 39:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/17\">",
"      van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005; 60:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/18\">",
"      File TM Jr, Niederman MS. Antimicrobial therapy of community-acquired pneumonia. Infect Dis Clin North Am 2004; 18:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/19\">",
"      Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002; 162:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/20\">",
"      Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 Suppl 3:iii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/21\">",
"      Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000; 31:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/22\">",
"      Arnold FW, Summersgill JT, Lajoie AS, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 2007; 175:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/23\">",
"      Shefet D, Robenshtock E, Paul M, Leibovici L. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev 2005; :CD004418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/24\">",
"      Lode H, File TM Jr, Mandell L, et al. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther 2002; 24:1915.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/ucm224370.htm (Accessed September 2, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/26\">",
"      Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/27\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/28\">",
"      Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/29\">",
"      Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46 Suppl 5:S378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/30\">",
"      Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/31\">",
"      Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005; 40:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/32\">",
"      Labandeira-Rey M, Couzon F, Boisset S, et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 2007; 315:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/33\">",
"      Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/34\">",
"      Graves SF, Kobayashi SD, Braughton KR, et al. Relative contribution of Panton-Valentine leukocidin to PMN plasma membrane permeability and lysis caused by USA300 and USA400 culture supernatants. Microbes Infect 2010; 12:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/35\">",
"      Li M, Diep BA, Villaruz AE, et al. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci U S A 2009; 106:5883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/36\">",
"      Diep BA, Chan L, Tattevin P, et al. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci U S A 2010; 107:5587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/37\">",
"      Bubeck Wardenburg J, Palazzolo-Ballance AM, Otto M, et al. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J Infect Dis 2008; 198:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/38\">",
"      Peyrani P, Allen M, Wiemken TL, et al. Severity of disease and clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus strains not influenced by the presence of the Panton-Valentine leukocidin gene. Clin Infect Dis 2011; 53:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/39\">",
"      Bernardo K, Pakulat N, Fleer S, et al. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 2004; 48:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/40\">",
"      Stevens DL, Ma Y, Salmi DB, et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007; 195:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/41\">",
"      Vesga O, Agudelo M, Salazar BE, et al. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob Agents Chemother 2010; 54:3271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/42\">",
"      Kallen AJ, Brunkard J, Moore Z, et al. Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. Ann Emerg Med 2009; 53:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/43\">",
"      Rodr&iacute;guez A, Mendia A, Sirvent JM, et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007; 35:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/44\">",
"      Mart&iacute;nez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/45\">",
"      Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. Chest 2007; 131:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/46\">",
"      Restrepo MI, Mortensen EM, Waterer GW, et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009; 33:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/47\">",
"      Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010; 36:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/48\">",
"      Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     Ceftaroline Fosamil for the Treatment of Community-acquired Bacterial Pneumonia and Complicated Skin and Skin Structure Infections, FDA Briefing Document for Anti-Infective Drugs Advisory Committee Meeting, September 7, 2010 file://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM224656.pdf (Accessed on January 25, 2011).",
"    </li>",
"    <li>",
"     Tigecycline Prescribing information, Wyeth Pharmaceuticals, Inc. Philadelphia, PA, 7/10 file://www.pfizerpro.com/content/showlabeling.asp?id=491 (Accessed on January 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/51\">",
"      Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004; 164:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/52\">",
"      Silber SH, Garrett C, Singh R, et al. Early administration of antibiotics does not shorten time to clinical stability in patients with moderate-to-severe community-acquired pneumonia. Chest 2003; 124:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/53\">",
"      Waterer GW, Kessler LA, Wunderink RG. Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest 2006; 130:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/54\">",
"      Metersky ML, Sweeney TA, Getzow MB, et al. Antibiotic timing and diagnostic uncertainty in Medicare patients with pneumonia: is it reasonable to expect all patients to receive antibiotics within 4 hours? Chest 2006; 130:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/55\">",
"      Welker JA, Huston M, McCue JD. Antibiotic timing and errors in diagnosing pneumonia. Arch Intern Med 2008; 168:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/56\">",
"      Mitka M. JCAHO tweaks emergency departments' pneumonia treatment standards. JAMA 2007; 297:1758.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Medicare and Medicaid Services and the Joint Commission. Specifications manual for national  hospital inpatient quality measures. www.jointcommission.org/specifications_manual_for_national_ (Accessed on July 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/58\">",
"      Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998; 279:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/59\">",
"      Men&eacute;ndez R, Torres A, Rodr&iacute;guez de Castro F, et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004; 39:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/60\">",
"      Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med 1999; 159:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/61\">",
"      Bruns AH, Oosterheert JJ, Prokop M, et al. Patterns of resolution of chest radiograph abnormalities in adults hospitalized with severe community-acquired pneumonia. Clin Infect Dis 2007; 45:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/62\">",
"      Mittl RL Jr, Schwab RJ, Duchin JS, et al. Radiographic resolution of community-acquired pneumonia. Am J Respir Crit Care Med 1994; 149:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/63\">",
"      El Solh AA, Aquilina AT, Gunen H, Ramadan F. Radiographic resolution of community-acquired bacterial pneumonia in the elderly. J Am Geriatr Soc 2004; 52:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/64\">",
"      Almirall J, Bol&iacute;bar I, Vidal J, et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 2000; 15:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/65\">",
"      Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/66\">",
"      Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999; 159:2449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/67\">",
"      Oosterheert JJ, Bonten MJ, Schneider MM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ 2006; 333:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/68\">",
"      Carratal&agrave; J, Garcia-Vidal C, Ortega L, et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Arch Intern Med 2012; 172:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/69\">",
"      Ramirez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med 2001; 161:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/70\">",
"      Dunn AS, Peterson KL, Schechter CB, et al. The utility of an in-hospital observation period after discontinuing intravenous antibiotics. Am J Med 1999; 106:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/71\">",
"      Nathan RV, Rhew DC, Murray C, et al. In-hospital observation after antibiotic switch in pneumonia: a national evaluation. Am J Med 2006; 119:512.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/72\">",
"      Dagan E, Novack V, Porath A. Adverse outcomes in patients with community acquired pneumonia discharged with clinical instability from Internal Medicine Department. Scand J Infect Dis 2006; 38:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/73\">",
"      Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 2007; 120:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/74\">",
"      Hayashi Y, Paterson DL. Strategies for reduction in duration of antibiotic use in hospitalized patients. Clin Infect Dis 2011; 52:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/75\">",
"      Combes A, Luyt CE, Fagon JY, et al. Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia. Am J Respir Crit Care Med 2004; 170:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/76\">",
"      Avdic E, Cushinotto LA, Hughes AH, et al. Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia. Clin Infect Dis 2012; 54:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/77\">",
"      Tang KL, Eurich DT, Minhas-Sandhu JK, et al. Incidence, correlates, and chest radiographic yield of new lung cancer diagnosis in 3398 patients with pneumonia. Arch Intern Med 2011; 171:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/78\">",
"      Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/79\">",
"      Arancibia F, Ewig S, Martinez JA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000; 162:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/80\">",
"      Men&eacute;ndez R, Torres A, Zalaca&iacute;n R, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004; 59:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/81\">",
"      Ros&oacute;n B, Carratal&agrave; J, Fern&aacute;ndez-Sab&eacute; N, et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004; 164:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/82\">",
"      Ewig S, de Roux A, Bauer T, et al. Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax 2004; 59:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/83\">",
"      Genn&eacute; D, Sommer R, Kaiser L, et al. Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2006; 25:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/84\">",
"      Ho PL, Cheng VC, Chu CM. Antibiotic resistance in community-acquired pneumonia caused by Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, and Acinetobacter baumannii. Chest 2009; 136:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/85\">",
"      Mortensen EM, Coley CM, Singer DE, et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 2002; 162:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/86\">",
"      Aliberti S, Amir A, Peyrani P, et al. Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. Chest 2008; 134:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/87\">",
"      Dalhoff K, Maass M. Chlamydia pneumoniae pneumonia in hospitalized patients. Clinical characteristics and diagnostic value of polymerase chain reaction detection in BAL. Chest 1996; 110:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/88\">",
"      Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/89\">",
"      Jasti H, Mortensen EM, Obrosky DS, et al. Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis 2008; 46:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/90\">",
"      Capelastegui A, Espa&ntilde;a Yandiola PP, Quintana JM, et al. Predictors of short-term rehospitalization following discharge of patients hospitalized with community-acquired pneumonia. Chest 2009; 136:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/91\">",
"      Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005; 171:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/92\">",
"      Garcia-Vidal C, Calbo E, Pascual V, et al. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 2007; 30:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/93\">",
"      Snijders D, Daniels JM, de Graaff CS, et al. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010; 181:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/94\">",
"      Meijvis SC, Hardeman H, Remmelts HH, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377:2023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/95\">",
"      Meduri GU, Bell WA, Confalonieri M. Glucocorticoid treatment in community-acquired pneumonia without severe sepsis: no evidence of efficacy. Am J Respir Crit Care Med 2010; 181:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/96\">",
"      Wunderink RG, Laterre PF, Francois B, et al. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2011; 183:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/97\">",
"      Centers for Medicare &amp; Medicaid Services (CMS), HHS. Medicare program; hospital inpatient value-based purchasing program. Final rule. Fed Regist 2011; 76:26490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/98\">",
"      File TM Jr, Gross PA. Performance measurement in community-acquired pneumonia: consequences intended and unintended. Clin Infect Dis 2007; 44:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/99\">",
"      Kanwar M, Brar N, Khatib R, Fakih MG. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. Chest 2007; 131:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/100\">",
"      Wachter RM, Flanders SA, Fee C, Pronovost PJ. Public reporting of antibiotic timing in patients with pneumonia: lessons from a flawed performance measure. Ann Intern Med 2008; 149:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/101\">",
"      Wilson KC, Sch&uuml;nemann HJ. An appraisal of the evidence underlying performance measures for community-acquired pneumonia. Am J Respir Crit Care Med 2011; 183:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/102\">",
"      Niederman MS. Recent advances in community-acquired pneumonia: inpatient and outpatient. Chest 2007; 131:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/1/40986/abstract/103\">",
"      Fee C, Weber EJ. Identification of 90% of patients ultimately diagnosed with community-acquired pneumonia within four hours of emergency department arrival may not be feasible. Ann Emerg Med 2007; 49:553.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7027 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-961E418322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_1_40986=[""].join("\n");
var outline_f40_1_40986=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR HOSPITALIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRINCIPLES OF ANTIMICROBIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Common pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Risk factors for drug resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Not in the ICU",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Admitted to an ICU",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - CA-MRSA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Fluoroquinolone monotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Macrolide-containing regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1600933\">",
"      - Influenza therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89730288\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Timing of antimicrobial initiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical response to therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Radiographic response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Switch to oral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Duration of hospitalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H610314277\">",
"      Follow-up chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      The nonresponding patient",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Further evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Risk factors for rehospitalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Adjunctive therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37793382\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37793367\">",
"      - Tissue factor pathway inhibitor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      VACCINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SMOKING CESSATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PERFORMANCE MEASURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7027\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7027|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/29/39390\" title=\"figure 1\">",
"      Microbiology CAP comprehensive testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7027|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/50/40751\" title=\"table 1\">",
"      Microbiology CAP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/18/8495\" title=\"table 2\">",
"      Microbiology CAP site of care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/46/43757\" title=\"table 3\">",
"      IDSA ATS CAP guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/43/14013\" title=\"table 4\">",
"      BTS CAP guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/63/20478\" title=\"table 5\">",
"      Pathogen-directed therapy for CAP in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/31/3579\" title=\"table 6\">",
"      Duration of pneumonia findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/14/21739\" title=\"table 7\">",
"      Comorbidities and pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/7/13435\" title=\"table 8\">",
"      PSI and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/48/12046\" title=\"table 9\">",
"      Pneumococcal vaccination indications for adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/63/5117\" title=\"table 10\">",
"      CAP diagnostic testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?43/42/44705?source=related_link\" title=\"calculator 1\">",
"      Calculator: Community-acquired pneumonia severity index (PSI) for adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?40/62/41952?source=related_link\" title=\"calculator 2\">",
"      Calculator: CURB-65 pneumonia severity score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29210?source=related_link\">",
"      Antibiotic studies for the treatment of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/30/1514?source=related_link\">",
"      Azithromycin, clarithromycin, and telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5400?source=related_link\">",
"      Cephalosporin-allergic patients: Subsequent use of cephalosporins and related antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38426?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38473?source=related_link\">",
"      Community-acquired pneumonia in adults: Risk stratification and the decision to admit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31514?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/57/12183?source=related_link\">",
"      Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28618?source=related_link\">",
"      Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/34/26152?source=related_link\">",
"      Important sites and pathogens causing infections in long-term care facilities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/5/3162?source=related_link\">",
"      Mycoplasma pneumoniae infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23945?source=related_link\">",
"      Nonresolving pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/29/12754?source=related_link\">",
"      Patient information: Community-acquired pneumonia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/38/30308?source=related_link\">",
"      Patient information: Pneumonia in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15672?source=related_link\">",
"      Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/4/13386?source=related_link\">",
"      Pneumococcal pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/6/7270?source=related_link\">",
"      Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1801?source=related_link\">",
"      Prognosis of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31494?source=related_link\">",
"      Pseudomonas aeruginosa pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21273?source=related_link\">",
"      Pulmonary infections in immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17591?source=related_link\">",
"      Sputum cultures for the evaluation of bacterial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33015?source=related_link\">",
"      Treatment and prevention of Legionella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15306?source=related_link\">",
"      Treatment of bacterial meningitis caused by specific pathogens in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24969?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults in the outpatient setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=related_link\">",
"      Treatment of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/47/15096?source=related_link\">",
"      Vancomycin dosing and serum concentration monitoring in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/2/16425?source=related_link\">",
"      Vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40758?source=related_link\">",
"      Virulence determinants of community acquired methicillin-resistant Staphylococcus aureus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_1_40987="Systemic disease spine pain";
var content_f40_1_40987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F69498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F69498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Categories of systemic disease associated with spine pain, and clues to their diagnosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prior history of cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Older age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unexplained weight loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No relief with bed rest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain exceeding one month",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Failure to improve with spine therapies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Spinal infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intravenous drug use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary tract infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Compression fractures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Older age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged glucocorticoid use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Rheumatologic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ankylosing spondylitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beh&ccedil;et disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crohn disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psoriatic arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulcerative colitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Whipple disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_1_40987=[""].join("\n");
var outline_f40_1_40987=null;
var title_f40_1_40988="Length time bias C";
var content_f40_1_40988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Length-time bias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 319px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Length-time bias occurs when screening detects less aggressive tumors. Cases that progress rapidly from onset (O) to symptoms and diagnosis (Dx) are less likely to be detected during a screening examination. Thus, patients whose tumors are identified by screening may appear to have better outcomes, but their tumors may differ biologically from the general cohort of patients with that cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Fletcher RH, Fletcher SW. Prevention. In: Clinical Epidemiology - The Essentials, 4th ed. Lippincott Williams &amp; Wilkins, Baltimore 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_1_40988=[""].join("\n");
var outline_f40_1_40988=null;
var title_f40_1_40989="ACC AHA Rx systolic HF";
var content_f40_1_40989=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Management of adults with current or prior symptoms of heart failure (HF) and a reduced left ventricular ejection fraction (LVEF) (HF stage C)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that the following approaches are effective in the management of patients with current or prior symptoms of HF and a reduced LVEF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Diuretics and salt restriction for fluid retention.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Angiotensin converting enzyme (ACE) inhibitors in all patients, unless contraindicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Beta blockers in all stable patients, unless contraindicated. One of the three beta blockers proven to reduce mortality should be used (bisoprolol, carvedilol, and sustained release metoprolol succinate).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Angiotensin II receptor blockers (ARBs) in patients who do not tolerate ACE inhibitors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Drugs that can adversely affect the patient's clinical status should be avoided or withdrawn, if possible. These include nonsteroidal antiinflammatory drugs, most antiarrhythmic drugs, and most calcium channel blockers.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Exercise training as an adjunctive approach to improve clinical status in ambulatory patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; An implantable cardioverter-defibrillator (ICD) for secondary prevention to prolong survival in patients with a history of cardiac arrest, ventricular fibrillation, or hemodynamically destabilizing ventricular tachycardia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; An ICD for primary prevention to reduce total mortality by preventing sudden cardiac death (SCD) in patients with non-ischemic or ischemic heart disease who meet the following criteria: at least 40 days post-myocardial infarction, an LVEF &le;35 percent, New York Heart Association functional class II or III symptoms despite optimal chronic medical therapy, and a reasonable expectation of survival with a good functional status for more than one year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Cardiac resynchronization therapy (CRT), with or without an ICD, unless contraindicated, in patients who meet the following criteria: cardiac dyssynchrony as defined by a QRS duration &gt;120 msec, LVEF &le;35 percent, sinus rhythm, and New York Heart Association functional class III or ambulatory class IV symptoms despite optimal medical therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Addition of an aldosterone antagonist is recommended in selected patients with moderately severe to severe symptoms of HF and reduced LVEF who can be carefully monitored for preserved renal function and normal potassium concentration. Creatinine should be &le;2.5 mg per dL in men or &le;2.0 mg per dL in women and potassium should be &lt;5.0 mEq per liter. Under circumstances in which monitoring for hyperkalemia and renal dysfunction is not anticipated to be feasible, the risks may outweigh the benefits of aldosterone antagonists.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; The combination of hydralazine and nitrates is recommended to improve outcomes for patients self-described as African-Americans, with moderate-severe symptoms on optimal therapy with ACE inhibitors, beta blockers, and diuretics.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence and/or opinion is in favor of the following approaches being effective in the management of patients with current or prior symptoms of HF and a reduced LVEF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; It is reasonable to treat patients with atrial fibrillation and HF with a strategy to maintain sinus rhythm or with a strategy to control ventricular rate alone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Maximal exercise testing with or without measurement of respiratory gas exchange is reasonable to facilitate prescription of an appropriate exercise program for patients presenting with HF.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; ARBs as an alternative to ACE inhibitors as first-line therapy in patients with mild to moderate HF, particularly those already taking an ARB for other indications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Digitalis in patients with current or prior symptoms of HF to reduce hospitalization for HF.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; The addition of the combination of hydralazine and a nitrate in patients with persistent symptoms who are already taking an ACE inhibitor and beta blocker.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; CRT with or without an ICD is reasonable in patients with an LVEF of &le;35 percent, a QRS &ge;0.12 seconds, and atrial fibrillation who have New York Heart Association functional class III or ambulatory class IV symptoms symptoms despite optimal chronic medical therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; CRT is reasonable in patients with an LVEF of &le;35 percent who have New York Heart Association functional class III or ambulatory class IV symptoms despite optimal medical therapy and who have frequent dependence of ventricular pacing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence and/or opinion is less well established for the following approaches in the management of patients with current or prior symptoms of HF and a reduced LVEF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; The combination of hydralazine and a nitrate in patients who cannot be given an ACE inhibitor or ARB because of drug intolerance, hypotension, or renal insufficiency.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Addition of an ARB in patients with persistent symptoms who are already being treated with an ACE inhibitor, beta blocker, and diuretics.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that the following approaches are not effective and may be harmful in the management of patients with current or prior symptoms of HF and a reduced LVEF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Routine use of triple therapy with an ACE inhibitor, an ARB, and an aldosterone receptor antagonist is not recommended.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Routine administration of calcium channel blockers is not indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Long-term infusion of a positive inotropic drug may be harmful and is not recommended, except as palliation for end-stage disease that cannot be stabilized with standard medical therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Nutritional supplements are not indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Hormonal therapies may be harmful and are not recommended unless given to replete hormone deficiencies.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_1_40989=[""].join("\n");
var outline_f40_1_40989=null;
var title_f40_1_40990="Causes CKD children age";
var content_f40_1_40990=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Distribution of the etiology of chronic kidney disease (CKD) in pediatric renal transplant recipients based on age at transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 601px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FSGS: focal segmental glomerulosclerosis; GN: glomerulonephritis; Structural: structural anomalies of the kidney and urinary tract.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: NAPRTCS: 2010 Annual Report, Rockville, MD. Full report available at:",
"     <a href=\"https://web.emmes.com/study/ped/annlrept/2010_Report.pdf\" target=\"_blank\">",
"      https://web.emmes.com/study/ped/annlrept/2010_Report.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_1_40990=[""].join("\n");
var outline_f40_1_40990=null;
var title_f40_1_40991="Omphalitis II";
var content_f40_1_40991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Omphalitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Omphalitis with induration and erythema surrounding the umbilicus in a newborn.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martin I. Lorin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_1_40991=[""].join("\n");
var outline_f40_1_40991=null;
